C

CANCER PHARMACOLOGY &

ANCER PHARMA

PHARMACOTHERAPY REVIEW

Francis P. Worden, Md, RPh

CANCER

anthony J. Perissinotti, PharmD, BCOP

Bernard L. Marini, PharmD

Cancer Pharmacology and Pharmacotherapy Review is the first book PHARMACOLOGY &

devoted entirely to providing the ‘must-know’ facts on each cancer agent—

including their pharmacokinetics, FDA-approved indications, toxicity, COL

interactions, and other important information that is commonly found on PHARMACOTHERAPY

board examinations and essential for any clinician or practitioner to review.

OG

The authors, an oncologist and two pharmacists, have developed a handy Y

question-and-answer format to present the material in digestible bursts.

&

REVIEW

As the pharmacology section continues to represent a major portion of the PHARMA

medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune Study Guide for

their knowledge on cancer drugs before the test. Not to mention, with ONCOLOGY BOARDS AND

recent advancements in the field of cancer treatment, it has become more CO

cumbersome to recall and maintain essential knowledge of every cancer MOC EXAMS

therapeutic—making this book not only an exam resource but also a handy THER

quick reference for oncologists and pharmacists alike.

KEY FEATURES

AP

• Conveniently organized and arranged by drug class and subtypes Y REVIEW

for easier recall and classification

• Includes proper dosage adjustments to account for liver and kidney dysfunction

• Features tables throughout that provide quick reference regarding FDA-approved medications

• Simplified diagrams and illustrations facilitate the P

pharmacokinetic processes

erissino

W

Recommended Shelving

Marini

orden

Category: oncoLogy

ISBN 978-1-62070-076-1

tti

11 W. 42nd Street

Francis P. Worden

New York, NY 10036

Anthony J. Perissinotti

www.demosmedical.com

9 781620 700761

Bernard L. Marini

Cancer Pharmacology and

Pharmacotherapy Review





Cancer Pharmacology and

Pharmacotherapy Review

Study Guide for Oncology

Boards and MOC Exams

Francis P. Worden, MD, RPh

Professor

Division of Hematology/Oncology

Department of Internal Medicine

University of Michigan Health System

Ann Arbor, Michigan

Anthony J. Perissinotti, PharmD, BCOP

Clinical Pharmacist Specialist, Inpatient Hematology Adjunct Clinical Assistant Professor

Department of Pharmacy

University of Michigan Health System

Ann Arbor, Michigan

Bernard L. Marini, PharmD

Clinical Pharmacist Specialist, Inpatient Hematology Adjunct Clinical Assistant Professor

Department of Pharmacy

University of Michigan Health System

Ann Arbor, Michigan

New York





Visit our website at www.demosmedical.com

ISBN: 9781620700761

e-book ISBN: 9781617052521

Acquisitions Editor: David D’Addona Compositor: Exeter Premedia Services Copyright © 2016 Springer Publishing Company.

Demos Medical Publishing is an imprint of Springer Publishing Company, LLC.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Medicine is an ever-changing science. Research and clinical experience are con-tinually expanding our knowledge, in particular our understanding of proper treatment and drug therapy. The authors, editors, and publisher have made every effort to ensure that all information in this book is in accordance with the state of knowledge at the time of production of the book. Nevertheless, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no war-ranty, expressed or implied, with respect to the contents of the publication. Every reader should examine carefully the package inserts accompanying each drug and should carefully check whether the dosage schedules mentioned therein or the contraindications stated by the manufacturer differ from the statements made in this book. Such examination is particularly important with drugs that are either rarely used or have been newly released on the market.

Library of Congress Cataloging-in-Publication Data Names: Worden, Francis P., author. | Perissinotti, Anthony J., author. |

Marini, Bernard L., author.

Title: Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J.

Perissinotti, Bernard L. Marini.

Description: New York : Demos Medical, [2016]

Identifi ers: LCCN 2015045238| ISBN 9781620700761 | ISBN 9781617052521

(ebook)

Subjects: | MESH: Antineoplastic Agents—pharmacology—Examination Questions.

| Neoplasms—drug therapy—Examination Questions.

Classifi cation: LCC RS431.A64 | NLM QV 18.2 | DDC 615.7/98076—dc23

LC record available at http://lccn.loc.gov/2015045238

Special discounts on bulk quantities of Demos Medical Publishing books are available to corporations, professional associations, pharmaceutical companies, health care organizations, and other qualifying groups. For details, please contact: Special Sales Department

Demos Medical Publishing

11 West 42nd Street, 15th Floor

New York, NY 10036

Phone: 800-532-8663 or 212-683-0072

Fax: 212-941-7842

E-mail: specialsales@demosmedical.com

Printed in the United States of America by McNaughton & Gunn.

16 17 18 19 / 5 4 3 2 1

We dedicate this book to our patients for their willingness to participate in clinical trials. Without their fortitude and willingness to participate in clinical trials, new drug discoveries and the advancement of the field of oncologic medicine would not be possible.





Contents

List of Figures ix

List of Tables xi

Preface xiii

Share Cancer Pharmacology and Pharmacotherapy Review:

Study Guide for Oncology Boards and MOC Exams

I. Traditional

Chemotherapy

1. Microtubule Inhibitors 3

Taxanes and Related Agents 3

Vinca

Alkaloids 11

2. Alkylating Agents 15

Nitrogen

Mustards 15

Non-Nitrogen

Mustards 23

Platinums 31

Antitumor

Antibiotics 35

3. Enzyme Inhibitors—Topoisomerase I Inhibitors 41

Camptothecans 41

4. Enzyme Inhibitors—Topoisomerase II Inhibitors 47

Epipodophyllotoxins 47

Anthracyclines 51

5. Antimetabolites 57

Antifolates 57

Purine

Antagonists 64

Purine

Analogues 69

Pyrimidine

Analogues/Fluoropyrimidines 73

Pyrimidine Analogues/Deoxycytidine Analogues 78

viii Contents

II. Next-Generation

Antineoplastics

6. Monoclonal Antibodies 85

7. VEGF Trap 103

Ziv-Aflibercept

(Zaltrap®) 103

8. Tyrosine Kinase Inhibitors 105

Angiogenesis Inhibitors and Multi-Kinase Inhibitors 105

Breakpoint Cluster Region-Abelson Murine Leukemia Viral

Oncogene Homolog 1 (BCR-ABL) Inhibitors 110

B-Cell Receptor (BCR) Pathway Inhibitors 114

EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors 118

Miscellaneous Oral Targeted Therapies 122

9. Antiandrogen Therapies 129

10. Mammalian Target of Rapamycin (mTOR) Inhibitors 131

11. Histone Deacetylase (HDAC) Inhibitors 133

12. Hypomethylating Agents 137

13. Proteasome Inhibitors 141

14. Immunomodulatory Agents 145

15. L-Asparaginase Enzymes 149

16. Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha

(PML-RAR) Translocation Inhibitors 153

III. Miscellaneous

Oncolytics

17. Sipuleucel-T (Provenge®) 159

18. Omacetaxine (Synribo®) 161

19. Estramustine (Emcyt®) 163

Appendix A: Agents Requiring Renal and/or Hepatic

Dose Adjustments 165

Appendix B: Extravasation Risk of Chemotherapeutic Agents 167

Index 171





List of Figures

Chapter 1

1.1 Mechanism of Action of Microtubule Inhibitors 4

Chapter 2

2.1 Cyclophosphamide and Ifosfamide Metabolic Pathway 17

2.2 Bendamustine Structure 18

2.3 Platinum Structure and Mechanism of Action 32

Chapter 3

3.1 Irinotecan Metabolism and Elimination 43

Chapter 5

5.1 Antifolates 58

5.2 Purine Antagonists 65

5.3 Pyrimidine Analogues 74

5.4 Cytarabine MOA and Metabolism 79

Chapter 8

8.1 Tyrosine Kinase and Monoclonals 115

Chapter 12

12.1 Hypomethylating Agent MOA 138





List of Tables

Chapter 1

FDA-Approved Uses of Taxanes 3

Differences in Side Effect Profile Between Weekly Dosing and Dosing

Every 3 Weeks of Paclitaxel and Docetaxel 9

Premedications Required for Taxanes 9

FDA-Approved Uses of Vinca Alkaloids 11

Chapter 2

FDA-Approved Uses of Nitrogen Mustard Alkylating

Agents 15

FDA-Approved Uses of Non-Nitrogen Mustard Alkylating

Agents 23

FDA-Approved Uses of Platinum Alkylating Agents 31

FDA-Approved Uses of Antitumor Antibiotics 35

Chapter 3

FDA-Approved Uses of Topoisomerase I Inhibitors 41

Chapter 4

FDA-Approved Uses of Topoisomerase II Inhibitors 47

FDA-Approved Uses of Anthracyclines 51

Maximum Lifetime Doses of Anthracyclines 56

Chapter 5

FDA-Approved Uses of Antifolates 57

Frequency of Side Effects of Antifolates 61

FDA-Approved Uses of Purine Antagonists 64

Recommended Starting Dosing of Mercaptopurine and Thioguanine in

Patients With TPMT Variants 68

FDA-Approved Uses of Purine Analogues 69

xii List of Tables

FDA-Approved Uses of Fluoropyrimidine Analogues 73

FDA-Approved Uses of Deoxycytidine Analogues 78

Chapter 6

Flowchart of How Monoclonal Antibodies Are Named 86

Agents in the Monoclonal Antibody Class 88

Chapter 8

FDA-Approved Uses of VEGFR Inhibitors 105

Targets for Each Tyrosine Kinase Inhibitor 106

Drug Interactions With Angiogenesis Inhibitors 108

FDA-Approved Uses of BCR-ABL Inhibitors 110

Drug Interactions With BCR-ABL Inhibitors 112

FDA-Approved Uses of BCR Pathway Inhibitors 114

Drug Interactions With BCR Pathway Inhibitors 116

FDA-Approved Uses of MAPK Pathway Inhibitors 118

Drug Interactions With MAPK Pathway Inhibitors 120

FDA-Approved Uses of Miscellaneous Oral Targeted Therapies 122

Drug Interactions With Miscellaneous Oral Targeted Therapies 125

Chapter 9

FDA-Approved Uses of Antiandrogen Therapies 129

Chapter 10

FDA-Approved Uses of mTOR Inhibitors 131

Chapter 11

FDA-Approved Uses of HDAC Inhibitors 133

Chapter 13

FDA-Approved Uses of Proteasome Inhibitors 141

Premedications Required for Proteasome Inhibitors 143

Chapter 14

FDA-Approved Uses of Immunomodulatory Agents (IMiDs) 145

Most Common Adverse Effects of IMiDs 146

Chapter 16

FDA-Approved Uses of PML-RARα Inhibitors 153





Preface

In preparing for clinics, rounding, or board examinations, understanding the pharmacology of the drugs and agents can be overwhelming. In medical school and residency, it is often difficult to keep up with the mechanisms of action, kinetics, and dosing schedules of so many common medications, let alone those that are used in more rare conditions, including cancer. When residents become hematology and oncology fellows, they are forced to learn a large cohort of medications very quickly, a task that is daunting, given the ever-expanding market of new chemotherapeutic agents.

Additionally, questions on the hematology and oncology board examinations related to pharmacology represent a relatively larger percent-age. This is true, given that the facts focusing on the mechanisms and side effects of these drugs do not change. Moreover, we are often asked dose-limiting side effects of medications as well as the requirements for dosage reductions related to kidney and liver failure. The University of Michigan Hematology/Oncology Fellowship Program recently published an oncology board review book, Oncology Boards Flash Review, to help solidify the knowledge one needs to have for his or her test. As a companion to this manual, we have written a similar board review book to summarize information that is most pertinent to the pharmacology of chemotherapeutic agents used by practicing hematologists and oncologists. This book contains concise summaries of the various chemotherapeutic drugs by class, pharmacology, pharmacokinetics, and toxicities and includes, to date, all of the U.S. Food and Drug Administration (FDA)-approved oncology agents available to practicing clinicians. It is our hope that fellows and practicing medical hematologists/oncologists preparing for ward rounds, outpatient clinical rotations, or for their certifi cation or recertifi -

cation examinations will fi nd our book to be a useful tool. Our goal is to

xiv Preface

help our readers summarize and solidify many important clinical facts and to help them build confi dence in their knowledge of oncologic drugs.

The successful completion of this project was made possible by the editorial staff of Demos Medical Publishing, especially David D’Addona, acquisitions editor, and Joseph Stubenrauch, production editor.

Francis P. Worden, MD, RPh

Anthony J. Perissinotti, PharmD, BCOP

Bernard L. Marini, PharmD





Share

Cancer Pharmacology and Pharmacotherapy Review:

Study Guide for Oncology Boards and MOC Exams





I

Traditional Chemotherapy





1

Microtubule Inhibitors

TAXANES AND RELATED AGENTS

What are the chemotherapy agents in the taxane class?

• Paclitaxel (Taxol®), nanoparticle albumin-bound (nab) paclitaxel (Abraxane®), docetaxel (Taxotere®), and cabazitaxel (Jevtana®)

• Ixabepilone (Ixempra®) is an epothilone

• Eribulin (Halaven®) is a halichondrin B analogue What malignancies are each taxane FDA approved for?

FDA-Approved Uses of Taxanes

Agent

FDA Approval

Paclitaxel

Breast cancer, non–small cell lung cancer

(NSCLC), ovarian cancer, Kaposi’s sarcoma

Nab-paclitaxel

Breast cancer, pancreatic cancer, NSCLC

Docetaxel

Breast cancer, NSCLC, prostate cancer, gastric adenocarcinoma, head and neck cancers

Cabazitaxel

Prostate (post-docetaxel)

Ixabepilone

Metastatic breast cancer

Eribulin

Metastatic breast cancer

Abbreviation: FDA, U.S. Food and Drug Administration.





4 I. Traditional Chemotherapy

How do the taxanes work? (See Figure 1.1)

• Summary: More microtubule assembly occurs than disassembly, resulting in abnormal arrays or bundles of microtubules throughout the cell cycle leading to apoptosis (primarily via caspase 9 activation) α-tubulin

β-tubulin

Taxanes and Epothilones

Vinca Alkaloids

Eribulin

Microtubule

disassembly

Microtubule

assembly

FIGURE 1.1. Mechanism of action of microtubule inhibitors: As a

class, microtubule inhibitors interfere with microtubule dynamics and the formation of the mitotic spindle, thus preventing cell cycle progression from the G2→M phase, ultimately leading to apoptosis. Vinca alkaloids prevent microtubule assembly by binding β-tubulin and promoting depolymerization. Eribulin binds to a site near the vinca-binding site, preventing microtubule assembly and causing formation of nonproductive tubulin aggregates. Uniquely, eribulin binds only to the “plus” end of microtubules and does not affect microtubule shortening. Taxanes bind to β-tubulin on the interior surface of microtubules, promoting stabilization of the microtubule and preventing dissociation of tubulin. Epothilones have a similar mechanism of action to taxanes and occupy the same binding site; however, they interact with β-tubulin through a different molecular binding mechanism.

1. MICROTUBULE INHIBITORS 5

• Microtubules lengthen and shrink via attachment/detachment of α- and β-tubulin dimers. In a normal cell, there is a dynamic equilib-rium of polymerization and depolymerization. This is termed dynamic instability. Taxanes block dynamic instability by binding to β-tubulin, causing less detachment of α- and β-tubulin dimers and more stability of the microtubules, leading them to be shifted to the assembled state. When more assembly occurs than disassembly, abnormal bundles of microtubules result and cellular function and replication cannot proceed

• Cell cycle specific to the G2/M phase

How do the mechanisms of nab-paclitaxel, cabazitaxel, ixabepilone, and eribulin differ?

• Nab-paclitaxel: preferentially delivers paclitaxel out of serum and into tumor interstitium via interactions with albumin receptors. In addition, serum protein acidic that is rich in cysteine (SPARC) can be overexpressed on tumors, which nab-paclitaxel can bind to, resulting in the tumor cell rapidly internalizing paclitaxel

• Cabazitaxel: poor affinity for the P-glycoprotein (P-gp) efflux pump, therefore active in cell lines that are resistant to paclitaxel/docetaxel and achieves greater central nervous system concentrations

• Ixabepilone: exhibits greater potency binding to paclitaxel binding site via different molecular interactions and is not affected by mutations in β-tubulin that cause resistance to taxanes; maintains activity despite tumors overexpressing P-gp, βIII-tubulin, and microtubule assembly proteins; also enhances caspase-2-induced apoptosis

• Eribulin: inhibits microtubule assembly without affecting disassembly by binding soluble tubulin (causing formation of aggregates) and binding to the growing () end of the microtubule What are common mechanisms of resistance to taxane therapy?

• Alterations in the α- and β-tubulin subunits can decrease the rate of polymerization into microtubules

• Overexpression of the MDR1 gene, which encodes for a membrane P-gp efflux pump

6 I. Traditional Chemotherapy

• Overexpression of βIII-tubulin and microtubule assembly proteins

• Interactions of microtubules with other cytoskeletal proteins

• Defects in apoptotic pathways

What are the common dosing ranges for each taxane?

• Paclitaxel: 50 to 200 mg/m2 intravenous (IV) over 1 to 3 hours or up to 250 mg/m2 IV over 24 hours every 3 weeks

• Nab-paclitaxel: 100 to 125 mg/m2 IV over 30 minutes on days 1, 8, and 15 of 21- to 28-day cycle; 260 mg/m2 IV over 30 minutes every 3 weeks

• Docetaxel: adult: 60 to 100 mg/m2 IV over 1 hour every 3 weeks; pediatric sarcomas: 75 to 125 mg/m2; 30 to 40 mg/m2 IV weekly for 3 weeks every 28 days

• Cabazitaxel: 25 mg/m2 IV over 1 hour every 3 weeks in combination with prednisone (10 mg orally (PO) once daily continuously)

• Ixabepilone: 40 mg/m2 IV over 3 hours every 3 weeks; max body surface area (BSA) 2.2 m2

• Eribulin: 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 every 21 days

What solvents are the taxanes in and why is this important?

• Paclitaxel: Cremophor® EL (use non–polyvinyl chloride [PVC] tubing, bag, and connectors; 0.2 to 1.2 micron in-line filter required)

• Nab-paclitaxel: delivered in an amorphous, nanoparticle form to overcome insolubility in aqueous solutions (no cremophor or polysorbate 80; no special tubing; in-line filter is not recommended)

• Docetaxel: polysorbate 80 (use non-PVC tubing, bag, and connectors; in-line filter not recommended)

• Cabazitaxel: polysorbate 80 (use non-PVC tubing, bag, and connectors; 0.2 to 1.2 micron in-line filter required)

• Ixabepilone: cremophor (use non-PVC bag, tubing, and connectors; 0.2 to 1.2 micron in-line filter)

• Eribulin: does not contain solvents such as cremophor or polysorbate 80 (non-PVC equipment, in-line filter not required)

1. MICROTUBULE INHIBITORS 7



– Cremophor leads to immediate hypersensitivities (monitor patient’s vital signs every 15 minutes during infusion; reactions usually occur within the first 10 minutes of infusion)



– Polysorbate 80 leads to delayed hypersensitivities such as fluid accumulations

Are the taxanes metabolized/eliminated renally or hepatically?

• All four taxanes are extensively metabolized hepatically

• All four taxanes (except eribulin) do not appear to require dose adjustments for renal dysfunction

Are there drug interactions with any of the taxanes?

Taxanes should be administered prior to platinum derivatives to limit myelosuppression and enhance efficacy

• Paclitaxel: affected by CYP3A4 and CYP2C8 inhibitors/inducers, P-gp inhibitors; sequence doxorubicin/epirubicin prior to paclitaxel as paclitaxel can increase the maximum concentration (Cmax) and decrease clearance of these agents resulting in profound neutropenia and stomatitis; sequence paclitaxel prior to cyclophosphamide to reduce myelosuppression

• Nab-paclitaxel: not well characterized; assumed to be similar to paclitaxel

• Docetaxel: affected by CYP3A4 inhibitors/inducers, radiotherapy (radiation recall and radiosensitization); sequence doxorubicin/epirubicin/vinorelbine/topotecan before docetaxel to reduce profound neutropenia

• Cabazitaxel: affected by CYP3A4 inhibitors/inducers

• Ixabepilone: affected by CYP3A4 inhibitors/inducers

• Eribulin: a CYP3A4 inhibitor and weak inhibitor of P-gp; thus will affect substrates of CYP3A4 and P-gp

What are the class adverse effects of the taxanes?

• Infusion reactions

• Myelosuppression

8 I. Traditional Chemotherapy

• Neuropathy

• Alopecia (generally full body)

• Myalgia

• Fatigue

What are the most common adverse effects of each taxane?

• Paclitaxel: myelosuppression (more thrombocytopenia), cardiovascular and hypersensitivity reactions (characterized by hypotension, dyspnea, flushing, and rash), peripheral sensory neuropathy, central nervous system (CNS) effects from dehydrated alcohol, alopecia, skin reactions, bradycardia, and radiation recall

• Nab-paclitaxel: myelosuppression (less thrombocytopenia), peripheral sensory neuropathy (appears more reversible than paclitaxel), alopecia, edema, skin rash, hypersensitivity (rare), and ocular disturbances (blurred vision and photopsia)

• Docetaxel: fluid retention (peripheral edema, generalized edema, pleural effusions, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention due to ascites), myelosuppression (more than paclitaxel), cutaneous reactions, less cardiotoxicity than paclitaxel, peripheral neuropathy, conjunctivitis, lacrimation, stomatitis/mucositis, diarrhea, hepatotoxicity, and myalgias/arthralgias

• Cabazitaxel: myelosuppression, febrile neutropenia, fatigue, urinary tract infections, dehydration, less hypersensitivity reactions, diarrhea, acute renal failure (from diarrhea/dehydration), less peripheral neuropathy, less alopecia, minimal fluid retention, minimal onychodys-trophy

• Ixabepilone: peripheral neuropathy, CNS effects (high concentration of dehydrated alcohol), radiation recall, myelosuppression, less hypersensitivity, constipation, stomatitis/mucositis, anorexia, alopecia, and arthralgias/myalgias

• Eribulin: peripheral neuropathy, myelosuppression, febrile neutropenia, QT prolongation, anorexia, arthralgias/myalgias, decreased liver function, and alopecia

1. MICROTUBULE INHIBITORS 9

What is the difference in the side effect profile between weekly dosing and dosing every 3 weeks of paclitaxel and docetaxel?

Differences in Side Effect Profi le Between Weekly Dosing and Dosing

Every 3 Weeks of Paclitaxel and Docetaxel

Weekly

Every 3 Weeks

Paclitaxel

Nail/skin changes

Myelosuppression

Edema

More alopecia (total body loss)

Neuropathy (but delayed) Myalgia

Generally better tolerated

Continuous infusion: more

myelosuppression, mucositis,

diarrhea, febrile neutropenia,

possibly less neuropathy

Docetaxel Tear duct changes

Myelosuppression

Nail/skin changes

Mucositis

Hand-foot syndrome

Myalgia

What are the premedications required?

Premedications Required for Taxanes

Drug

Premedication

Paclitaxel

Dexamethasone 20 mg IV, diphenhydramine 50 mg IV, and famotidine 20 mg IV

Nab-paclitaxel None required

Docetaxel

1. Dexamethasone (8 mg PO twice daily for 3 days starting 1 day prior to treatment)

2. Prostate cancer: dexamethasone (8 mg PO at 12 hr, 3 hr, and 1 hr prior to the docetaxel infusion) 3. Simplified: 20 mg IV dexamethasone

Cabazitaxel

Dexamethasone 10 mg IV, diphenhydramine 50 mg IV, and famotidine 20 mg IV

Ixabepilone

Diphenhydramine 50 mg IV and famotidine 20 mg IV

Eribulin

None

10 I. Traditional Chemotherapy What is the emetogenicity level of the taxanes?

• All six agents are categorized as low

Are the taxanes vesicants or irritants?

• Paclitaxel: irritant with vesicantlike properties

• Nab-paclitaxel: irritant

• Docetaxel: irritant

• Cabazitaxel: irritant

• Ixabepilone: irritant

• Eribulin: nonvesicant/nonirritant





1. MICROTUBULE INHIBITORS 11

VINCA ALKALOIDS

What are the chemotherapy agents in the vinca alkaloid class?

• Vincristine (Oncovin®)

• Liposomal vincristine (Marqibo®)

• Vinblastine (Velban®)

• Vinorelbine (Navelbine®)

What malignancies are each vinca alkaloid FDA approved for?

FDA-Approved Uses of Vinca Alkaloids

Agent

FDA Approval

Vincristine

Acute lymphoblastic leukemia (ALL),

Hodgkin’s (HL) and non-Hodgkin’s lymphoma

(NHL), Wilms’ tumor, neuroblastoma,

rhabdomyosarcoma

Liposomal vincristine ALL

Vinblastine

HL and NHL, testicular cancer, breast

cancer, Kaposi’s sarcoma, histiocytosis,

choriocarcinoma

Vinorelbine

Non–small cell lung cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the vinca alkaloids work? (See Figure 1.1)

• Derived from the Madagascar periwinkle plant ( Catharanthus roseus)

• Binds to β-tubulin, which prevents polymerization and therefore inhibits microtubule assembly/promotes disassembly (reminder: taxanes prevent the disassembly of microtubules)

• Cell cycle specific to the G2/M phase

• Liposomal vincristine is a sphingomyelin/cholesterol liposome–

encapsulated formulation of vincristine sulfate

12 I. Traditional Chemotherapy What are the common mechanisms of resistance to vinca alkaloid therapy?

• Overexpression of the mdr-1 gene, which encodes for a membrane P-gp efflux pump

• Alterations in the α- and β-tubulin subunits What are the common dosing ranges for each vinca alkaloid?

• Vincristine: 1.4 mg/m2 (capped at 2 mg; exception EPOCH)

• Liposomal vincristine: 2.25 mg/m2 IV over 1 hour once every 7 days (no cap)

• Vinblastine: 4 to 7.4 mg/m2 every 7 to 14 days

• Vinorelbine: 20 to 30 mg/m2 every 7 days Are the vinca alkaloids metabolized/eliminated renally or hepatically?

• All four are extensively metabolized hepatically

• All four vinca alkaloids do not appear to require dose adjustments for renal dysfunction

Are there drug interactions with any of the vinca alkaloids?

• Vincristine and liposomal vincristine: CYP3A4 and P-gp inhibitors/

inducers

• Vinblastine: CYP3A4, CYP2D6, and P-gp inhibitors/inducers

• Vinorelbine: CYP3A4 and CYP2D6 inhibitors/inducers What are the most common adverse effects of each vinca alkaloid?

• Vincristine and liposomal vincristine: constipation, ileus, loss of deep tendon reflex, peripheral neuropathy, jaw pain, syndrome of inappropriate antidiuretic hormone secretion (SIADH)

• Vinblastine: myelosuppression, alopecia, hypertension (due to auto-nomic dysfunction), malaise, SIADH, less peripheral neuropathy

1. MICROTUBULE INHIBITORS 13

• Vinorelbine: myelosuppression, granulocytopenia, peripheral neuropathy, constipation, aspartate transaminase (AST)/alanine transaminase (ALT) elevation, alopecia, SIADH, less peripheral neuropathy than vincristine but more than vinblastine

What is the emetogenicity level of the vinca alkaloids?

• All four agents are categorized as low

Are the vinca alkaloids vesicants or irritants?

• All four are vesicants





2

Alkylating Agents

NITROGEN MUSTARDS

What are the chemotherapy agents in the nitrogen mustard class?

• Mechlorethamine (Mustargen®)

• Cyclophosphamide (Cytoxan®)

• Ifosfamide (Ifex®)

• Bendamustine (Treanda®)

• Chlorambucil (Leukeran®)

• Melphalan (Alkeran®)

What malignancies are each agent FDA approved for?

FDA-Approved Uses of Nitrogen Mustard Alkylating Agents

Agent

FDA Approval

Mechlor-

Chronic lymphocytic leukemia (CLL), chronic ethamine

myeloid leukemia (CML), Hodgkin’s lymphoma (HL), lymphosarcoma, mycosis fungoides, polycythemia vera, squamous cell carcinoma of the bronchus Cyclophos-Acute lymphoblastic leukemia (ALL), acute

phamide

myeloid leukemia (AML), breast cancer, Burkitt’s lymphoma, CLL, CML, HL, malignant histiocytosis, malignant lymphoma—mixed small and large cell, malignant lymphoma—small lymphocytic, mantle cell lymphoma, multiple myeloma (MM), mycosis fungoides, neuroblastoma (disseminated disease), non-Hodgkin’s lymphoma (NHL)

( continued)

16 I. Traditional Chemotherapy FDA-Approved Uses of Nitrogen Mustard Alkylating Agents ( continued ) Agent

FDA Approval

Ifosfamide

Testicular cancer (germ cell tumor)

Bendamustine CLL, NHL (indolent B cell)

Chlorambucil

CLL, HL, mycosis fungoides, NHL

Melphalan

Ovarian cancer (unresectable/palliative), MM

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the nitrogen mustards work?

• Summary: Form cross-links with DNA, inhibiting DNA replication and causing apoptosis

• Nitrogen mustards form reactive, positively charged aziridinium rings by loss of a chloride ion (Figure 2.1). The aziridinium ring then reacts with the nucleophilic centers on DNA (most commonly N-7 of guanine) to form the initial alkylated product. A second aziridinium ring is then formed, which binds to another DNA base, producing a DNA cross-link

• Cyclophosphamide and ifosfamide are prodrugs that are activated to their active metabolites via CYP450 enzymes in the liver

• Bendamustine causes extensive, durable DNA damage due to additional effects on mitotic checkpoints and DNA repair pathways. It is has also been hypothesized that the benzimidazole ring may act as a purine analogue and function as an antimetabolite (Figure 2.2), although this has yet to be proven clinically

• Cross-linking via nitrogen mustards is primarily interstrand

• Cell cycle nonspecific

What are the common mechanisms of resistance to nitrogen mustard therapy?

• Reduced cellular uptake of the drug. Melphalan uptake is dependent on transport via the choline transport system and melphalan is transported via amino acid transport systems. High levels of amino acids, such as leucine, can compete with melphalan for active transport into malignant cells

2. ALKYLATING AGENTS 17

Carboxyphosphamide

or

carboxyifosfamide

CI

Inactive

CI

O

ALDH

metabolite

N

P

O

NH

Aldophosphamide

Cyclophosphamide

4-OH-metabolite

or

O H

aldoifosfamide

O

N

CYP metabolism

P

CI (3A4, 2C9, 2C19, 2B6)

N

CI

Ifosfamide

CYP

Phosphoramide

Acrolein

metabolism

mustard

(3A4/5, 2B6)

Responsible for

Active metabolite

hemorrhagic

cystitis

Chloroacetaldehyde

(Responsible for CNS

toxicity and possibly

nephrotoxicity)

DNA cross-linking

FIGURE 2.1. Cyclophosphamide and ifosfamide metabolic pathway:

Both cyclophosphamide and ifosfamide act as prodrugs and are metabolized via CYP enzymes to a 4-OH-metabolite. This exists as a tautomer with the aldophosphamide form. The aldophosphamide metabolite either is metabolized via aldehyde dehydrogenase (ALDH) to the inactive carboxy metabolites or undergoes spontaneous breakdown in cells to the active metabolite phosphoramide mustard and the acrolein metabolite, which is responsible for hemorrhagic cystitis. Mercaptoethane sulfonate (mesna) is used to inactivate the acrolein metabolite and prevent bladder irritation and hemorrhagic cystitis. Of note, CYP enzymes also convert cyclophosphamide and ifosfamide to the chloroacetaldehyde metabolite, which is thought to be responsible for central nervous system (CNS) toxicity as well as potential nephrotoxicity.

• Inactivation of alkylating agents via increased expression of glutathione and glutathione S-transferase

• Increased expression of aldehyde dehydrogenase (ALDH) within malignant cells may increase the conversion of cyclophosphamide and ifosfamide to inactive carboxy metabolites (Figure 2.1 )

• Enhanced DNA repair pathways including nucleotide excision repair (NER) and homologous recombination repair

• Defective cell checkpoint function and apoptotic pathways in response to DNA damage

18 I. Traditional Chemotherapy Nitrogen mustard general

Purine nucleotide general

structure

structure

H

CI

CI

N

N

N

N

R

N

O

CH3

OH

N

CI

N

N

Bendamustine

CI

FIGURE 2.2. Bendamustine structure: Bendamustine contains a mechlorethamine group that is responsible for its nitrogen mustard alkylating agent activity as well as a benzimidazole ring that mimics the structure of purine analogues, and has been theorized to act as an antimetabolite.



– Loss of mismatch repair (MMR) proteins, which initiate apoptosis



– Loss of normal p53 function



– Upregulation of antiapoptotic proteins (eg, BCL-2, BCL-X ) L

What are the common dosing ranges for each nitrogen mustard?

• Mechlorethamine: 6 mg/m2 intravenous (IV) on days 1 and 8 q28

days (MOPP regimen for Hodgkin’s lymphoma [HL])

• Cyclophosphamide: Wide range of dosing, see common examples in the following text



– CyBORD (multiple myeloma [MM]): 300 mg/m2 orally (PO) days 1, 8, 15, and 22 of a 28-day cycle



– AC (breast cancer): 600 mg/m2 IV day 1 q21 days

2. ALKYLATING AGENTS 19



– CHOP (lymphoma): 750 mg/m2 IV day 1 q21 days



– CALGB8811 (acute lymphoblastic leukemia [ALL]): 1,200 mg/m2 IV

day 1 of a 28-day cycle



– HyperCVAD (ALL, lymphoma): 300 mg/m2 IV q12h days 1 to 3

• Ifosfamide:



– ICE (lymphoma): 5 g/m2 IV continuous infusion day 2 of a 14- to 21-day cycle



– Sarcoma, lymphoma, testicular (several different regimens): 1 to 3

g/m2 IV 3 to 5 days

• Bendamustine: 70 to 120 mg/m2 days 1 and 2 of a 21- to 28-day cycle

• Chlorambucil: 0.1 to 0.2 mg/kg PO daily 3 to 6 weeks; larger doses may be given less frequently (ex: 0.5 mg/kg PO every 2 weeks)

• Melphalan:



– MM (with prednisone): 4 to 6 mg/m2/day for 7 days every 4 weeks



– MM (conditioning for autologous stem cell transplant): 140 to 200

mg/m2 IV 1

Are nitrogen mustards metabolized/eliminated renally or hepatically?

• Cyclophosphamide and ifosfamide are prodrugs, which are metabolized via CYP450 enzymes (2B6, 2C9, 2C19, 3A4) to active metabolites.

Both drugs are eliminated renally (mostly as metabolites, including active metabolites and the acrolein metabolite responsible for hemorrhagic cystitis)



– Hepatic dysfunction may decrease production of active phosphoramide mustard metabolites, potentially decreasing efficacy



– Ifosfamide requires dosage adjustment for renal dysfunction; cyclophosphamide may be used safely in cases of renal dysfunction, although caution should be exercised in patients with severe renal impairment

• Chlorambucil and bendamustine are metabolized hepatically.

Bendamustine possesses two active metabolites (formed via CYP1A2

metabolism), although metabolite concentrations are significantly lower in plasma than parent drug, indicating only a minor contribu-tion to the cytotoxic activity of bendamustine

20 I. Traditional Chemotherapy

• Melphalan undergoes chemical hydrolysis. A small component is eliminated unchanged in urine; thus, in high doses, dosage adjustment may be required for renal impairment

• Mechlorethamine undergoes rapid inactivation in the plasma via hydrolysis

Are there drug interactions with any of the nitrogen mustards?

• Cyclophosphamide/ifosfamide: CYP450 inducers (eg, carbamazepine, phenytoin, rifampin) may increase the production of active metabolites and enhance toxicity. CYP450 inhibitors (eg, azole antifungals, amiodarone, clarithromycin) may decrease the production of active metabolites and compromise efficacy.

• Use of aprepitant/fosaprepitant: may enhance the risk of neurotoxicity with ifosfamide via CYP induction. Because aprepitant and fosaprepitant are also CYP inhibitors, efficacy of cyclophosphamide/ifosfamide may also be compromised.

• Bendamustine: allopurinol may increase the risk of skin reactions with bendamustine, including rash, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Inhibitors or inducers of CYP1A2 will alter the production of active minor metabolites of bendamustine. The clinical impact of this interaction is unknown.

What are the class adverse effects of the nitrogen mustards?

• Myelosuppression

• Nausea/vomiting

• Infertility (depends on dose and agent used)

• Mucositis

• Secondary malignancies:



– Treatment-related acute myeloid leukemia (AML) is typically associated with deletions in chromosome 5 or 7 and usually occurs 4 to 7 years after exposure

What unique side effects are present with each nitrogen mustard?

• Cyclophosphamide:



– Hemorrhagic cystitis (more common with higher doses)

2. ALKYLATING AGENTS 21



– Syndrome of inappropriate antidiuretic hormone (SIADH; more common with higher doses)



– Cardiotoxicity (serious hemorrhagic myocarditis, which is infrequent and seen at higher doses for stem cell transplant)

• Ifosfamide:



– Neurotoxicity/encephalopathy (wide spectrum of signs and symptoms, including sedation, confusion, hallucinations, cerebellar symptoms, seizures, and coma)



– Hemorrhagic cystitis (more common than cyclophosphamide at equivalent doses)



– Renal impairment

• Bendamustine and chlorambucil: skin rashes, hypersensitivity reactions

• Melphalan:



– Mucositis with high doses (conditioning for autologous stem cell transplant; can use ice chips during infusion to lower the risk of severe mucositis)



– SIADH

What are the premedications required?

• Cyclophosphamide/ifosfamide: mercaptoethane sulfonate (mesna)—

dose varies depending on regimen



– Continuous infusion (typically 100% of ifosfamide/cyclophosphamide dose)



– Intermittent dosing (60%–100% of ifosfamide/cyclophosphamide dose given with/prior to dose, and 4 and 8 hours after dose)



– When using oral mesna, dose should be doubled to account for approximately 50% bioavailability

What is the emetogenicity level of the nitrogen mustards?

• High: cyclophosphamide (1,500 mg/m2), mechlorethamine

• Moderate: cyclophosphamide (1,500 mg/m2), ifosfamide, melphalan, bendamustine

• Minimal: chlorambucil

22 I. Traditional Chemotherapy Are the nitrogen mustards vesicants or irritants?

• Vesicant: mechlorethamine

• Irritant: bendamustine, melphalan, ifosfamide





2. ALKYLATING AGENTS 23

NON-NITROGEN MUSTARDS

What are the chemotherapy agents in the non-nitrogen mustard alkylating agent class?

Alkyl alkane sulfonates

• Busulfan (Busulfex®, Myleran®)

Nitrosoureas

• Carmustine (BCNU, BiCNU®, Gliadel®)

• Lomustine (CCNU, CeeNU®)

• Streptozocin (Zanosar®)

Aziridines

• Altretamine (Hexalen®)

• Thiotepa (Tepadina®)

Methylating agents

• Dacarbazine (DTIC-Dome®)

• Procarbazine (Matulane®)

• Temozolomide (Temodar®)

What malignancies are each agent FDA approved for?

FDA-Approved Uses of Non-Nitrogen Mustard Alkylating Agents

Agent

FDA Approval

Busulfan

Chronic myeloid leukemia (CML)

Carmustine

Brain tumors, multiple myeloma, Hodgkin’s

lymphoma (HL; relapsed/refractory), non-

Hodgkin’s lymphomas (NHL; relapsed/refractory) Lomustine

Brain tumors, HL (relapsed/refractory)

Streptozocin

Metastatic islet cell carcinoma of the pancreas Altretamine

Ovarian cancer (persistent/recurrent)

( continued)

24 I. Traditional Chemotherapy FDA-Approved Uses of Non-Nitrogen Mustard Alkylating Agents ( continued )

Agent

FDA Approval

Thiotepa

Bladder cancer, breast cancer, ovarian cancer, intracavitary effusions due to metastatic tumors Dacarbazine

Malignant melanoma, HL

Procarbazine

HL

Temozolomide

Anaplastic astrocytoma (refractory), glioblastoma multiforme (newly diagnosed)

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the alkylating agents work?

• Summary: form cross-links with DNA, inhibiting DNA replication and causing apoptosis

• Alkylating agents form reactive intermediates that react with nucleophilic centers on DNA (most commonly N-7 of guanine) but also may bind to proteins, amino acids, and nucleotides

• Alkylating agents with two reactive groups (bifunctional alkylating agents) form DNA cross-links



– Streptozocin is a nitrosourea that contains a glucose moiety, which may explain its selectivity toward pancreatic beta cells

• Methylating agents (procarbazine, dacarbazine, temozolomide) transfer a single methyl group to DNA bases



– Procarbazine and dacarbazine primarily create O-6 methylguanine adducts. Temozolomide primarily methylates N–7 of guanine; adducts to the O-6 of guanine are critical for cytotoxicity



– Procarbazine and dacarbazine are metabolized in the liver to active metabolites. Temozolomide spontaneously converts to its active metabolite [3-methyl-(triazen-1-yl)imidazole-4-carboxamide—MTIC]

in aqueous solution

• DNA cross-linking and alkylation inhibits DNA synthesis. Attempts at repair of DNA alkylation and cross-linking lead to DNA strand breakage

• Cell cycle checkpoint proteins recognize the DNA damage, halt cell cycle progression, and initiate apoptosis

2. ALKYLATING AGENTS 25

• Cross-linking with bifunctional alkylating agents is primarily interstrand

• Cell cycle nonspecific

What are the common mechanisms of resistance to alkylating agent therapy?

• Inactivation of alkylating agents via increased expression of glutathione and glutathione S-transferase

• Enhanced DNA repair pathways, including base excision repair, enzymes that catalyze the removal of alkyl groups from guanine bases (alkylguanine-O6-alkyltransferase [AGT], encoded by the O6-methylguanine methyltransferase [MGMT] gene), NER, and homologous recombination repair



– Lower AGT levels due to methylation of the promoter region of the MGMT gene lead to enhanced sensitivity of tumors to alkylating agents (eg, improved survival of glioblastoma patients with methylated MGMT promoters receiving temozolomide and radiation therapy)



– AGT is the primary mechanism of resistance to the methylating agents temozolomide, procarbazine, and dacarbazine, and this enzyme contributes resistance to lomustine and carmustine as well

• Defective cell checkpoint function and apoptotic pathways in response to DNA damage



– Induction of the Akt signaling pathway, which inhibits apoptotic pathways



– Loss of MMR proteins, which initiate apoptosis



– Loss of normal p53 function



– Upregulation of antiapoptotic proteins (eg, BCL-2, BCL-X ) L

What are the common dosing ranges for each alkylating agent?

• Busulfan:



– 3.2 to 4 mg/kg/day IV (may be given in divided dosing) 2 to 4

days (bone marrow transplant [BMT] conditioning)



– 1 to 8 mg/day PO (chronic myeloid leukemia [CML], essential thrombocythemia [ET], polycythemia vera [PV])

26 I. Traditional Chemotherapy

• Carmustine:



– 150 to 200 mg/m2 IV q6–8 weeks (may be given over 2 days)



– Autologous hematopoietic stem cell transplantation (HSCT): 300 to 600 mg/m2 prior to transplant (eg, BEAM, CBV regimens)



– Glioblastoma multiforme: Up to eight wafers (61.6 mg) in resection cavity

• Lomustine: 100 to 130 mg/m2 PO 1 q6 weeks

• Streptozocin:



– 500 mg/m2/day 5 days q6 weeks



– 1,000 to 1,500 mg/m2 once weekly

• Altretamine:



– 260 mg/m2 daily in four divided doses 14 to 21 days of a 28-day cycle

• Thiotepa:



– BMT conditioning: 250 mg/m2/day 3 days or 150 mg/m2 q12h 6 doses



– Ovarian/breast cancer: 0.3 to 0.4 mg/kg q1–4 weeks



– Intravesicular: 60 mg in 30 to 60 mL normal saline (NS) retained for 2 hours weekly 4 weeks



– Intrathecal (leptomeningeal metastases): 10 mg twice a week (days 1 and 4) 8 weeks

• Dacarbazine:



– ABVD: 375 mg/m2 days 1 and 15 q28 days



– Metastatic melanoma: 250 mg/m2/dose days 1 to 5 q3 weeks or 1,000 mg/m2 IV every 3 to 4 weeks

• Procarbazine: 60 to 100 mg/m2 PO 7 to 14 days

• Temozolomide:



– Glioblastoma (newly diagnosed, concomitant radiotherapy): 75 mg/m2 PO daily 42 days



– 150 mg/m2 PO daily 5 days every 28 days (increase to 200 mg/m2

next cycle if nadir blood counts acceptable)

2. ALKYLATING AGENTS 27

Are alkylating agents metabolized/eliminated renally or hepatically?

• Busulfan: Extensively hepatically metabolized; dose adjust for hepatic dysfunction

• Carmustine: Metabolized hepatically to active metabolites and excreted in the urine; dose adjust for renal dysfunction and severe hepatic dysfunction

• Lomustine: Metabolized hepatically to active metabolites and excreted in the urine; dose adjust for renal dysfunction and severe hepatic dysfunction

• Streptozocin: Metabolized hepatically and excreted in the urine; dose adjust for renal dysfunction and severe hepatic dysfunction

• Altretamine: Metabolized hepatically to active metabolites and excreted in the urine; dose adjust for renal dysfunction and severe hepatic dysfunction

• Thiotepa: Metabolized hepatically to active and inactive metabolites and excreted in the urine; dose adjust for renal and severe hepatic dysfunction

• Dacarbazine: Hepatically metabolized to active metabolites and excreted in the urine; dose adjust for renal dysfunction and/or severe hepatic dysfunction

• Procarbazine: Hepatically oxidized to active metabolites (further metabolized to inactive metabolites); dose adjust for hepatic dysfunction

• Temozolomide: Eliminated renally; dose adjust for severe renal dysfunction

Are there drug interactions with any of the alkylating agents?

• Procarbazine inhibits monoamine oxidase (MAO); avoid tyramine-containing foods, sympathomimetics (eg, dopamine), tricyclic an-tidepressants, other serotonin and norepinephrine concentration modifying drugs (selective serotonin reuptake inhibitors [SSRIs], serotonin– norepinephrine reuptake inhibitors [SNRIs], linezolid), and other MAO inhibitors to prevent risk of hypertensive crisis and serotonin syndrome

28 I. Traditional Chemotherapy

• Procarbazine may produce a disulfiram-like reaction when taken with alcohol

• Procarbazine/dacarbazine: Metabolized via CYP enzymes to active metabolite. CYP450 inducers (eg, carbamazepine, phenytoin, rifampin) may increase the production of active metabolites and enhance toxicity.

CYP450 inhibitors (eg, azole antifungals, amiodarone, clarithromycin) may decrease the production of active metabolites and compromise efficacy

• Busulfan is metabolized primarily by conjugation via glutathione S-transferase and partially via CYP450 metabolism. Interactions resulting in increased busulfan concentrations have been reported with azole antifungals (itraconazole), acetaminophen, metronidazole, phenytoin, and phenytoin. Phenytoin concentrations should also be monitored in patients receiving busulfan, as reductions in phenytoin levels have been observed

– Although the IV formulation has improved delivery of busulfan, due to variability in busulfan pharmacokinetics, first-dose therapeutic drug monitoring may be useful in select patients

• Cimetidine has been reported to enhance myelosuppression due to carmustine and lomustine (mechanism unknown)

• Altretamine used in combination with MAO inhibitors increases the risk of severe orthostatic hypotension

What are the class adverse effects of the alkylating agents?

• Myelosuppression

• Nausea/vomiting

• Infertility (depends on dose and agent used)

• Secondary malignancies



– Treatment-related AML is typically associated with deletions in chromosome 5 or 7 and usually occurs 4 to 7 years after exposure What unique side effects are present with each alkylating agent?

• Procarbazine: hemolysis (in G6PD-deficient patients), neurotoxicity (central nervous system [CNS] depression—avoid other CNS-depressing agents—dizziness, drowsiness, confusion), hypersensitivity reactions (rash, pneumonitis [rarely])

2. ALKYLATING AGENTS 29

• Dacarbazine: flulike syndrome (fevers, chills, myalgias for several days after therapy), photosensitivity

• Temozolomide: myelosuppression (primarily lymphopenia—prophylaxis for Pneumocystis pneumonia (PCP) should be initiated for those receiving concomitant temozolomide and radiation therapy and in those who become lymphopenic)

• Busulfan: mucositis, skin hyperpigmentation and rash, alopecia, pulmonary fibrosis (“busulfan lung”), hepatotoxicity (veno-occlusive disease [VOD]), neurotoxicity (CNS depression, anxiety, headache, confusion, dizziness, seizures; use prophylactic anticonvulsants when using for BMT conditioning)

• Carmustine: mucositis, pulmonary fibrosis (risk increases at cumulative doses 1,400 mg/m2), hepatotoxicity (VOD), neurotoxicity (ataxia, dizziness, headache), alcohol intoxication with high doses (formulated with ethanol), facial flushing, skin irritation and injection site pain, hypotension (infuse over 2 hours to minimize injection site pain, flushing, and hypotension), skin hyperpigmentation and pain (after skin contact), alopecia

• Lomustine: pulmonary fibrosis (uncommon at doses 1,100 mg/m2), neurotoxicity (confusion, ataxia, lethargy, disorientation), nephrotoxicity

• Streptozocin: hyperglycemia/glucose intolerance (due to pancreatic beta cell toxicity), nephrotoxicity, pain/irritation at injection site, liver function test (LFT) elevations (usually transient)

• Altretamine: peripheral sensory neuropathy, neurotoxicity (mood disturbances, somnolence, agitation, depression, dizziness)

• Thiotepa: mucositis, alopecia, dermatologic changes (dermatitis, erythema, pruritus, pigmentation changes), hepatotoxicity (VOD), neurotoxicity (dizziness, headache, seizures, confusion), hypersensitivity reactions, pneumonitis

What are the premedications required?

• Busulfan: prophylactic anticonvulsants should be utilized with BMT

(seizures usually occur during administration or within 24 to 48 hours after the last dose)

• All other non-nitrogen mustard alkylating agents do not require premedications

30 I. Traditional Chemotherapy What is the emetogenicity level of the alkylating agents?

• High: procarbazine, dacarbazine, carmustine (250 mg/m2), streptozocin, altretamine, thiotepa (300 mg/m2 in children)

• Moderate: temozolomide, busulfan, carmustine (250 mg/m2), lomustine, thiotepa (adults; 300 mg/m2 in children) Are the alkylating agents vesicants or irritants?

• Dacarbazine, busulfan, carmustine, and streptozocin are irritants

• All other agents are neither vesicants nor irritants





2. ALKYLATING AGENTS 31

PLATINUMS

What are the chemotherapy agents in the platinum class?

• Cisplatin (Platinol®)

• Carboplatin (Paraplatin®)

• Oxaliplatin (Eloxatin®)

What malignancies are each platinum FDA approved for?

FDA-Approved Uses of Platinum Alkylating Agents

Agent

FDA Approval

Cisplatin

Advanced bladder cancer, metastatic

testicular cancer, metastatic ovarian cancer Carboplatin

Advanced ovarian cancer

Oxaliplatin

Stage III colon cancer, advanced colorectal cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the platinums work? (See Figure 2.3)

• Form cross-links between purine nucleosides (guanine and adenine) of DNA (~95% intrastrand), causing DNA kinking, interference with normal DNA function, and ultimately cell death

• Cross-linking of DNA triggers DNA repair via the NER pathway and double-strand break repair process. When DNA cross-links are not effectively repaired, cell death occurs

• May also bind RNA and various cellular proteins; however, majority of cytotoxicity thought to be related to DNA intrastrand cross-links

• Binding to nuclear and cytoplasmic proteins may result in cytotoxic effects

• Synergistic with radiation (a radiosensitizer) and other DNA-damaging agents

• Cell cycle–nonspecific agent



32 I. Traditional Chemotherapy

Carrier group Platinum core Leaving group

NH

Cl

2

Cisplatin

Pt

NH2

Cl

O

O

NH2

Pt

Carboplatin

Pt

NH2

O

Carrier group

O

H

O

O

N

Oxaliplatin

Pt

N

H

O

O

Cross-links by platinum

analogues cause DNA kinking

FIGURE 2.3. Platinum structure and mechanism of action.

What are the common mechanisms of resistance to platinum therapy?

• Increased activity of DNA repair pathways (eg, NER)

• Inactivation of drug by binding to sulfhydryl groups on cytosolic proteins (eg, glutathione)

• Reduced uptake into or active efflux out of cells via copper transport pathways (CTR1, ATP7A, ATP7B)

• Decreased apoptosis in response to DNA damage



– Loss of MMR proteins, which initiate apoptosis What are the common dosing ranges for each platinum?

• Cisplatin: 50 to 100 mg/m2 every 3 to 4 weeks

• Carboplatin: Use Calvert equation to calculate dose (usual area under the curve [AUC] 5–6). If estimating glomerular filtration rate (GFR), FDA recommends considering capping GFR at 125 mL/min



– Dose = Target AUC (GFR 25)

• Oxaliplatin: 85 to 130 mg/m2 every 2 to 3 weeks

2. ALKYLATING AGENTS 33

Are the platinums metabolized/eliminated renally or hepatically?

• Platinums are eliminated via the kidney and require dose adjustments



– Carboplatin is dosed via GFR and the Calvert equation

• Platinums do not require dosage adjustment for hepatic dysfunction Are there drug interactions with the platinums?

Platinums should be administered after taxane derivatives to limit myelosuppression and enhance efficacy

• Cisplatin/carboplatin—concomitant nephrotoxic drugs, IV thiosulfates may inactivate drug, phenytoin, lithium (due to cation wasting with nephrotoxicity)

• Oxaliplatin—synergistic with 5-fluorouracil (5-FU), must be prepared in dextrose solutions (other platinums are stabilized by NS) What are the class adverse effects of the platinums?

• Nephrotoxicity—cisplatin carboplatin oxaliplatin

• Nausea/vomiting—cisplatin carboplatin/oxaliplatin

• Neuropathy

• Myelosuppression—carboplatin cisplatin oxaliplatin

• Acute hypersensitivity (usually occurs after 6th–8th exposure to the drug)

What are the most common adverse effects of each platinum?

• Cisplatin—Nausea/vomiting (highly emetogenic), nephrotoxicity with cation wasting (hypomagnesemia, hypokalemia, hypocalcemia), myelosuppression (more thrombocytopenia), ototoxicity (high tone loss), peripheral neuropathy, hypersensitivity

• Carboplatin—Myelosuppression (more thrombocytopenia and neutropenia), nausea/vomiting (moderate), nephrotoxicity, peripheral neuropathy, hypersensitivity

34 I. Traditional Chemotherapy

• Oxaliplatin—Acute neuropathy (usually within 7 days) commonly triggered by cold exposure (patients should avoid cold beverages/

foods to prevent laryngopharyngeal dysesthesia), cumulative and chronic neuropathy, nausea/vomiting (moderate), myelosuppression (less than other platinums—likely related to concomitant 5-FU use), and hepatotoxicity

What are the premedications required?

• Premedications (other than antiemetics) are generally not required for platinum derivatives

• Prior to cisplatin administration, hydration with 1 to 2 L of fluid is recommended; adequate hydration should be maintained for 24 hours after administration

• Do not give ice chips or cold beverages/foods during (or within 7 days) of oxaliplatin infusion

What is the emetogenicity level of the platinums?

• Cisplatin—high

• Carboplatin/oxaliplatin—moderate

Are the platinums vesicants or irritants?

• Platinums are classified as irritants





2. ALKYLATING AGENTS 35

ANTITUMOR ANTIBIOTICS

What are the chemotherapy agents in this class?

• Bleomycin (Blenoxane®)

• Dactinomycin (Cosmegen®, actinomycin D)

• Mitomycin C (Mutamycin®, MMC)— Streptomyces caespitosus What malignancies are the antitumor antibiotics FDA approved for?

FDA-Approved Uses of Antitumor Antibiotics

Agent

FDA Approval

Bleomycin

Head and neck cancers, Hodgkin’s lymphoma,

malignant pleural effusions, testicular and other germ cell tumors

Dactinomycin

Choriocarcinoma, pediatric sarcomas, Wilms’

tumor, neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma

Mitomycin

Anal carcinomas and bladder instillation in bladder cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the antitumor antibiotics work?

• Bleomycin: A peptide

2



– Generates free radicals by binding to Fe, causing single and double DNA strand breaks



Oxygen binds to iron leading to the formation of Fe(II)-

bleomycin-O 2

The complex binds in the minor groove to guanosine-cytosine–

rich portions of DNA by forming an “S” tripeptide and partial intercalation of the bithiazole rings. This will stabilize the Fe(II)-

bleomycin-O complex. In the absence of DNA, the complex will 2

self-destruct

36 I. Traditional Chemotherapy Reactive oxygen species (ROS) will cause double and single DNA strand breaks

Inhibits RNA and protein synthesis to a lesser degree

• Dactinomycin

– Intercalation of double-stranded DNA by chromophore of dactinomycin, inserts between the guanine-cytidine base pairs



– Binds to single-stranded DNA, prevents reannealing of DNA, and stabilizes unusual hairpins resulting in inhibition of transcription

• Mitomycin



– Forms DNA adducts by cross-linking complementary double-stranded and single-stranded DNA (alkylator) → inhibits DNA replication

Binds different parts of guanine depending on the way it formed a ROS



– Anaerobic: Undergoes reduction reaction to form reactive unstable intermediates, which forms a covalent monoadduct with DNA



– Aerobic: DT-diaphorase (DTD) enzyme and nicotinamide adenine dinucleotide phosphate (NADPH) metabolize MMC to reactive cytotoxic species (prodrug)

What are common mechanisms of resistance to each agent?

• Bleomycin: bleomycin hydrolase enzyme hydrolyzes terminal amine, inhibiting the iron-binding capacity (and cytotoxic activity) of the drug



– Enzyme protects normal tissue, but is in low concentration in the skin and lungs

• Dactinomycin: efflux by P170 glycoprotein pump encoded by the MDR gene

• Mitomycin: loss of MMC activation capacity, increased DNA repair mechanisms, P170 efflux pump

What are the common dosing ranges for each agent?

• Bleomycin



– HL

2. ALKYLATING AGENTS 37

ABVD: 10 units/m2 on days 1 and 15 of each 28-day cycle BEACOPP: 10 units/m2 on day 8 of each 21-day cycle Stanford 5: 5 units/m2 weeks 2, 4, 6, 8, 10, and 12



– Testicular cancer and other germ cell tumors, BEP: 30 units/week 12 doses



– Intrapleural or intraperitoneal injections for malignant effusions to breast, lung, and ovarian cancers: 60 units/m2 in 50 to 100 mL of NS

• Dactinomycin



– Pediatric dosing: 12 to 15 mcg/kg/day 5 days each cycle



– Adult dosing: 300 to 600 mcg/m2/day 5 days each cycle

• Mitomycin



– Stomach and pancreas adenocarcinoma: 20 mg/m2 every 6 to 8 weeks



– Anal carcinoma: 10 mg/m2 every 4 weeks



– Intravesicular instillation for bladder cancer: 40-mg dose 1 or 20 mg weekly 6 weeks, then monthly for 3 years Are the agents metabolized/eliminated renally or hepatically?

• Bleomycin: renal

• Dactinomycin: renal and biliary

• Mitomycin: hepatic metabolism, renal elimination Are there drug interactions with any of the agents?

• Bleomycin

a. Will form complexes with copper, cobalt, iron, zinc, and manganese b. Cisplatin decreases bleomycin clearance c. Radiation therapy produces additive free radical damage to DNA resulting in additive pulmonary toxicity

d. Brentuximab and filgrastim/pegfilgrastim can increase lung toxicity when given with bleomycin

• Dactinomycin: radiosensitizer

• Mitomycin: radiosensitizer

38 I. Traditional Chemotherapy What are the adverse effects of each agent?

• Bleomycin: Thrombophlebitis, rash, blisters, hyperkeratosis, hyperpigmentation, fevers, hypersensitivities (chills, fever, anaphylaxis; test dose not predictive), pulmonary dysfunction (pneumonitis, fibrosis), Raynaud’s disease, very low likelihood for myelosuppression a. Pulmonary fibrosis (dose-limiting toxicity [DLT], cumulative above 400 units)

i. Develops slowly; usually presents as pneumonitis with cough, dyspnea, dry inspiratory crackles, and chest x-ray infiltrates ii. Causes direct inflammatory response, epithelial apoptosis, and progressive deposition of collagen over 1 to 2 weeks → pulmonary fibrosis

iii. Increased risk with age 70 (40 for germ cell tumor patients), underlying pulmonary dysfunction, or chest radiation therapy, decreased renal function, growth factors (filgrastim/pegfilgrastim), single doses 25 units/m2

iv. Due to lack of bleomycin hydrolase in lung v. Associated with single high doses versus smaller daily doses

• Dactinomycin: Myelosuppression (DLT), nausea/vomiting, diarrhea, alopecia, rare VOD, radiation recall, interstitial pneumonitis

• Mitomycin: Gastrointestinal (GI) side effects are mild and infrequent, hemolytic uremic syndrome, interstitial pneumonitis, cardiomyopathy, rare VOD

a. Myelosuppression

i. Common with low daily doses, less common with boluses every 4 to 8 weeks

ii. Rare 50 mg/m2; at higher doses, thrombocytopenia is more common than anemia and leukocytopenia

What are the premedications required?

• Bleomycin: some investigators advocate for test doses for lymphoma patients due to rare instances of allergic reactions

• Antiemetics

2. ALKYLATING AGENTS 39

What is the emetogenicity level of the antitumor antibiotics?

• Bleomycin: minimal

• Dactinomycin: moderate

• Mitomycin: low

Are the antitumor antibiotics vesicants or irritants?

• Bleomycin: nonvesicant, nonirritant

• Dactinomycin: vesicant—requires cold compress

• Mitomycin: vesicant—requires cold compress and dimethyl sulfoxide (DMSO)





3

Enzyme Inhibitors—Topoisomerase I

Inhibitors

CAMPTOTHECANS

What are the chemotherapy agents in the topoisomerase I inhibitor class?

• Irinotecan (Camptosar®) and topotecan (Hycamtin®) What malignancies are the topoisomerase I inhibitors approved for by the U.S. Food and Drug Administration (FDA)?

FDA-Approved Uses of Topoisomerase I Inhibitors

Agent

FDA Approval

Irinotecan

Metastatic colorectal cancer

Topotecan

Cervical cancer, metastatic ovarian cancer, small cell lung cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the topoisomerase I inhibitors work?

• Topoisomerase I is an enzyme that relieves tension and supercoil-ing of DNA by binding to DNA and creating transient single-strand breaks, forming what is known as the cleavable complex

• Topoisomerase I inhibitors bind to the enzyme and stabilize the normally transient cleavable complex and prevent religation of DNA

42 I. Traditional Chemotherapy

• Collision of the DNA replication fork with the cleavable complex prevents DNA replication and produces DNA strand breaks, leading to apoptosis. Accumulation of supercoils ahead of the replication fork also contributes to cytotoxicity

• Irinotecan is a prodrug that must be converted to its active metabolite, SN-38, via a carboxylesterase enzyme (Figure 3.1)

• Cell cycle phase specific (S phase)

What are the common mechanisms of resistance to topoisomerase inhibitors?

• Point mutations in topoisomerase I that prevent camptothecin binding

• Alterations in carboxylesterase enzyme concentrations may reduce activation of irinotecan to its active metabolite, SN38 (Figure 3.1)

• Decreased expression of topoisomerase I within tumor cells

• Active efflux and reduced accumulation in tumor cells secondary to active transport mechanisms (P-glycoprotein [P-gp], organic anion-transporting polypeptides [OATPs])

• Altered intracellular localization of topoisomerase I (nucleolus vs.

nucleus/cytoplasm), reducing its interaction with DNA and subsequent cellular cytotoxicity in the presence of camptothecins

• Reduced cell death in response to camptothecin/topoisomerase I/

DNA complex formation secondary to alterations in DNA damage checkpoint and apoptotic pathways (eg, ERK, BCL-2, Chk-1/Chk-2, MAPK) What are the common dosing ranges for the topoisomerase I inhibitors?

• Irinotecan (several dosing strategies exist, the most common are in the following text)

• 65 to 125 mg/m2 intravenous (IV) weekly 4 weeks (6-week cycle)

• 165 to 180 mg/m2 IV every 2 weeks (FOLFIRINOX)

• 250 to 350 mg/m2 IV every 3 weeks

• Topotecan



– 0.75 to 1.5 mg/m2 IV 3 to 5 days every 21 days

3. ENZYME INHIBITORS—TOPOISOMERASE I INHIBITORS 43

APC

Irinotecan

metabolite

CYP3A4

Carboxylesterases

SN-38

Active

metabolite

UGT1A1

SN-38G

Biliary

Mucosal

excretion

injury

Bacterial

SN-38

glucuronidases

SN-38G

Elimination

FIGURE 3.1. Irinotecan metabolism and elimination: Irinotecan is converted via carboxylesterases (primarily carboxylesterase 2 in humans) to an active metabolite, SN-38. It also undergoes hepatic oxidation, primarily via CYP3A4, to a 100-fold less-active metabolite, APC. The SN-38 metabolite is responsible for the majority of cytotoxicity of irinotecan. This agent undergoes glucuronidation via several UGT1A isoforms, with UGT1A1 being the most predominant. Polymorphisms exist in the UGT1A1 enzyme, and patients with UGT1A1*28 alleles have reduced glucuronidation of active SN-38 and are at increased risk for irinotecan toxicities (neutropenia and diarrhea). SN-38G is excreted via the biliary route. Bacterial glucuronidases in the gastrointestinal (GI) tract convert SN-38G back to the active SN-38, and this may be responsible for the late-onset diarrhea of irinotecan. Several studies have utilized cephalosporin prophylaxis to reduce bacterial conversion of SN-38G to active SN-38 to reduce diarrhea and improve compliance, primarily in pediatric patients.

44 I. Traditional Chemotherapy



– 2.3 mg/m2 orally (PO) 5 days every 21 days



– 4 mg/m2 days 1, 8, and 15 every 28 days

Are the topoisomerase I inhibitors metabolized/eliminated renally or hepatically?

• Irinotecan—Primarily eliminated hepatically (Figure 3.1) and excreted via biliary routes; dose adjust for hepatic dysfunction



– Patients homozygous for the UGT1A1*28 allele are at higher risk for severe neutropenia and may require reduced initial doses of irinotecan

• Topotecan—Primarily renally eliminated (undergoes glucuronidation and minor hepatic metabolism) and requires dose adjustment for moderate/severe renal impairment

Are there drug interactions with any of the topoisomerase I inhibitors?

• Irinotecan—valproic acid (reports of increased/decreased SN-38

concentrations), drugs that interfere with glucuronidation via UGT1A1

(inhibitors decrease SN-38 concentrations/ efficacy, inducers increase SN-38 concentrations/toxicity), drugs that affect CYP3A4

• Topotecan—P-gp inhibitors/inducers

What are the class adverse effects of the topoisomerase I inhibitors?

• Myelosuppression (neutropenia predominates), alopecia, mucositis What are the most common adverse effects of each topoisomerase I inhibitor?

• Irinotecan—early-onset diarrhea (during infusion or within first 12–24 hours), associated with flushing, diaphoresis, and cramping (due to inhibition of acetylcholinesterase activity by irinotecan; treat with atropine), late-onset diarrhea ( manage with antidiarrheals; consider cephalosporin use—see Figure 3.1), myelosuppression (primarily neutropenia, less common with weekly administration), nausea/vomiting, increased liver function tests (LFTs), fatigue

3. ENZYME INHIBITORS—TOPOISOMERASE I INHIBITORS 45

• Topotecan—late-onset diarrhea (does not produce cholinergic reaction like irinotecan), mucositis, myelosuppression, fatigue, nausea/

vomiting, rash, increased LFTs

What are the premedications required?

• No routine premedications (other than standard antiemetics) required

• Can consider premedication with atropine in patients who experience cholinergic symptoms with irinotecan

What is the emetogenicity level of the topoisomerase I inhibitors?

• Irinotecan and topotecan have a low emetogenic potential Are the topoisomerase I inhibitors vesicants or irritants?

• Irinotecan and topotecan are irritants





4

Enzyme Inhibitors—Topoisomerase II

Inhibitors

EPIPODOPHYLLOTOXINS

What are the chemotherapy agents in the topoisomerase II Inhibitor class?

• The epipodophyllotoxins, etoposide (Toposar®; Vepesid®; VP-16), etoposide phosphate (Etopophos®), and teniposide (Vumon®; VM-26)



– Etoposide phosphate is a water-soluble prodrug of etoposide that is rapidly and completely converted to etoposide in plasma with equivalent bioavailability

What malignancies are the topoisomerase II inhibitors FDA approved for?

FDA-Approved Uses of Topoisomerase II Inhibitors

Agent

FDA Approval

Etoposide

Small cell lung cancer, testicular cancer (refractory) Teniposide

Acute lymphoblastic leukemia (ALL) (refractory) Abbreviation: FDA, U.S. Food and Drug administration.

How do the topoisomerase II inhibitors work?

• Topoisomerase II is an enzyme that relieves tension and supercoil-ing of DNA by binding to DNA and creating transient double-strand breaks, forming what is known as the cleavable complex

48 I. Traditional Chemotherapy

• Epipodophyllotoxins are pure topoisomerase II inhibitors (no free radical formation or DNA intercalation, unlike anthracyclines). These agents bind to the enzyme and stabilize the normally transient cleavable complex, preventing religation of DNA and producing DNA strand breaks

• Epipodophyllotoxins produce a mixture of DNA single- and double-strand breaks (compared to anthracyclines, more single-strand breaks are produced)

• Cell cycle phase specific (S/G phase)

2

What are the common mechanisms of resistance to topoisomerase II inhibitors?

• Active efflux and reduced drug accumulation in tumor cells due to active transport mechanisms (P-glycoprotein [P-gp], multidrug resistance–associated proteins [MRPs], breast cancer resistance protein

[BCRP])

• Reduced drug accumulation in the nucleus, possibly due to nuclear efflux transporters or sequestration in the cytoplasm

• Decreased expression of topoisomerase II within tumor cells

• Altered intracellular localization of topoisomerase II (a shift from the nucleus to the cytoplasm), reducing its interaction with DNA and subsequent cellular cytotoxicity in the presence of topoisomerase II inhibitors

• Alterations in phosphorylation of topoisomerase II (both hypophos-phorylation and hyperphosphorylation have been associated with drug resistance)

• Reduced cell death in response to drug-induced DNA damage secondary to alterations in DNA damage checkpoint and apoptotic pathways (eg, B-cell lymphoma 2 [BCL-2])

What are the common dosing ranges for the topoisomerase II inhibitors?

• Etoposide—50 to 100 mg/m2 intravenous (IV) 3 to 5 days q3–4

weeks



– Note: Oral bioavailability is variable and ranges from approximately 25% to 75%

4. ENZYME INHIBITORS—TOPOISOMERASE II INHIBITORS 49



– Etoposide phosphate is a prodrug of etoposide that is rapidly and completely converted to etoposide in plasma

• Teniposide—165 mg/m2/dose IV days 1, 4, 8, 11

Are the topoisomerase II inhibitors metabolized/eliminated renally or hepatically?

• Etoposide—metabolized hepatically via CYP3A4/3A5 (some metabolites are active metabolites), as well as through glucuronide (via UGT1A1) and glutathione conjugation. Approximately 50% of a dose is eliminated unchanged in the urine. Dose adjust if both renal and hepatic dysfunction present (renal excretion can compensate for hepatic dysfunction).



– Because of a high degree of protein binding, dose reductions may be required in the setting of hypoalbuminemia where the unbound fraction of etoposide is higher (eg, in the setting of severe hepatic dysfunction or poor nutritional status).

• Teniposide—primarily eliminated hepatically; dose adjust for hepatic dysfunction.

Are there drug interactions with any of the topoisomerase II inhibitors?

• Drugs that inhibit/induce CYP3A4

• P-gp inhibitors/inducers

• Other highly protein-bound drugs that compete with topoisomerase II inhibitors for albumin protein binding (eg, warfarin, valproic acid, phenytoin)

What are the most common adverse effects of the topoisomerase II inhibitors?

• Myelosuppression (neutropenia predominates), alopecia, mucositis, nausea/vomiting, secondary malignancies (frequently involving MLL

gene [found at chromosome band 11q23] rearrangements; latency period is typically shorter [median ~1–2 years] than that expected with alkylating agent–associated malignancies), hypotension associated with more rapid infusion.

50 I. Traditional Chemotherapy

• Etoposide and teniposide are formulated with polysorbate 80 and Cremophor® EL, respectively, in addition to containing significant alcohol content (~30%–40% v/v). These excipients may play a role in hypersensitivity reactions, hypotension, and ethanol intoxication side effects (with higher doses used in stem cell transplantation). Etoposide phosphate does not contain these excipients.

What are the premedications required?

• No routine premedications (other than standard antiemetics) required

What is the emetogenicity level of the topoisomerase II inhibitors?

• Etoposide and teniposide have a low emetogenic potential Are the topoisomerase II inhibitors vesicants or irritants?

• Etoposide and teniposide are irritants





4. ENZYME INHIBITORS—TOPOISOMERASE II INHIBITORS 51

ANTHRACYCLINES

What are the chemotherapy agents in this class?

• Doxorubicin (Adriamycin®), liposomal doxorubicin (Doxil®, Lipodox®)

• Epirubicin (Ellence®)

• Mitoxantrone (Novantrone®)—is an anthracenedione

• Daunorubicin (Cerubidine®), liposomal daunorubicin (DaunoXome®)

• Idarubicin (Idamycin PFS®)

What malignancies are the anthracyclines FDA approved for?

FDA-Approved Uses of Anthracyclines

Agent

FDA Approval

Doxorubicin

Breast cancer

Metastatic cancers or disseminated

neoplastic conditions:

acute myeloid leukemia (AML), acute

lymphoblastic leukemia (ALL), Wilms’

tumor, neuroblastoma, soft tissue

and bone sarcomas, ovarian cancer,

transitional cell bladder carcinoma,

gastric carcinoma, Hodgkin’s

lymphoma (HL), non-Hodgkin’s

lymphoma (NHL), bronchogenic

carcinoma, thyroid cancer

Liposomal doxorubicin

Ovarian (2nd line after platinums),

multiple myeloma (2nd line with

bortezomib), AIDS-related Kaposi’s

sarcoma

Epirubicin

Breast cancer

( continued)

52 I. Traditional Chemotherapy FDA-Approved Uses of Anthracyclines ( continued ) Agent

FDA Approval

Mitoxantrone

Acute nonlymphocytic leukemias

(myelogenous, promyelocytic,

monocytic, erythroid), hormone-

refractory prostate cancer

Idarubicin

AML

Daunorubicin

AML and ALL

Liposomal daunorubicin

AIDS-related Kaposi’s sarcoma,

ovarian cancer, multiple myeloma

Abbreviation: FDA, U.S. Food and Drug administration.

How do the anthracyclines work?

• Complex with DNA and topoisomerase II



– Topoisomerase II relieves torsional strain by breaking the phosphate backbone of DNA during replication and reannealing it after replication is complete



– Topoisomerase II–induced strand breaks are potentiated by binding of anthracyclines



– The binding of anthracyclines also prevents reannealing of the DNA phosphate backbone

• Anthracyclines also may intercalate with DNA



– Inhibits DNA and RNA synthesis

• Some anthracyclines produce free radicals leading to direct DNA, cell membrane, and mitochondrial damage (doxorubicin has greater free radical production than other anthracyclines) What are the common mechanisms of resistance to anthracycline therapy?

• MDR1 gene coding for P170 glycoprotein responsible for the efflux of anthracyclines out of a cell

4. ENZYME INHIBITORS—TOPOISOMERASE II INHIBITORS 53

• Other adenosine triphosphate (ATP)-dependent efflux transporters (MRP, BRCP) pump anthracyclines out of tumor cells and into normal host tissue (eg, liver)

• Reduction or absence of topoisomerase II activity

• Overexpression of BCL-2 and mutations of p53

• Increased DNA repair systems

What are the common dosing ranges for each anthracycline?

Anthracyclines have generally equivalent antitumor activity (but different toxicities) whether dosed as a single large monthly bolus, single large weekly bolus, or prolonged infusion

• Doxorubicin



– Dose-response relationship in solid tumors



– 40 to 75 mg/m2 every 3 weeks



– 25 to 30 mg/m2 every 7 to 14 days

• Liposomal doxorubicin



– 20 to 30 mg/m2 every 21 days



– 50 mg/m2 every 28 days

• Epirubicin



– 100 to 120 mg/m2 every 21 to 28 days (breast cancer)



– 60 mg/m2 every week

• Mitoxantrone



– 8 to 14 mg/m2 every 21 to 28 days



– 6 mg/m2 6 days (MEC)

• Idarubicin



– 8 to 12 mg/m2 3 days

• Daunorubicin



– 30 to 90 mg/m2/day 3 days

54 I. Traditional Chemotherapy Are the anthracylines metabolized/eliminated renally or hepatically?

• All anthracyclines undergo hepatic metabolism with biliary excretion

• All should be dose adjusted for hepatic dysfunction

• Dose adjustments for renal dysfunction vary in clinical practice Are there drug interactions with any of the anthracyclines?

• Doxorubicin:



– Overlapping cardiotoxicity with other agents (bevacizumab, trastuzumab)



– P-gp, cytochrome P450 3A4 and 2D6 interactions



– P-gp inducer; inhibits CYP2B6 (moderate), CYP2D6 (weak), CYP3A4

(weak)



– Taxanes decrease doxorubicin metabolism, but docetaxel has less of an interaction. Administer doxorubicin prior to paclitaxel when used concomitantly

• Liposomal doxorubicin: less cardiotoxicity interactions, otherwise same as conventional form

• Epirubicin: clinically significant interactions have not been fully elucidated

• Mitoxantrone: clinically significant interactions have not been fully elucidated

• Idarubicin: clinically significant interactions have not been fully elucidated

• Daunorubicin: clinically significant interactions have not been fully elucidated

What are the class adverse effects of the anthracyclines?

• Cardiotoxicity



– Cumulative



– Associated with large bolus doses



– Acute: EKG changes, arrhythmias

4. ENZYME INHIBITORS—TOPOISOMERASE II INHIBITORS 55



– Chronic: heart failure, cardiomyopathy



– Increased risk with prior cardiovascular disease, concurrent cardiotoxic drugs, prior anthracycline therapy, prior or concurrent chest irradiation, older age, and infants/children



– Decreased incidence with liposomal doxorubicin and continuous infusions over 24 to 96 hours



– Epirubicin, idarubicin, and mitoxantrone have less cardiotoxicity

• Myelosuppression, mucositis, alopecia



– More common with prolonged infusions of conventional and liposomal doxorubicin

• Radiosensitization

• Body fluid discoloration (red; except blue for mitoxantrone)

• Secondary malignancies; commonly associated with MLL gene (11q23) rearrangements, which most often occur with a 2- to 3-year latency

• Extravasation

What are the premedications required?

• Premedications (other than standard antiemetics) are not required What is the emetogenicity level of the anthracyclines?

• Doxorubicin: moderate (60 mg/m2) or high (60 mg/m2 or in AC

regimen)

• Liposomal doxorubicin: low

• Epirubicin: moderate (90 mg/m2) or high (60 mg/m2)

• Mitoxantrone: low

• Idarubicin: moderate

• Daunorubicin: moderate

Are the anthracyclines vesicants or irritants?

• Vesicants; however liposomal doxorubicin is an irritant

56 I. Traditional Chemotherapy What is the maximum lifetime dose of each anthracycline?

Maximum Lifetime Doses of Anthracyclines

Equivalent Dosing Estimates

Ranges

Max

(Doxorubicin: other

Below

anthracycline)

Doxorubicin

50 mg/m2

1:1

450

Daunorubicin

50–60 mg/m2

1:1–1.2

550

Epirubicin

75 mg/m2

1:1.5–2

900

Idarubicin

10 mg/m2

1:0.2–0.33

150

Mitoxantrone

12.5 mg/m2

1:0.25–0.33

140





5

Antimetabolites

ANTIFOLATES

What are the chemotherapy agents in the antifolate class?

• Methotrexate (Trexall®)

• Pemetrexed (Alimta®)

• Pralatrexate (Folotyn®)

What malignancies are the antifolates FDA approved for?

FDA-Approved Uses of Antifolates

Agent

FDA Approval

Methotrexate

Acute lymphoblastic leukemia (ALL), trophoblastic neoplasms (gestational choriocarcinoma,

chorioadenoma destruens, and hydatidiform mole), breast cancer, head and neck cancer, cutaneous T-cell lymphoma (CTCL), lung cancer (squamous cell and small cell), non-Hodgkin’s lymphomas (NHLs; advanced), osteosarcoma

Pemetrexed

Mesothelioma, non–small cell lung cancer (NSCLC; locally advanced or metastatic nonsquamous; not indicated for squamous cell NSCLC)

Pralatrexate

Peripheral T-cell lymphoma (PTCL; relapsed or refractory)

Abbreviation: FDA, U.S. Food and Drug Administration.

58 I. Traditional Chemotherapy How do the antifolates work? (See Figure 5.1)

• Antifolates disrupt the synthesis of reduced folates, essential cofactors that act as one-carbon carriers in the synthesis of DNA precursors

• Rapidly dividing cells uptake antifolates via the reduced folate carrier system, the folate receptor system, or through a proton-coupled transporter. Methotrexate relies primarily on the reduced folate carrier system for entry, although pralatrexate and pemetrexed have relatively higher affinity for this transporter compared to methotrexate.

Pemetrexed is efficiently transported by all three transport mechanisms AICARTF

Purine

synthesis

Prolonged intracellular

GARTF

retention

MTX PG(n)

Thymidylate

TS

synthesis

H+

MTX

DHFR

FR

DHF

THF

MTX

RFC

MTX

One-carbon source for

MTX

purine biosynthesis

FIGURE 5.1. Antifolates.

Abbreviations: AICARTF, aminoimidazole carboxamide ribonucleotide transformylase; DHF, dihydrofolate; DHFR, dihydrofolate reductase; FR, folate receptor; GARTF, glycinamide ribonucleotide transformylase; H+, proton-coupled transporter; MTX, methotrexate; PG, polyglutamate; RFC, reduced folate carrier; THF, tetrahydrofolate; TS, thymidylate synthase.

5. ANTIMETABOLITES 59

• By mimicking the natural folate structure, the antifolate compounds bind and inhibit dihydrofolate reductase (DHFR), a key enzyme in the folate synthesis pathway that normally converts folate into its active, reduced tetrahydrofolate form

• This depletes the pool of reduced folate compounds required for purine analogue synthesis

• Methotrexate and other antifolates are also converted into polyglutamate derivatives by folylpolyglutamyl synthetase (FPGS). These derivatives are potent inhibitors of other folate-dependent enzymes (eg, aminoimidazole carboxamide ribonucleotide transformylase

[AICARTF], glycinamide ribonucleotide transformylase [GARTF], thymidylate synthase [TS]) critical for purine and thymidylate synthesis.

Polyglutamated antifolates are also selectively retained within cells, thus prolonging intracellular half-life in tumor cells

• Unlike the other antifolates in clinical use, pemetrexed is a potent inhibitor of TS but a relatively weak inhibitor of DHFR

• Cell cycle phase specific (S-phase)

What are the common mechanisms of resistance to antifolates?

• Decreased transport of antifolates into cancer cells

• Active efflux of antifolates out of cancer cells (eg, multidrug resistance–associated protein [MRP]-1, 2, 3, breast cancer resistance protein

[BCRP])

• A reduction in the formation of the polyglutamate forms of the antifolate compounds

• Mutations in DHFR resulting in reduced antifolate binding affinity

• Increased expression of DHFR within cancer cells What are the common dosing ranges for the antifolates?

• Methotrexate—Dosing varies widely



– Orally (PO)/intramuscular (IM)/subcutaneous (SQ): doses vary, 20 mg/m2 weekly PO for acute lymphoblastic leukemia (ALL)



– Intrathecal (IT): usually 12 mg (max 15 mg); ½ dose in Ommaya reservoir

60 I. Traditional Chemotherapy



– High-dose intravenous (IV) (ALL, diffuse large B-cell lymphoma

[DLBCL]): 1 to 3 g/m2 IV with leucovorin rescue



– Capizzi methotrexate (ALL): Start at 100 mg/m2 IV, escalate by 50 mg/m2/dose



– Central nervous system (CNS) lymphoma: 3.5 to 8 g/m2 IV with leucovorin rescue



– Osteosarcoma: 8 to 14 g/m2/dose IV with leucovorin rescue



– Breast cancer (CMF): 40 mg/m2 days 1 and 8 every 4 weeks

• Pemetrexed—500 mg/m2 IV q21 days

• Pralatrexate—15 to 30 mg/m2 IV once weekly for 6 weeks of 7-week cycle

Are the antifolates metabolized/eliminated renally or hepatically?

• All of the antifolates are primarily eliminated renally; dose adjust for renal dysfunction

Are there drug interactions with any of the antifolates?

• Drugs that prevent active tubular secretion of antifolates (penicillins

[ok to use cephalosporins for febrile neutropenia], probenecid, aspirin/

nonsteroidal anti-inflammatory drugs [NSAIDs], proton pump inhibitors) can delay clearance and increase toxicity. These interactions are most significant with methotrexate, in particular in high-dose r egimens.

• Sulfonamides (eg, trimethoprim/sulfamethoxazole [TMP/SMX]) and other drugs that displace methotrexate from albumin binding (eg, salicylates, phenytoin, tetracyclines) may increase the free fraction of methotrexate. The trimethoprim component of TMP/SMX also inhibits DHFR, potentially increasing toxicity in combination with antifolates.

• Asparaginase, when given prior to antifolate compounds such as methotrexate, is antagonistic. The asparaginase products on the market (pegaspargase and Erwinia asparaginase) also contain significant glutaminase activity. By depleting glutamine, the formation of antifolate-polyglutamates is greatly reduced, decreasing the efficacy of the antifolate compounds. In contrast, administering methotrexate 4 hours prior to asparaginase (as in the MOAD regimen for ALL) may result in synergistic cytotoxicity.

5. ANTIMETABOLITES 61

• Leucovorin rescue in higher doses can abrogate the cytotoxic effects of the antifolate compounds on malignant cells; the minimum dose necessary to prevent host toxicity should be utilized (methotrexate elimination curves to guide leucovorin dosing have been published and are useful in this regard).

• Drugs that inhibit P-glycoprotein (P-gp) may increase methotrexate levels.

• Drugs that decrease renal clearance may increase levels of the antifolates (eg, NSAIDs, calcineurin inhibitors, other nephrotoxic agents).

What are the most common adverse effects of each antifolate?

• Methotrexate (side effects depend on dose and regimen—see table in the following text): myelosuppression, mucositis (usually precedes fall in blood counts), acute kidney injury (renal tubular precipitation and potentially direct renal tubule toxicity), hepatotoxicity (rapid and reversible LFT elevations after high-dose methotrexate; chronic oral therapy may lead to cirrhosis—less common with “pulse” dosing), alopecia, pneumonitis, and three distinct types of neurotoxicity ([a] chemical arachnoiditis— immediate, characterized by headache, nuchal rigidity, vomiting, fever; [b] subacute—typically after three to four courses of IT methotrexate, can lead to motor paralysis, seizures, coma; [c] chronic demyelinating—occurs primarily in children after IT administration, leading to dementia and limb spasticity)

Frequency of Side Effects of Antifolates

Dose in mg/m2

Heme Renal Liver Mucositis Lung Neuro

Intermediate IV





continuous

infusion 500–1,000

High-dose IV bolus





3,500–12,000

Low-dose PO daily 5–25





Low-dose PO pulse





Intrathecal





Note: = very common; = rare.

Abbreviations: IV, intravenous; PO, orally.

62 I. Traditional Chemotherapy

• Pemetrexed: fatigue, myelosuppression, mucositis, rash (can manage/prevent with corticosteroids), increased LFTs, conjunctivitis and increased lacrimation (with long-term use/maintenance therapy)

• Pralatrexate: myelosuppression, nausea/vomiting, mucositis, increased LFTs

What are the premedications and supportive care precautions required?

• High-dose methotrexate (1 g/m2): Hydration and urine alkalinization to achieve and maintain urine output of at least 100 mL/hr and a urine pH of 7.0 or greater prior to beginning infusion.



– Methotrexate penetrates into third-space fluid collections, creating a reservoir of methotrexate that prolongs drug half-life leading to significant toxicity. Ensure no fluid collections (eg, ascites, pleural effusions) present prior to and during infusion



– Daily methotrexate drug level monitoring



– Leucovorin rescue beginning 24 to 36 hours after methotrexate infusion initiation (use elimination curves to guide appropriate dosing) until methotrexate levels fall below 0.05 to 0.1 mcg/mL



– In case of delayed elimination and acute kidney injury or other severe toxicity:

Increase leucovorin dosing per published elimination curves or institutional guidelines

Continue aggressive hydration and urinary alkalinization Consider high-flux hemodialysis to remove methotrexate Consider administering glucarpidase 50 units/kg IV: Glucarpidase is a recombinant bacterial carboxypeptidase that metabolizes methotrexate to the inactive 4-diamino-N(10)-meth-ylpteroic acid (DAMPA) metabolite. The DAMPA metabolite can be detected on methotrexate immunoassay, resulting in falsely high levels of methotrexate; consider high-performance liquid chroma-tography (HPLC) monitoring in this case. Hold leucovorin 2 to 4 hours before and 1 to 2 hours after glucarpidase, as it can compete with methotrexate for binding to the enzyme. Although glucarpidase is successful in rapidly cleaving methotrexate, the average time

5. ANTIMETABOLITES 63

to normalization of renal function is still approximately 3 weeks.

Aggressive leucovorin rescue remains the most important intervention for delayed methotrexate elimination

• Pemetrexed and pralatrexate: B12 and folic acid supplementation should be provided prior to starting therapy as well as throughout therapy to prevent excessive toxicity.

• Pemetrexed: Dexamethasone 4 mg BID 3 days starting the day prior to infusion to reduce the incidence of rash.

What is the emetogenicity level of the antifolates?

• The antifolates have a low emetogenic potential Are the antifolates vesicants or irritants?

• The antifolate compounds are neither vesicants nor irritants





64 I. Traditional Chemotherapy

PURINE ANTAGONISTS

What are the chemotherapy agents in the purine antagonist class?

• Mercaptopurine (Purinethol®, 6-MP)

• Thioguanine (Tabloid®)

What malignancies are each purine antagonist FDA approved for?

FDA-Approved Uses of Purine Antagonists

Agent

FDA Approval

Mercaptopurine

Acute lymphoblastic leukemia (ALL)

Thioguanine

Acute myeloid leukemia (however, used more

often in ALL)

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the purine antagonists work? (See Figure 5.2)

• Mercaptopurine and thioguanine are metabolized through independent pathways to thioguanine monophosphate (TGMP), which is then metabolized in several steps to active thioguanine nucleotides (6-deoxy-thioguanosine triphosphate)



– Incorporated into DNA or RNA, interfere with DNA/RNA replication, and induce cytotoxicity

• Also inhibit de novo purine synthesis (by methylmercaptopurine nucleotides)



– Less inhibition from 6-TG than 6-MP

• The primary enzyme involved in their activation is hypoxanthine-guanine phosphoribosyltransferase (HGPRT)

• The primary enzyme involved in their deactivation is thiopurine methyltransferase (TPMT)



– See TPMT deficiency clinical pearls at end of chapter

• Cell cycle specific (S phase)





5. ANTIMETABOLITES 65

6-MP

XO

meMP

meTG

(inactive)

(inactive)

6-TU

(inactive)

TPMT

TPMT

6-MP

6-TG

HGPRT

HGPRT

Several enzymatic

steps

6-thioguanine nucleotides

TIMP

Incorporated into DNA/RNA

TPMT

meTIMP

Inhibits

purine synthesis

p

y

TPMT

meTGNs

(inactive)

Nucleus

FIGURE 5.2. Purine antagonists: Intracellularly, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are processed by both a catabolic and an anabolic pathway. Catabolically, both are methylated and inactivated by thiopurine methyltransferase (TPMT) to methyl-MP (meMP) and methyl-TG (meTG). Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) converts 6-MP to thioinosine monophosphate (TIMP). TIMP is further converted to methyl-TIMP (meTIMP) via TPMT and has the ability to inhibit purine synthesis. TIMP is also converted via several enzymatic steps to active metabolites, 6-thioguanine nucleotides. These are incorporated into DNA/RNA and ultimately lead to apoptosis. 6-TG is directly converted to 6-thioguanine nucleotides. 6-thioguanine nucleotides also undergo catabolism to be inactivated via TPMT. 6-MP is also converted to an inactive metabolite, 6-thiouric acid (6-TU), via xanthine oxidase (XO).

What are the common mechanisms of resistance to purine antagonists?

• The most extensively characterized mechanism of resistance is the reduced activity of HGPRT

• Reduced influx by transporter cells

• Increased expression of TPMT (although decreased expression is more common)

66 I. Traditional Chemotherapy What are the common dosing ranges for each purine antagonist?

• Mercaptopurine: Various treatment regimens exist:



– Maintenance for ALL: 50 mg PO three times daily



– 60 to 80 mg/m2/day during various courses of ALL (round to near-est 25 mg)



– Absorption is improved if given 1/2 hour before or 1 hour after meals. Concurrent milk products can decrease absorption and 6-MP

effect is enhanced if given at bedtime on an empty stomach

• Thioguanine: 60 mg/m2/day PO on days 29 to 42 for CALGB10403

and CALGB8811 (Larson protocol) during delayed intensification (Course IV)



– Administer 1 hour after evening meal, preferably at bedtime (avoid milk or citrus products)

Are the purine antagonists metabolized/eliminated renally or hepatically?

• Both are extensively metabolized hepatically via first pass; however, a high interpatient variability exists; therefore, no formal dosing recommendations for patients with liver dysfunction; in severe dysfunction, it is generally held until resolution since mercaptopurine/thioguanine can exacerbate hepatic impairment



– 6-MP is metabolized via methylation (via TPMT) and oxidation in the liver (also metabolized by xanthine oxidase)



– 6-TG is metabolized via deamination and methylation (via TPMT) in the liver (it is NOT metabolized by xanthine oxidase)

• Both are renally excreted; however, no formal dose reduction exists for patients with renal impairment

Are there drug interactions with any of the purine antagonists?

• Mercaptopurine: Allopurinol inhibits xanthine oxidase and therefore inhibits metabolism of mercaptopurine (avoid use or reduce initial mercaptopurine by 33% in ALL regimens and dose adjust for response and toxicity)

5. ANTIMETABOLITES 67

• Mercaptopurine: Warfarin’s anticoagulant effects may be decreased; unknown mechanism; monitor international normalized ratio (INR) and adjust warfarin

• Mercaptopurine and thioguanine: Mesalamine, sulfasalazine, ol-salazine can inhibit TPMT

What are the most common adverse effects of each purine antagonist?

• Mercaptopurine: myelosuppression (primarily leukopenia and thrombocytopenia); gastrointestinal toxicities (stomatitis, diarrhea, abdominal pain); and hepatotoxicity

• Thioguanine: myelosuppression (more than 6-MP); gastrointestinal toxicities are less than 6-MP (stomatitis, diarrhea, abdominal pain); splenomegaly; and hepatotoxicity

What is the emetogenicity level of the purine antagonists?

• Both agents have minimal to low emetogenicity What is TPMT deficiency and what are some clinical pearls regarding it?

• Diminished TPMT activity leads to a shunting of TGMP metabolism toward greater production of active thioguanine nucleotides

• When treated with full-dose therapy, 35% of TPMT heterozygous patients and 100% of homozygous patients will require dose reductions, compared with only 7% of patients without mutations

• One in 300 patients has complete TPMT deficiency, and 11% carry a single defective allele

• TPMT deficiency is diagnosed according to either phenotypic test-ing of erythrocyte TPMT activity and/or genotyping for TPMT gene mutations

• Use of preemptive genotyping is recommended; however, in those with unknown TPMT activity who experience disproportionate myelosuppression (2 weeks), genotyping should be conducted

• Patients identified as TPMT deficient receive either empiric dose reduction or full-dose therapy with enhanced myelotoxicity monitoring

68 I. Traditional Chemotherapy

Recommended Starting Dosing of Mercaptopurine and Thioguanine in

Patients With TPMT Variants

TPMT

Mercaptopurine Dosing

Thioguanine Dosing

Genotype

Heterozygous 30%–70% of full dose

50%–70% of full dose

2–4 weeks to reach steady

2–4 weeks to reach

state

steady state

Homozygous

10% of full dose given

10% of full dose given

three times/week

three times/week

4–6 weeks to reach steady

4–6 weeks to reach

state

steady state

Abbreviation: TPMT, thiopurine methyltransferase.

Source: Adapted from Relling MV, Gardner EE, Sandborn WJ, et al.

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013

update. Clin Pharmacol Ther. 2013;93:324–325. Copyright John Wiley and Sons, used with permission.





5. ANTIMETABOLITES 69

PURINE ANALOGUES

What are the chemotherapy agents in the purine analogue class?

• Cladribine (Leustatin®)

• Clofarabine (Clolar®)

• Fludarabine (Fludara®)

• Nelarabine (Arranon®)

• Pentostatin (Nipent®)

What malignancies are each purine analogue FDA approved for?

FDA-Approved Uses of Purine Analogues

Agent

FDA Approval

Cladribine

Hairy cell leukemia

Clofarabine

Pediatric acute lymphoblastic leukemia (ALL) (ages 1 to 21 y); relapsed refractory ALL

Fludarabine Chronic lymphocytic leukemia

Nelarabine

Relapsed/refractory T-cell ALL and T-cell

lymphoblastic lymphoma

Pentostatin

Hairy cell leukemia

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the purine analogues work?

• Cladribine, clofarabine, and fludarabine mimic deoxyadenosine, while nelarabine mimics deoxyguanosine

• All are activated inside the cell to 5’-triphosphate form, incorporated into DNA, and inhibit chain elongation by inhibiting DNA polymerase

• Their structure (chloride and/or fluoride additions) makes them resistant to their respective deaminases

• The purine analogues also inhibit ribonucleotide reductase activity, decreasing the production of normal deoxyribonucleotides (dNTPs) available for DNA synthesis

70 I. Traditional Chemotherapy

• Due to a reduction in the dNTP pools, inhibition of ribonucleotide reductase also enhances deoxycytidine kinase, which is the rate- limiting enzyme in purine/pyrimidine phosphorylation into DNA



– This is the premise behind administering a purine analogue 4 hours prior to cytarabine



– Higher deoxycytidine kinase leads to higher active triphosphate metabolite of cytarabine (arabinofuranosylcytosine triphosphate [ara-CTP]) = synergy

• Clofarabine can also directly affect the mitochondrion altering the transmembrane potential and releasing cytochrome C, which leads to apoptosis via the apoptosome

• Pentostatin is an adenosine deaminase inhibitor, leading to the accumulation of cytotoxic deoxyadenosine triphosphate, which inhibits ribonucleotide reductase, as well as DNA methylation, replication, and repair, ultimately resulting in apoptosis

What are the common mechanisms of resistance to purine analogue therapy?

• Decreased drug transport into cells

• Decreased expression of deoxycytidine kinase

• Increased expression of ribonucleotide reductase What are the common dosing ranges for purine analogues?

Cladribine:

• Hairy cell: 0.09 mg/kg/day IV 7 days (continuous infusion), repeat every 28 to 35 days

• Chronic lymphocytic leukemia (CLL): 0.1 mg/kg/day 7 days OR

0.028 to 0.14 mg/kg/day 5 days

• Chronic myeloid leukemia (CML): 15 mg/m2/day 5 days

• Acute myeloid leukemia (AML): 5 mg/m2/day 5 days Clofarabine:

• Acute lymphoblastic leukemia (ALL): 52 mg/m2 IV over 2 hours daily 5 days every 2 to 6 weeks

5. ANTIMETABOLITES 71

• AML: 15 to 40 mg/m2 IV daily 5 days every 4 to 6 weeks (mono-therapy)

• Bone marrow transplant (BMT): 40 mg/m2

Fludarabine:

• 25 mg/m2 IV 5 days every 28 days

Nelarabine:

• 1,500 mg/m2/day over 2 hours on days 1, 3, and 5; repeat every 21 days; pediatric dosing is 650 mg/m2/day over 1 hour on days 1 to 5

Pentostatin:

• Hairy cell: 4 mg/m2 every 2 weeks

• CLL: 2 mg/m2 (first line) or 4 mg/m2 (salvage) weekly every 3 weeks 6 weeks

• T-cell lymphoma: 3.75 to 5 mg/m2 daily for 3 days every 3 weeks

• Graft-versus-host disease (GVHD): 1.5 mg/m2 daily for 3 days (acute); 4 mg/m2 every 2 weeks 12 doses (chronic)

Are the purine analogues metabolized/eliminated renally or hepatically?

• All purine analogues are renally eliminated Are there drug interactions with any of the purine analogues?

• Cladribine: ethanol—gastrointestinal (GI) irritation

• Clofarabine: azole antifungals—increased hepatotoxicity

• Fludarabine: cytarabine (increased activity); cyclophosphamide, cisplatin, mitoxantrone (increased activity); pentostatin—increases drug levels and pulmonary toxicity

• Nelarabine: pentostatin—decreases drug levels

• Pentostatin: fludarabine—pulmonary toxicity; nelarabine—reduced efficacy; cyclophosphamide—increased risk of cardiac toxicity What is the purine analogue class adverse effect?

• Myelosuppression

72 I. Traditional Chemotherapy What are the adverse effects of each purine analogue?

• Cladribine: myelosuppression with longer duration of nadir (recover 4 to 8 weeks), fever, rash; neurotoxicity with high doses of continuous infusion

• Clofarabine: hepatotoxicity (usually within days and reversible in 14

days), rash, capillary leak syndrome

• Fludarabine: autoimmune hemolytic anemia/thrombocytopenia, idiopathic thrombocytopenic purpura

• Nelarabine: central nervous system (dose-limiting toxicity; headache, altered mental status, seizures, somnolence, convulsions, peripheral neuropathy), peripheral edema, hepatotoxicity

• Pentostatin: neurotoxicity (doses 4 mg/m2) (headache, lethargy, fatigue), nephrotoxicity, fever, fatigue, rash, myalgia; hepatotoxicity Which are the premedications required?

• No routine premedications (other than standard antiemetics) required

What is the emetogenicity level of the purine analogues?

• Clofarabine is moderate

• Cladribine, fludarabine, and nelarabine are minimal

• Pentostatin is low

Are the purine analogues vesicants or irritants?

• Cladribine is an irritant

• All others are nonvesicants/nonirritants





5. ANTIMETABOLITES 73

PYRIMIDINE ANALOGUES/FLUOROPYRIMIDINES

What are the chemotherapy agents in this class?

• Fluorouracil (5-FU) (Adrucil®)

• Capecitabine (Xeloda®)—prodrug of 5-FU

• Floxuridine (FUDR®)

What malignancies are each fluoropyrimidine analogue FDA approved for?

FDA-Approved Uses of Fluoropyrimidine Analogues

Agent

FDA Approval

Fluorouracil (5-FU) Carcinoma of the breast, pancreas, colon, rectum, and stomach

Capecitabine

Adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer

Floxuridine

Gastric and colorectal cancer metastatic to the liver

Abbreviation: FDA, U.S. Food and Drug Administration.

How do fluoropyrimidine analogues work? (Figure 5.3)

• Interfere with DNA synthesis, RNA synthesis, and/or thymidylate synthetase (TS) resulting in apoptosis

How does the metabolism/mechanisms of each agent differ?

• 5-fluorouracil is converted to three main metabolites (5-fluorouridine triphosphate [5-FUTP], which is incorporated into RNA, 5-fluorodeoxyuridine triphosphate [5-FdUTP], which is incorporated into DNA, and 5-fluorodeoxyuridine monophosphate [5-FdUMP], which inhibits thymidylate synthetase)



– Of note, leucovorin is metabolized to 5-methyl-tetrahydrofolate, which stabilizes the bond between FdUMP and TS. This enhances TS

inhibition and decreases the production of thymidylate

• Capecitabine is enzymatically converted in the liver and tissues to 5-FU

74 I. Traditional Chemotherapy FBAL

Elimination

Dihydropyrimidine

dehydrogenase (DPD)

5FU

Floxuridine

(5-FUDR)

Capecitabine

5-FdUMP

5-FdUTP

5-FUTP

Thymidylate synthetase

DNA incorporation

RNA incorporation

(leucovorin stabilizes)

FIGURE 5.3. Pyrimidine analogues: Capecitabine (cape) is an oral prodrug metabolized to fl uorouracil (5-FU). 5-FU is intracellularly bioactivated (anabolic pathway) through several steps to 5-fl uorodeoxyuridine monophosphate (5-FdUMP), which inhibits thymidylate synthetase (TS), causing cellular cytotoxicity. Leucovorin metabolizes to 5-methyl-tetrahydrofolate, which stabilizes the bond between FdUMP and TS. This enhances TS inhibition and decreases the production of thymidylate.

Fluorodeoxyuridine triphosphate (5-FdUTP) and fl uorouridine triphosphate (5-FUTP) are incorporated into DNA and RNA, respectively, as false base pairs. Floxuridine (5-FUDR) is a metabolite of 5-FU and a precursor to 5-FdUMP, which ultimately inhibits TS or can be converted back into 5-FU. The rate-limiting step for 5-FU elimination is an alternative metabolic pathway (catabolic pathway) catalyzed by dihydropyrimidine dehydrogenase (DPD). Majority of 5-FU will follow the catabolic pathway; therefore, defi ciencies in DPD can lead to severe toxicities as more active metabolites will be created.

• Floxuridine (5-FUDR) is converted to FdUTP (incorporated into DNA) and FdUMP (inhibits TS)



– Rationale for use in liver metastases:

When liver metastases grow above 2 to 3 mm, the blood supply is delivered from the hepatic artery (not portal circulation)

5. ANTIMETABOLITES 75

Drugs that are highly extracted by the liver during first-pass metabolism can result in high hepatic levels and low systemic concentrations, thereby minimizing systemic toxicity The best drugs for hepatic arterial infusion (HAI) are agents that have high hepatic extraction with conversion to inactive metabolites, high total body clearance, and short plasma half-life If the drug is not rapidly cleared by the liver, the regional advan-tage is lost because of systemic recirculation What are common mechanisms of resistance to fluoropyrimidine analogue therapy?

• Increased production of TS, p53 mutations, efflux pumps, increase in uridine production, decreased levels of reduced folate cofactor, DNA repair mechanisms, decreased incorporation of 5-FU into RNA/DNA, dihydropyrimidine dehydrogenase (DPD) overexpression What are the common dosing ranges for each fluoropyrimidine analogue?

• 5-FU: Bolus (200 to 800 mg/m2); continuous infusion (200 to 2,600

mg/m2/day); radiosensitization (300 mg/m2/day)



– Clinical pearl: Leucovorin helps stabilize 5-FU binding and inhibition of TS with bolus dosing due to the short half-life of 5-FU, but there is no evidence it is necessary with continuous infusion of 5-FU

or with capecitabine

• Capecitabine: 850 to 1,250 mg/m2 BID 2 weeks, then 1 week of rest.

Taken orally 30 minutes after a meal; radiosensitization (1,650 mg/m2/

day split BID on days of radiation)

• Floxuridine: 0.1 to 0.6 mg/kg/day or 4 to 20 mg/day intra-arterial 7 to 14 days

Are the pyrimidine analogues metabolized/eliminated renally or hepatically?

• Hepatic metabolism via a dehydrogenase enzyme



– Metabolism is not via cytochrome p450 enzymes or glucuronidation



– No FDA-approved labeling dose adjustments

76 I. Traditional Chemotherapy

• Renally adjust for capecitabine (contraindicated if creatinine clearance 30 mL/min)

Are there drug interactions with any of the fluoropyrimidine analogues?

• 5-FU: inhibits CYP2C9; leucovorin (enhances antitumor activity/

toxicity of bolus, not infusion)

• Capecitabine: inhibits CYP2C9 (eg, warfarin, phenytoin)

• Floxuridine: leucovorin (enhances antitumor activity/toxicity) What are the most common adverse effects of each fluoropyrimidine analogue?

IV Bolus 5-FU

Continuous Infusion

5-FU/Capecitabine

Myelosuppression (dose-limiting toxicity Less myelosuppression

[DLT])

Mucositis (higher incidence)

Mucositis (more severe)

Diarrhea (more severe)

Diarrhea (higher incidence)

Hand-foot syndrome is uncommon

Hand-foot syndrome

Note: Other notable toxicities: fingernail discoloration, discoloration from IV infusion (veins turn gray), conjunctivitis, hair loss or thinning, phototoxicity, cardiotoxicity (coronary vasospasm, angina, dysrhythmias, cardiogenic shock, sudden death, ECG changes, and cardiomyopathy), neurotoxicity (mood changes, depression, confusion, hallucinations, nervousness, difficulty sleeping, dizziness, drowsiness, clumsiness, difficulty walking, or restlessness).

Abbreviations: 5-FU, fluorouracil; IV, intravenous.

FLOXURIDINE

Local and regional effects of intra-arterial infusion

• Floxuridine is metabolized to fluorouracil, but the full spectrum of fluorouracil toxicity is not expected due to regional administration of the drug

5. ANTIMETABOLITES 77

• Arterial aneurysm, arterial ischemia, arterial thrombosis, bleeding at catheter site, blocked/displaced/leaking catheter, embolism, fi-bromyositis, infection at catheter site, hepatic necrosis, abscesses, and thrombophlebitis

• Peptic ulcer disease, gastritis, biliary sclerosis, chemical hepatitis, cholecystitis

What are the premedications required?

• Premedication is not required for any of the agents What is the emetogenicity level of the fluoropyrimidine analogues?

• All are classified as low emetogenic risk Are fluoropyrimidine analogues vesicants or irritants?

• 5-FU is an irritant

Clinical Pearl: What is DPD deficiency and how does it affect fluoropyrimidine therapy?

• Normally, most of 5-FU/capecitabine is not bioactivated and instead converted to inactive metabolites by DPD and eliminated

• Patients with lower DPD activity have a higher propensity for life-threatening toxicities (myelosuppression, gastrointestinal toxicity, mucositis/stomatitis, and hand-foot syndrome)





78 I. Traditional Chemotherapy

PYRIMIDINE ANALOGUES/DEOXYCYTIDINE

ANALOGUES

What are the chemotherapy agents in this class?

• Deoxycytidine analogues



– Cytarabine



– Gemcitabine (Gemzar®)

What malignancies are each deoxycytidine analogue FDA approved for?

FDA-Approved Uses of Deoxycytidine Analogues

Agent

Approval

Cytarabine

Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) (blast phase), meningeal leukemia

Gemcitabine Non–small cell lung cancer (NSCLC), pancreatic, metastatic breast, ovarian cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do deoxycytidine analogues work?

• Cytarabine is activated to the nucleotide metabolite arabinofuranosylcytosine triphosphate (ara-CTP) by deoxycytidine kinase and incorporated into DNA



– Also inhibits DNA polymerase and weakly inhibits ribonucleotide reductase (see Figure 5.4)



– Cell cycle specific to the S Phase

• Gemcitabine is activated intracellularly by deoxycytidine kinase and is incorporated into DNA as a false base pair



– Also inhibits ribonucleotide reductase, which leads to decreased production of dNTPs and increased deoxycytidine kinase activity



– Cell cycle specific to the S phase



5. ANTIMETABOLITES 79

Cytidine deaminase

Extracellular

ARA-C

ARA-UTP

Renal elimination

Deoxycytidine

Intracellular

kinase

ARA-C

Ara-CMP

Deoxycitidylate kinase

Ara-CDP

Nucleoside diphosphate kinase

Ara-CTP

Ribonucleotide

Nucleus

Reductase

FIGURE 5.4. Cytarabine MOA and metabolism: Extracellular cytarabine (ara-C) is transported via an active transport system (human equilibrative nucleoside transporter 1 [hENT1]) when given in a low dose (100–200 mg/m2) continuous infusion and by passive diffusion when given at high doses (1,000–3,000 mg/m2). ara-C must be converted to its active metabolite ara-CTP. The rate-limiting step in the activation of ara-C is via deoxycytidine kinase. ara-CTP is incorporated into DNA during S phase of the cell cycle. Extracellularly, ara-C is degraded by cytidine deaminase (present in granulocytes, leukemia cells, plasma, liver, spleen, and red blood cells) into ara-UTP and renally eliminated. Patients with poor renal function can accumulate ara-UTP and exhibit symptoms of cerebellar neurotoxicity.

Abbreviation: MOA, Mechanism of Action.

What are the common mechanisms of resistance to deoxycytidine analogue therapy?

• Cytarabine: increased cytidine deaminase, increased deoxycyti-dylate deaminase, decreased transport into the cell (reduced expression of the human equilibrative nucleoside transporter 1, increased expression of CTP synthetase)

• Gemcitabine: similar to cytarabine

80 I. Traditional Chemotherapy What are the common dose ranges for each deoxycytidine analogue?

• Cytarabine: 100 to 200 mg/m2/day via continuous IV infusion; high dose—1,000 to 3,000 mg/m2 IV; 25 to 100 mg intrathecally

• Gemcitabine: 800 to 1,200 mg/m2 IV over 30 minutes



– May be given as a fixed dose rate (FDR) (10 mg/m2/min); for example, 900 mg/m2 is given over 90 minutes or 700 mg/m2 is given over 70 minutes

What is the premise behind FDR gemcitabine?

• Deoxycytidine kinase is the enzyme that catalyzes the conversion of gemcitabine to its active triphosphate metabolite

• Deoxycytidine kinase is saturated at the standard 30-minute infusion

• FDR of 10 mg/m2/min avoids enzyme saturation

• Permits greater intracellular accumulation Are the deoxycytidine analogues metabolized/eliminated renally or hepatically?

• Metabolism is not via cytochrome p450 enzymes or glucuronidation

• Renally adjust for high-dose cytarabine (not required for 100–200

mg/m2 continuous infusion dosing)



– Extracellularly, cytarabine is converted to ara-U (neurotoxic metabolite) via cytidine deaminase

ara-U is eliminated renally

Are there drug interactions with any of the deoxycytidine analogues?

• Cytarabine:



– Purine analogues (fludarabine, clofarabine, cladribine) enhance de-oxycitidine kinase and inhibit riboucleotide reductase, thus increasing conversion of cytarabine to active ara-CTP



– 5-FU—cytarabine reduces efficacy of 5-FU



– Methotrexate—increases ara-CTP formation/activity of cytarabine



– Alkylating agents—alkylators inhibit DNA repair, increasing cytarabine cytotoxicity

• Gemcitabine: cisplatin (enhances cytotoxicity of cisplatin), also a potent radiosensitizer

5. ANTIMETABOLITES 81

What are the most common adverse effects of each deoxycytidine analogue?

• Gemcitabine: myelosuppression (all three lineages), flulike symptoms and fever, peripheral edema, LFT abnormalities, dyspnea and pulmonary toxicity, infusion reactions, transient rash (typically erythematous, pruritic, and maculopapular; reversible and respond to local therapy)

• Cytarabine:

Standard-Dose ara-C

High-Dose ara-C (1–3 g/m2)

Myelosuppression

Myelosuppression

Nausea—low

Nausea—moderate

Diarrhea

More diarrhea

Mucositis

Mucositis

Alopecia

Neurotoxicity (cerebellar)

Rash

Conjunctivitis (requires steroid eye drops) Alopecia

• Other ara-C side effects: hand-foot syndrome, hepatotoxicity, ara-C

syndrome (fever, myalgia, bone pain, maculopapular rash, malaise) What are the clinical features of cytarabine-induced cerebellar toxicity?

• Symptoms: gait ataxia, nystagmus, dysmetria, dysarthria (slurred speech), and somnolence; rarely: seizure, coma, cerebral dysfunction

• Risk factors: age, cumulative dose, renal and hepatic dysfunction, rate of administration, CNS involvement, previous neurotoxicity from ara-C

• Time period: usually occurs between the 3rd and 8th day of therapy and typically resolves in 3 to 10 days (sometimes can persist and be fatal)

• Prevention/treatment: hemodialysis to remove neurotoxic ara-U

metabolite

What are the premedications required?

• Premedication is not required for any of the agents

82 I. Traditional Chemotherapy What is the emetogenicity level of the deoxycytidine analogues?

• Moderate risk: cytarabine (200 mg/m2)

• Low risk: gemcitabine, cytarabine (200 mg/m2) Are deoxycytidine analogues vesicants or irritants?

• Gemcitabine is an irritant





II

Next-Generation Antineoplastics





6

Monoclonal Antibodies

What is a monoclonal antibody?

• Protein (immunoglobulin) produced by memory B cells (or plasma cells) that binds to a specific epitope

• As a monoclonal antibody (as opposed to polyclonal antibody), it has monovalent affinity—meaning it binds to one specific epitope What are the various isotypes of antibodies?

• Immunoglobulin G (IgG; IgG1 through 4), IgA (IgA 1 through 2), IgM, IgD, IgE

• Therapeutic monoclonal antibodies are of the IgG isotype How do monoclonal antibodies induce cytotoxicity in target cells?

(Refer to Figure 8.1)

• Antibody-dependent cell-mediated cytotoxicity (ADCC): An effector cell (eg, natural killer [NK] cells, monocytes, macrophages) recognizes the antibody bound to the target cell through Fc receptors and destroys the target cell.

• Complement-dependent cytotoxicity (CDC): Antibody bound to the target cell activates the complement cascade via the classical pathway, ultimately leading to the formation of the membrane attack complex and lysis of the cell.

• Direct killing: Binding of antibody to the epitope on target cells leads to transmission of intracellular signals resulting in apoptosis or programmed cell death.

86 II. Next-Generation Antineoplastics How are monoclonal antibodies named?

Flowchart of How Monoclonal Antibodies Are Named

1. Prefix unique

to drug

2. Target/

-tu-, -t- =

-li-, -l- = immu-

-ki-, -k- =

-ne-, -n- =

disease class

tumor

nomodulator

interleukins

neurons

as target

-so-, -s- =

-ci-, -c- =

-vi-, -v- =

-ba-, -b- =

bone

circulatory

antiviral

bacterial

system

-gro-, -gr- =

-tox-, -toxa- =

-fu-, -f- =

growth

toxin

fungus

factor

3. Antibody

-o- = mouse

-xi- = chimeric

-zu- = hu-

-u- =

source

(100%

(~75%

manized

human

foreign)

human/~25%

(~95%

= fully

foreign)

human/~5%

human

foreign)

(100%

human)

4. Suffix = mab

Are there drug interactions with any of the monoclonal antibodies?

• Monoclonal antibodies are not metabolized via cytochrome P450; therefore no classic, pharmacokinetic drug interactions exist

• Pharmacodynamic interactions are dependent on the specific monoclonal antibody and its pharmacologic effects Are the monoclonal antibodies metabolized/eliminated renally or hepatically?

• No renal or hepatic metabolism/elimination; therefore no dose adjustments necessary

• Typically eliminated by the reticuloendothelial system

6. MONOCLONAL ANTIBODIES 87

Are the monoclonal antibodies vesicants or irritants?

• Ado-trastuzumab emtansine is classified as an irritant, as reactions secondary to extravasation have occurred

• Other monoclonal antibodies are classified as nonvesicants and nonirritants

What is the emetogenicity level of the monoclonal antibodies?

• Low emetogenicity

What are the agents in the monoclonal antibody class?

Agents in the Monoclonal Antibody Class

Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Alemtuzumab

CLL, relapsed

CD52

CLL: 30 mg IV/

• Pancytopenia

• Prophylaxis: herpes simplex

(Campath®)

multiple sclerosis

subcutaneous

• Infusion reactions and

and Pneumocystis jirovecii

(Lemtrada®)

TIW 4–12

fever

• Premedicate: acetaminophen

weeks (titrate

• Headache, fatigue, skin

Benadryl glucocorticoids

88

up on first cycle;

rash, infections (moni-

• Not commercially available—

3 mg, 10 mg,

tor CMV/EBV)

Campath Distribution

30 mg)

• Autoimmune thyroid

Program

disease

• Reinitiate dose escalation

• Antibody development

if treatment withheld for

(not associated with

7 days

decreased efficacy)

• Available as subcutaneous

• Increase in malignancy

route for CLL, which may have

(thyroid cancer, mela-

more injection site reactions

noma, and lymphoma)

and may require a longer dose

escalation

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Bevacizumab

Cervical cancer,

VEGF

5–15 mg/kg IV

• Black box warning:

• Hold around surgery

(Avastin®)

colorectal cancer,

q2–3 weeks

hemorrhage, GI perfora- • Potentiates concomitant glioblastoma,

tion, compromised

chemotherapy toxicities

nonsquamous

wound healing

NSCLC, ovarian

• Fistula formation,

cancer, fallopian

hypertension, wound

tube cancer,

dehiscence, peripheral

89

primary peritoneal

edema, venous and

cancer, renal cell

arterial thrombotic ef-

carcinoma

fects, proteinuria

Blinatumomab

ALL

CD3-CD19

First cycle: 9

• Cytokine release syn-

• Premedicate: IV dexametha-

(Blincyto™)

mcg/day 7

drome

sone

[bi-specific

days, then 28

• Neurotoxicity

• Hospitalize for first 9 days on

T-cell engager]

mcg/day 21

• B-cell aplasia

cycle 1

days

• Tumor lysis syndrome

• Short half-life; therefore is a

Subsequent

• Infection, fever

continuous infusion pump

cycles: 28 mcg

that needs to be changed every

daily 28 days

24–48 hours

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Brentuximab

Refractory

CD30

1.8 mg/kg (max

• Black box warning:

• Premeds: acetaminophen,

vedotin

HL, systemic

180 mg) q3 weeks

JC virus

antihistamine

(Adcetris®)

anaplastic large cell

• Peripheral neuropathy

• Contraindicated with

[Antibody-drug lymphoma

(sensory and motor),

bleomycin due to pulmonary

conjugate]

neutropenia, and

toxicity

thrombocytopenia

• Antibody-drug conjugate:

90

• Hepatotoxicity, tumor

(a) CD30 antibody, (b) MMAE

lysis syndrome, infu-

(microtubule inhibitor),

sion-related reactions

(c) protease-cleavable dipep-

possible, skin rash

tide linker

• Induces cell cycle arrest in

G2/M

• MMAE is metabolized via

CYP3A4 and renally elimi-

nated (no data to suggest dose

modifications)

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Cetuximab

Metastatic

EGFR

400 mg/m2 LD,

• Black box warning:

• Premeds: acetaminophen,

(Erbitux®)

colorectal cancer

then 250 mg/

infusion reactions, car-

antihistamine

KRAS WT, head

m2 weekly. If

diopulmonary arrest

• Anti-cetuximab antibodies

and neck squamous

concurrent with

• Fatigue, skin rash

form in 5% of patients; unclear

cell

radiation, give 1

(acneiform, erythema,

if this affects efficacy

dose/week

pruritus), hand-foot

• High prevalence of hypersen-

91

(off-label 500

syndrome, diarrhea,

sitivity reactions to cetuxi-

mg/m2 every

periungual/nail al-

mab in Southeastern United

2 weeks)

terations, hypomagne-

States (Tennessee, North

semia, nausea,

Carolina, Virginia, Missouri,

warning for cardio-

Arkansas)—due to IgE anti-

pulmonary arrest with

body against galactose-α-1,

XRT, interstitial lung

3-galactose present on Fab por-

disease, trichomegaly

tion of cetuximab (not present

and poliosis of the

in panitumumab)

eyelashes

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Denosumab

Prevention of

RANKL

120 mg

• Hypocalcemia, bone

• Prevents osteoclastic bone

(Xgeva®)

skeletal-related

subcutaneous

fractures, rash, oste-

resorption

events in patients

every 4 weeks

onecrosis of the jaw,

• Administer with vitamin D

with bone

Osteoporosis/

musculoskeletal pain,

and calcium

metastasis from

bone loss—60 mg

fatigue

• Caution in renal impairment

solid tumors, giant

subcutaneous

cell tumor of the

every 6 months

92

bone, osteoporosis/

bone loss (Prolia®)

Dinutuximab

Neuroblastoma

GD2

17.5 mg/m2/

• Extreme pain, periph-

• ADCC and CDC

(Unituxin™)

(pediatric)

day 4 days

eral neuropathy, bone

• Premeds: opioids, hydration,

5 cycles (on

marrow suppression,

antihistamine acetami-

different days of

capillary leak syn-

nophen

cycle depending

drome, hypotension,

• Requires pain management

on odd or even

hyponatremia, hypoka-

because GD2 is expressed on

cycle)

lemia, hypocalcemia,

nerves

syndrome of inap-

propriate antidiuretic,

ocular toxicity, HUS

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Eculizumab

Atypical HUS, PNH C5 comp-

900 mg (600 mg)

• Infections with encap-

• Vaccinate for encapsulated

(Soliris®)

lement

weekly 4

sulated organisms and

organisms

protein

doses, then 1,200

aspergillus, hyperten-

• Blocks formation of C5b thereby

mg (900 mg)

sion, peripheral edema,

inhibiting the formation of

every 2 weeks

headache, diarrhea,

the terminal membrane attack

() PNH dosing

nausea

complex C5b-9, preventing

complement-induced cell death

Gemtuzumab

(approved for AML CD33

6–9 mg/m2

• Cerebral hemorrhage,

• Premeds: acetaminophen,

ozogamicin

but pulled from

q14–28 days

93

2

bone marrow suppres-

antihistamine

(Mylotarg®)

market) potential

doses

sion, hepatotoxicity

• Due to safety concerns and

[Antibody-drug future uses APL,

including veno-occlu-

lack of clinical benefit, with-

conjugate]

AML

sive disease, pulmonary

drawn from the market

toxicity (higher risk

• Antibody-drug conjugate:

with WBC 30)

(a) CD33 antibody, (b) cali-

cheamicin (antitumor antibiotic)

• Antibody-drug conjugate deliv-

ered into cell upon binding to

CD33 via endocytosis

• Covalent link is hydrolyzed in

the acidic cellular environment

and calicheamicin is released.

G2/M cell cycle arrest

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Ibritumomab

Relapsed/

CD20

Within 4 hours of • Black box warning:

• B-cell recovery in 3 months

tiuxetan

refractory, low-

rituximab

bone marrow suppres-

• Antibody-drug conjugate:

(Zevalin®)

grade or follicular

-Plts 150,000:

sion, thrombocytopenia

(a) CD20 antibody, (b)

[Antibody-

NHL; previously

0.4 mCi/kg

(nadir 50 days), neutro-

tiuxetan chelator that binds

radioisotope

untreated follicular

-Plts 100,000–

penia (nadir 60 days),

the yttrium-90 (radioactive

conjugate]

NHL patients who

150,000: 0.3 mCi/

anemia (nadir 70 days),

isotope)—β-emission induces

achieve a partial or

kg (max 32 mCi)

infusion reactions, and

in vitro apoptosis due to free

complete response

mucocutaneous reac-

radical formation in CD20 cells

94

to first-line

tions

and in lymphoid cells/

chemotherapy

• Secondary malignan-

nodules/organs

cies and MDS, respira-

• Affects surrounding cells due

tory reactions, radiation

to path length of 100–200 cells

necrosis, delayed radia-

(collateral damage)

tion injury (1 month)

• Avoid in plts 100

Ipilimumab

Unresectable

CTLA-4

3 mg/kg IV q3

• Black box warning:

• CTLA-4 downregulates T-cell

(Yervoy®)

metastatic

weeks 4 doses

induces GVHD-like

activation; blockade of CTLA-4

melanoma

symptoms (enterocol-

allows T-cell activation and

itis, hepatitis, dermati-

proliferation

tis, endocrinopathies)

• Clinical response and toxici-

ties take weeks to months to

manifest

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

• Fatigue, headache,

• Manage severe (grade 3–4)

nausea, diarrhea, rare

toxicities with high-dose

but fatal neurotoxicity

corticosteroids; may require

(hypophysitis)

other immunosuppressants if

refractory (eg, TNF-α inhibi-

tors, mycophenolic acid)

Nivolumab

Unresectable

PD-1

3 mg/kg IV

• Fatigue, rash, vitiligo,

• Binds to PD-1 receptor to block

95

(Opdivo®)

or metastatic

every 2 weeks

pruritus, diarrhea

PD1 ligands from binding

melanoma with

• Immunological tox-

• Prevents the suppression of T

progression

icities are much less

cells thereby inducing antitu-

following

than ipilimumab but

mor immune responses

ipilimumab and

possible (hepatotoxic-

• Clinical response and toxici-

a BRAF inhibitor,

ity, endocrinopathies,

ties take weeks to months to

metastatic

colitis, skin rash)

manifest

squamous cell

• Manage immunologic toxici-

NSCLC progressed

ties similar to ipilimumab

on platinum

chemotherapy

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Obinutuzumab

Untreated CLL in

CD20

1,000 mg on days • Black box warning:

• Premeds: acetaminophen, anti-

(Gazyva™)

combination with

1, 8, and 15 of

HBV reactivation and

histamine corticosteroid

chlorambucil

cycle 1 and on

PML

• Type 2 monoclonal antibody

day 1 of cycles 2

• Infusion-related reac-

(does not induce redistribution

through 6 (28-day

tions (generally with

of CD20 into detergent-resist-

cycles) (titrate

first cycle only)

ant lipid rafts)

up on first cycle;

• Tumor lysis syndrome

• More direct cytotoxicity and

100 mg on day 1;

(greater risk and

ADCC than rituximab

900 mg on day 2)

infusion reactions than

• Less CDC than rituximab

96

rituximab)

• Binds to large loop of CD20

receptor

Ofatumumab

CLL

CD20

Untreated: 1,000

• Infusion-related reac-

• Premeds: acetaminophen, anti-

(Arzerra®)

mg IV every

tions (generally with

histamine corticosteroid

28 days 3–12

first cycle only)

• Type 1 monoclonal antibody

cycles (titrate up

• Tumor lysis syndrome

• Similar ADCC and direct cell

on first cycle)

• HBV reactivation

kill as rituximab

Refractory: 300

• PML

• More CDC than rituximab

mg week 1, then

• Binds to small and large loops

2,000 mg weekly

of CD20 receptor, to an epitope

7 doses, then

closer to cell membrane

2,000 mg q4

weeks (4 doses)

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Panitumumab

Metastatic

EGFR

6 mg/kg every 14 • Black box warning:

• Less infusion reactions than

(Vectibix®)

colorectal cancer,

days until disease

dermatologic toxicity

cetuximab

KRAS WT

progression or

• Fatigue, skin rash

• Safe option for patients

toxicity

(acneiform, erythema,

sensitized to galactose-α-

pruritus), hand-foot

1,3-galactose antigen (see

syndrome, diarrhea,

cetuximab)

periungual/nail altera-

tions, hypomagnesemia,

nausea, interstitial lung

97

disease, trichomegaly and

poliosis of the eyelashes

Pembrolizumab Unresectable

PD-1

2 mg/kg

• Fatigue, rash, vitiligo,

• Binds to PD-1 receptor to block

(Keytruda®)

or metastatic

every 3 weeks

pruritus, diarrhea

PD1 ligands from binding

melanoma with

until disease

• Immunological tox-

• Prevents the suppression of T

progression

progression or

icities are much less

cells thereby inducing antitu-

following

unacceptable

than ipilimumab but

mor immune responses

ipilimumab and a

toxicity

possible (hepatotoxic-

• Clinical response and toxici-

BRAF inhibitor

ity, endocrinopathies,

ties take weeks to months to

colitis, skin rash)

manifest

• Manage immunologic toxici-

ties similar to ipilimumab

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Pertuzumab

HER2 breast

HER2

840 mg LD then

• Alopecia, rash/hand-

• Combined with trastuzumab

(Perjeta®)

cancer (neoadjuvant

420 mg q3 weeks

foot syndrome, dry

because it binds a different site

and metastatic)

skin, fatigue, mucositis,

on the HER2 receptor, prevent-

febrile neutropenia,

ing HER2 dimerization and

peripheral neuropa-

leading to a more complete

thy, diarrhea, nausea/

blockade of HER2 signaling

vomiting, neutropenia,

• Administer docetaxel after

cardiotoxicity, infusion-

HER2 blockers

98

related reactions

Ramucirumab

Advanced/

VEGFR2

8 mg/kg IV every • Black box warning:

• Premeds: H1 antagonist

(Cyramza®)

metastatic gastric

2 weeks (gastric

hemorrhage, GI perfora-

dexamethasone and acetami-

cancer, NSCLC

and colorectal

tion, compromised

nophen

cancer);

wound healing

• Specific for VEGF2 receptor

10 mg/kg IV

• Fistula formation,

• May potentiate concomitant

every 3 weeks

diarrhea, hypertension,

chemotherapy toxicities

(NSCLC)

wound dehiscence, pe-

ripheral edema, venous

and arterial thrombotic

effects, proteinuria, in-

fusion-related reactions

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Rituximab

CD20-positive

CD20

Initial: 375–500

• Black box warning: infu- • Premeds: acetaminophen (Rituxan®)

NHLs, CLL in

mg/m2 once

sion-related reactions

antihistamine

combination with

weekly to every 3

(generally with first

• Type 1 monoclonal antibody

fludarabine and

weeks

cycle only), mucocuta-

• Binds to large loop of CD20

cyclophosphamide

neous reactions, HBV

receptor

reactivation, PML

• Tumor lysis syndrome,

99

infections, hypogam-

maglobulinemia

Tositumomab

Relapsed/

C20

Requires

• Black box warning:

• Requires thyroid protection

(Bexxar®)

refractory CD20

dosimetry

Bone marrow suppres-

• Premeds: acetaminophen,

[Antibody-

low-grade,

calibration

sion (prolonged and

Benadryl

radioisotope

follicular or NHL

Plts 150,000: 35

severe), anaphylaxis

• Human anti-mouse antibody

conjugate]

(failed rituximab)

mg tositumomab

• Hypothyroidism, infu-

seroconversion (10% of

with iodine-131

sion reactions, second-

patients)

(I-131) to deliver

ary leukemia, fever,

• Antibody-drug conjugate:

75 cGy TBI

rash, nausea, abdominal

(a) CD20 antibody, (b) I-131

pain, diarrhea, weak-

ness, myalgia

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

-Plts <100,000–

• Antibody-radioisotope conju-

150,000: 35 mg

gate delivered into cell upon

tositumomab

binding to CD20 via endocyto-

with 65 cGy TBI,

sis. Covalent link is hydrolyzed

single treatment

in the acidic environment and

I-131 is released. Apoptosis,

10

CDC, ADCC, radiation-in-

0

duced cell death occur

Trastuzumab

HER2 breast

HER2

4 mg/kg LD,

• Black box warning: car-

• Not interchangeable with ado-

(Herceptin®)

cancer (adjuvant,

then 2 mg/kg

diotoxicity: avoid with

trastuzumab

metastatic), HER2

weekly

anthracyclines (gener-

• Adjuvant duration is 52 weeks

metastatic gastric

8 mg/kg LD,

ally transient and revers-

or 1 year

cancer

then 6 mg/kg

ible over 1–3 months),

every 3 weeks

infusion reactions,

(can also give

embryo-fetal toxicity

6 mg/kg LD and

• Pain, headache, nausea/

4 mg/kg every

vomiting, diarrhea, infec-

2 weeks)

tion, pulmonary toxicity

( continued)

Agents in the Monoclonal Antibody Class ( continued ) Name

FDA-Approved

Target

Dose Range

Toxicities (notable)

Comments

Indication

Ado-

HER2 breast

HER2

3.6 mg/kg every

• Black box warning: not

• Antibody-drug conjugate:

trastuzumab

cancer (metastatic

3 weeks

interchangeable with

(a) trastuzumab (b) DM1-

emtansine

patients who have

trastuzumab, cardio-

microtubule inhibitor (may-

(Kadcyla®)

failed trastuzumab

toxicity, hepatotoxicity,

tansine) (c) linker: thioether

and taxane)

embryo-fetal toxicity

• Cell cycle arrest in G2/M

• Thrombocytopenia

phase and apoptosis

(and bleeds), anemia,

• Maytansine is metabolized by

neutropenia

CYP3A4

10

• Hypokalemia, hepatotox-

• An irritant: reactions due

1

icity, pulmonary toxicity

to extravasation have been

• Fatigue, headache, pe-

reported

ripheral neuropathy

Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia ; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus ; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CYP, cytochrome P450; EBV, Epstein–Barr Virus; EGFR, epidermal growth factor receptor; FDA, U.S. Food and Drug Administration; GVHD, graft-versus-host disease; HBV, hepatitis B virus; HER2, human epidermal growth factor receptor type 2; HL, Hodgkin’s lymphoma; HUS, hemolytic uremic syndrome; IgE, immunoglobulin E; IV, intravenous; JC virus, John Cunningham virus; LD, loading dose; MDS, myelodysplastic syndrome ; MMAE, monomethyl auristatin E; NHL, non-Hodgkin’s lymphoma; NSCLC, non–small cell lung cancer; Plt, platelet; PML, progressive multifocal leukoencephalopathy; PNH, paroxysmal nocturnal hemoglobinuria; RANKL, receptor activator of NF kappa B ligand; TBI, total body irradiation; TIW, three times a week; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; WBC, white blood cell; WT, wild type; XRT, radiation therapy.





7

VEGF Trap

ZIV-AFLIBERCEPT (ZALTRAP®)

What malignancy is ziv-aflibercept approved for?

• Metastatic colorectal cancer

How does ziv-aflibercept work?

• Ziv-aflibercept works by inhibiting angiogenesis, essential for tumor growth

• Ziv-aflibercept is a recombinant fusion protein consisting of portions of the binding domains for vascular endothelial growth factor receptor-1 and -2 (VEGFR1-2), attached to the Fc portion of human immunoglobulin G1 (IgG1), creating a “VEGF Trap” protein

• This fusion protein acts as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PIGF), thus preventing VEGFR binding and activation of angiogenesis

What is the usual dose of ziv-aflibercept?

• 4 mg/kg intravenously (IV) over 1 hour every 2 weeks Is ziv-aflibercept metabolized/eliminated renally or hepatically?

• Ziv-aflibercept is neither metabolized hepatically nor eliminated renally

Are there drug interactions with ziv-aflibercept?

• No clinically important drug-drug interactions have been reported for ziv-aflibercept

104 II. Next-Generation Antineoplastics What are the most common adverse effects of ziv-aflibercept?

• Headache, fatigue

• Hypertension

• Bleeding

• Gastrointestinal (GI) perforation, fistula formation, and delayed wound healing (all rare but possible)



– It is recommended to suspend ziv-aflibercept at least 4 weeks prior to surgery and to wait at least 4 weeks after surgery (and after wound has fully healed) to resume therapy

• Proteinuria

• Venous thromboembolism (VTE) and arterial thromboembolic events (transient ischemic attacks [TIAs], cerebrovascular accidents

[CVAs], angina, etc.)

• Dysphonia

• Increased liver function tests (LFTs)

• Diarrhea, mucositis

• Hand-foot syndrome, skin hyperpigmentation

• Neutropenia and thrombocytopenia

• Infections

What is the emetogenicity level of ziv-aflibercept?

• Ziv-aflibercept is categorized as low emetic risk (10%–30%) Is ziv-aflibercept a vesicant or irritant?

• Ziv-aflibercept is neither a vesicant nor an irritant





8

Tyrosine Kinase Inhibitors

ANGIOGENESIS INHIBITORS AND

MULTI-KINASE INHIBITORS

What are the agents in the angiogenesis inhibitor class?

• Sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), axitinib (Inlyta®), regorafenib (Stivarga®), lenvatinib (Lenvima™), cabozantinib (Cometriq®), vandetanib (Caprelsa®) What malignancies are each vascular endothelial growth factor receptor (VEGFR) inhibitor FDA approved for?

FDA-Approved Uses of VEGFR Inhibitors

Agent FDA

Approval

Sorafenib

Renal cell carcinoma, hepatocellular carcinoma, thyroid cancer

Sunitinib

Renal cell carcinoma, gastrointestinal stromal tumor, pancreatic neuroendocrine tumors

Pazopanib

Renal cell carcinoma, soft tissue sarcoma

Axitinib

Renal cell carcinoma

Regorafenib

Colorectal cancer (metastatic)

Lenvatinib

Differentiated thyroid cancer (radioactive iodine-refractory)

Cabozantinib

Progressive, metastatic medullary thyroid cancer Vandetanib

Medullary thyroid cancer, locally advanced or metastatic

Abbreviation: FDA, U.S. Food and Drug Administration.

106 II. Next-Generation Antineoplastics How do the angiogenesis inhibitors work?

• Vascular endothelial growth factor (VEGF) binds to its receptor tyrosine kinase, VEGFR, to promote angiogenesis and vasculogenesis.

VEGFR inhibitors bind intracellularly to the tyrosine kinase, preventing downstream signaling and angiogenesis necessary for tumor growth.

• Platelet-derived growth factor (PDGF) binds to its receptor tyrosine kinase, PDGFR, promoting angiogenesis and activation of various signal transduction pathways leading to proliferation, differentiation, and cell migration. Tyrosine kinase inhibitors of this pathway bind PDGFR

intracellularly, preventing this signal transduction and downstream effects.

How do the mechanisms of these tyrosine kinase inhibitors differ?

• Each tyrosine kinase inhibitor has a unique profile of tyrosine kinase targets

Targets for Each Tyrosine Kinase Inhibitor

Agent

Tyrosine Kinase Targets

Sorafenib

VEGFR-1,2,3; PDGFR-β; cKIT; FLT-3; RET; C/BRAF

Sunitinib

VEGFR-1,2,3; PDGFR-α,β; CSF-1R; cKIT; FLT-3; RET

Pazopanib

VEGFR-1,2,3; PDGFR-α,β; FGFR-1,3; cKIT; Itk; c-FMS; Lck

Axitinib

VEGFR-1,2,3

Regorafenib

VEGFR-1,2,3; PDGFR-α,β; FGFR-1,2; TIE2; DDR2; Trk2A; Eph2A; cKIT; RAF-1; BRAF; SAPK2; PTK5; RET; Abl

Lenvatinib

VEGFR-1,2,3; FGFR-1,2,3,4; PDGFR-α; cKIT; RET

Cabozantinib VEGFR-1,2,3; RET; MET; FLT-3; cKIT; TKRB; AXL; TIE-2

Vandetanib

EGFR; VEGFR; RET; BRK; TIE2; EPH kinase receptors; SRC kinase receptors

8. TYROSINE KINASE INHIBITORS 107

• Medullary thyroid cancer is commonly associated with mutations in the rearranged during transfection (RET) proto-oncogene. Thus, cabozantinib and vandetanib, in addition to targeting VEGFR and other key signaling pathways, inhibit RET signaling.

• Gastrointestinal stromal tumor (GIST) is characteristically driven by mutations in cKIT; thus, sunitinib and other agents utilized in GIST (see imatinib in “Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 [BCR-ABL] Inhibitors”) are targeted against inhibition of cKIT signaling.

What are the common dose ranges for each angiogenesis inhibitor?

• Sorafenib: 400 mg orally, twice a day BID (empty stomach)

• Sunitinib: 50 mg orally, daily; 4 weeks on and 2 weeks off, or for some indications, 37.5 mg orally continuous

• Pazopanib: 800 mg orally, daily (empty stomach)

• Axitinib: 5 mg orally, BID (titrate up to 10 mg if no grade 2 events)

• Regorafenib: 160 mg orally, once daily with food (a low-fat break-fast); 3 weeks on and 1 week off

• Lenvatinib: 24 mg orally, daily

• Cabozantinib: 140 mg orally, daily (empty stomach)

• Vandetanib: 300 mg orally, daily

Are the angiogenesis inhibitors metabolized/eliminated renally or hepatically?

• All eight agents are metabolized hepatically

• Cabozantinib, vandetanib, and lenvatinib require dose adjustments for renal impairment (~25% is eliminated renally) Are there drug interactions with any of the angiogenesis inhibitors?

• All eight agents have drug interactions with cytochrome P450

inhibitors/inducers

108 II. Next-Generation Antineoplastics

Drug Interactions With Angiogenesis Inhibitors

CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 UGT1A1 UGT1A9

Sorafenib

INH

INH

SUB

INH

SUB;

INH

Sunitinib

SUB

Pazopanib

SUB

SUB;

INH

SUB;

INH

INH

INH

Axitinib

SUB

SUB

SUB

SUB

Regorafenib

SUB

INH

SUB;

INH

Lenvatinib

SUB

Cabozantinib

SUB

SUB

Abbreviations: SUB, substrate (bold if major); INH, inhibitor (bold if strong); IND, inducer (bold if strong).

• In vitro, lenvatinib inhibits CYP1A2, 2C8, 2C9, 2C19, 2D6, 3A4, and UGT1A1; however, the clinical significance of this in vitro effect is unknown

• Pazopanib requires an acidic pH for absorption; avoid with agents that raise gastric pH. Consider use of short-acting antacids separated by several hours from administration over longer-acting agents such as proton pump inhibitors (PPIs; suppress acid for ~24 hrs) or H2 receptor antagonists (H2RAs; suppress acid for ~12 hrs) What are the class adverse effects of the angiogenesis inhibitors?

• Hypertension

• Liver dysfunction

• Rash

• Nausea

• Proteinuria

• Fatigue

• Hair/skin depigmentation

• Hand-foot syndrome

• Delayed wound healing

• Bleeding

8. TYROSINE KINASE INHIBITORS 109

• Diarrhea

• Hypothyroidism

What are the most common adverse effects of each angiogenesis inhibitor?

• Sorafenib: hand-foot syndrome, rash, alopecia, hypophosphatemia

• Sunitinib: hand-foot syndrome, mucositis/stomatitis, myelosuppression, dysgeusia, fatigue, hair color changes

• Pazopanib: hypertension, hepatotoxicity, hair color changes

• Axitinib: hypertension, nausea, diarrhea

• Regorafenib: hand-foot skin reaction, fatigue, diarrhea, hypertension, dysphonia, and rash or desquamation

• Lenvatinib: hypertension, diarrhea, fatigue or asthenia, decreased appetite, decreased weight, mucositis, myalgia/arthralgia, dysphonia, and nausea

• Cabozantinib: diarrhea (black box warning for GI perforations, GI fistulas, and GI hemorrhage), rash, hand-foot syndrome, weight loss, decreased appetite, hypertension, increased liver function test (LFTs)

• Vandetanib: diarrhea, QT prolongation (black box warning), re-stricted access, rash, acne/dermatitis, nausea, hypertension, hypogly-cemia

What is the emetogenicity level of the angiogenesis inhibitors?

• All agents are categorized as minimal to low except for lenvatinib

• Lenvatinib is considered moderate to high emetic risk





110 II. Next-Generation Antineoplastics

BREAKPOINT CLUSTER REGION-ABELSON MURINE

LEUKEMIA VIRAL ONCOGENE HOMOLOG 1

(BCR-ABL) INHIBITORS

What are the agents in the breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) inhibitor class?

• Imatinib (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), ponatinib (Iclusig®)

What malignancies are each BCR-ABL inhibitor FDA approved for?

FDA-Approved Uses of BCR-ABL Inhibitors

Agent

FDA Approval

Imatinib

CML (chronic, accelerated, and blast phases), Philadelphia chromosome-positive ALL,

myelodysplastic/myeloproliferative disorders with PDGFR gene rearrangements, aggressive systemic mastocytosis (without D816V c-kit mutations), hypereosinophilic syndrome, chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase,

dermatofibrosarcoma protuberans, GISTs

Dasatinib

CML (chronic, accelerated, and blast phases) Nilotinib

CML (chronic and accelerated phases; not blast phase) Bosutinib

CML (chronic, accelerated, and blast phases) Ponatinib

CML (chronic, accelerated, and blast phases) Abbreviations: ALL, acute lymphoblastic leukemia; BCR-ABL, breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1; CML, chronic myeloid leukemia; FDA, U.S. Food and Drug administration; GIST, gastrointestinal stromal tumor; PDGFR, platelet-derived growth factor receptor.

How do the BCR-ABL inhibitors work in chronic myeloid leukemia (CML)?

• The hallmark genetic driver of CML (and Philadelphia chromosome-positive ALL) is BCR-ABL. ABL is a proto-oncogene that encodes

8. TYROSINE KINASE INHIBITORS 111

a tyrosine kinase. Upon ABL translocation from chromosome 9 to a position adjacent to BCR on chromosome 22, the resulting BCR-ABL

fusion gene produces a BCR-ABL tyrosine kinase that is constitutively active. The overall net effect is leukemogenesis due to constant signaling via the BCR-ABL tyrosine kinase driving cells to divide and prolif-erate. Cells also lose their ability to undergo apoptosis.

• BCR-ABL inhibitors work by binding to amino acids at the adenosine triphosphate (ATP) binding site of the BCR-ABL tyrosine kinase. This prevents tyrosine kinase autophosphorylation and phosphorylation of downstream signaling pathways that promote leukemogenesis.

• Each BCR-ABL inhibitor binds to the tyrosine kinase differently and with differing potency. Point mutations in the tyrosine kinase lead to resistance to certain BCR-ABL inhibitors.

• The gatekeeper T315I (substitution of a bulky isoleucine residue) mutation blocks access to the ATP binding site, leading to resistance to the majority of tyrosine kinase inhibitors. Ponatinib is structurally designed to contain a carbon-carbon triple bond linkage to avoid steric hindrance from the isoleucine residue, making it the only agent with activity against the T315I mutation.

• Each BCR-ABL inhibitor has multiple other tyrosine kinase targets in addition to BCR-ABL kinase.

What other targets do the BCR-ABL inhibitors have activity against?

• Imatinib: cKIT, PDGFR-α, PDGFR-β, ABL2, CSF1R, SCF

• Dasatinib: SRC family kinases, cKIT, PDGFR-α, PDGFR-β, ABL2, CSF1R (dasatinib inhibits several other kinases)

• Nilotinib: cKIT, PDGFR-α, PDGFR-β, ABL2, CSF1R

• Bosutinib: Src family kinases (does not inhibit cKIT or PDGFR, thus has less myelosuppression)

• Ponatinib: VEGFR-1,2,3, SRC, cKIT, PDGFR-α, PDGFR-β, ABL2, CSF1R (ponatinib inhibits several other kinases) What are the common dose ranges for each BCR-ABL inhibitor?

• Imatinib: 400 to 600 mg orally, daily (with food); 400 mg orally, BID

(with food) for dermatofibrosarcoma protuberans

112 II. Next-Generation Antineoplastics

• Dasatinib: 100 to 140 mg orally, daily

• Nilotinib: 300 to 400 mg orally, BID (empty stomach)

• Bosutinib: 500 to 600 mg orally, daily (with food)

• Ponatinib: 30 to 45 mg orally, daily

Are the BCR-ABL inhibitors metabolized/eliminated renally or hepatically?

• All five agents are metabolized hepatically

• Imatinib requires dose adjustments for renal impairment Are there drug interactions with any of the BCR-ABL inhibitors?

• All five agents will have drug interactions with cytochrome P450

inhibitors/inducers

Drug Interactions With BCR-ABL Inhibitors

CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 UGT1A1

Imatinib

SUB

SUB

SUB;

SUB

SUB;

SUB;

INH

INH

INH

Dasatinib

SUB;

INH

Nilotinib

INH;

INH;

INH

SUB;

INH

IND

IND

INH

Bosutinib

SUB

Ponatinib

SUB

SUB

SUB

Abbreviations: BCR-ABL, breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1; SUB, substrate (bold if major); INH, inhibitor (bold if strong); IND, inducer (bold if strong).

• BCR-ABL inhibitors (with the exception of imatinib) require an acidic pH for absorption; avoid with agents that raise gastric pH. Consider use of short-acting antacids separated by several hours from administration over longer-acting agents such as PPIs (suppress acid for ~24 hrs) or H2RAs (suppress acid for ~12 hrs)

8. TYROSINE KINASE INHIBITORS 113

What are the most notable adverse effects of each BCR-ABL inhibitor?

• Imatinib: edema/fluid retention, myalgia, hypophosphatemia, diarrhea, nausea, neutropenia

• Dasatinib: pleural/pericardial effusions, increased bleeding risk, pulmonary arterial hypertension, thrombocytopenia, more neutropenia than imatinib

• Nilotinib: pancreatitis, indirect hyperbilirubinemia (due to inhibition of UGT1A1), hyperglycemia, QT prolongation, peripheral arterial occlusive disease and cardiovascular events, neutropenia

• Bosutinib: diarrhea, nausea/emesis, rash, hepatotoxicity, less myelosuppression than all

• Ponatinib: pancreatitis, hypertension, rash, arterial and venous thrombotic events, hepatotoxicity, more myelosuppression than imatinib

What is the emetogenicity level of the BCR-ABL inhibitors?

• All agents are categorized as minimal to low





114 II. Next-Generation Antineoplastics

B-CELL RECEPTOR (BCR) PATHWAY INHIBITORS

What are the agents in the B-cell receptor (BCR) pathway inhibitor class?

• Ibrutinib (Imbruvica®)

• Idelalisib (Zydelig®)

What malignancies are each BCR pathway inhibitor FDA approved for?

FDA-Approved Uses of BCR Pathway Inhibitors

Agent

FDA Approval

Ibrutinib

Mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia (WM) Idelalisib

CLL (in combination with rituximab), follicular lymphoma, small lymphocytic lymphoma

Abbreviations: BCR, B-cell receptor; FDA, U.S. Food and Drug Administration.

How do the BCR pathway inhibitors work? (Figure 8.1)

• The BCR is composed of membrane immunoglobulins associated with Igα and Igβ heterodimers (CD79a/CD79b). The membrane immunoglobulins bind antigen extracellularly and activate the heterodimers; intracellular signal transduction results

• Antigen- or ligand-independent signaling also occurs (tonic signaling)

• Both antigen-dependent and antigen-independent signaling lead to activation of the Src family kinases, Syk, Bruton’s tyrosine kinase (BTK), phospholipase C (PLCγ2), phosphoinositide 3-kinase (PI3K), and other signaling molecules and cascades

• As a result, many cellular processes occur, such as differentiation, proliferation, motility, homing, adhesion, chemotaxis, and survival How do the mechanisms of ibrutinib and idelalisib differ? (Figure 8.1)

• Ibrutinib: BTK inhibitor (although also has several other targets)



8. TYROSINE KINASE INHIBITORS 115

EGFR

Cetuximab

Receptor

panitumumab

B-cell

Receptor

EGFR tyrosine

kinase

Gefitinib, erlotinib, afatinib

LYN

SYK

Ras

Vemurafenib

Ibrutinib BTK

PI3K Idelalisib

Raf

dabrafenib

PLCg2

AKT

MEK

Trametinib

PKC

mTOR

ERK/MAPK

Nucleus

FIGURE 8.1. Tyrosine kinase and monoclonals: Mutations in epidermal growth factor receptor (EGFR) and BRAF lead to hyperstimulation of the EGFR-Ras-Raf-MEK-ERK/MAPK pathway resulting in hyperproliferation, reduced apoptosis, and increased invasiveness/metastatic potential of cancer cells. Monoclonal antibodies bind to receptors extracellularly.

Cetuximab and panitumumab bind to the EGFR receptor and block downstream signal transduction. Tyrosine kinase inhibitors act intracellularly to inhibit tyrosine kinase signaling. The tyrosine kinase inhibitors gefi tinib, erlotinib, and afatinib bind and inhibit the EGFR tyrosine kinase, preventing phosphorylation and thereby inhibiting further downstream signaling.

Vemurafenib and dabrafenib bind and inhibit the BRAF kinase preventing phosphorylation and thereby inhibiting further downstream signaling.

Trametinib binds and inhibits MEK, which is downstream of BRAF.

The B-cell receptor is activated by both antigen-dependent and antigen-independent signaling. Overactivation of the Src family kinases (Lyn and Syk), BTK, PLCγ2, PI3K, and other signaling molecules and cascades can occur in various lymphomas/leukemias. As a result, many cellular processes occur such as proliferation, motility, homing, adhesion, chemotaxis, and survival. Ibrutinib inhibits BTK and idelalisib inhibits PI3K-δ.

116 II. Next-Generation Antineoplastics

• Idelalisib: phosphoinositide 3-kinase delta (PI3Kδ) kinase inhibitor (although also has several other targets)

What are the common dosing ranges for each BCR pathway inhibitor?

• Ibrutinib: 420 mg orally, daily (for chronic lymphocytic leukemia

[CLL] and Waldenström’s macroglobulinemia [WM]); 560 mg orally, daily (for mantle cell lymphoma [MCL])

• Idelalisib: 150 mg orally, BID

Are the BCR pathway inhibitors metabolized/eliminated renally or hepatically?

• Both agents are metabolized hepatically with little renal excretion Are there drug interactions with any of the BCR pathway inhibitors?

• Both agents have drug interactions with cytochrome P450 inhibitors/

inducers

Drug Interactions With BCR Pathway Inhibitors

CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 UGT1A1 UGT1A4

Ibrutinib

SUB

Idelalisib

INH

INH

SUB;

INH

SUB

INH

Abbreviations: INH, inhibitor (bold if strong); SUB, substrate (bold if major).

• Ibrutinib should be avoided in patients on warfarin due to bleeding risk from the antiplatelet effect of ibrutinib; ibrutinib should also be used with caution in those taking other therapeutic anticoagulants or antiplatelet drugs, as bleeding risk can increase significantly

• While systemic ibrutinib is unlikely to inhibit P-glycoprotein (P-gp), higher local concentrations in the GI tract may lead to an effect on P-gp substrates in the GI tract. Use caution when coadminister-ing ibrutinib with substrates of P-gp with a narrow therapeutic index (eg, digoxin)

8. TYROSINE KINASE INHIBITORS 117

What are the most notable adverse effects of each BCR pathway inhibitor?

• Ibrutinib: diarrhea, bruising, rash, petechiae, bleeding, atrial fibril-lation, lymphocytosis, neutropenia

• Idelalisib: diarrhea (early and late onset; late onset is thought to be an immune-mediated colitis), pyrexia, fatigue, neutropenia, rash, hepatotoxicity, pneumonitis, intestinal perforation What is the emetogenicity level of the BCR pathway inhibitors?

• Both agents are considered minimal to low risk





118 II. Next-Generation Antineoplastics

EGFR-RAS-RAF-MEK-ERK (MAPK)

PATHWAY INHIBITORS

What are the agents in the mitogen-activated protein kinase (MAPK) pathway inhibitor class?

• Epidermal growth factor receptor (EGFR) inhibitors—gefitinib (Iressa®), erlotinib (Tarceva®), afatinib (Gilotrif™)

• BRAF inhibitors—vemurafenib (Zelboraf®), dabrafenib (Tafinlar®)

• MEK inhibitor—trametinib (Mekinist™)

What malignancies are each MAPK pathway inhibitor FDA approved for?

FDA-Approved Uses of MAPK Pathway Inhibitors

Agent

FDA Approval

Gefitinib

Non–small cell lung cancer (NSCLC)

Erlotinib

NSCLC, pancreatic cancer

Afatinib

NSCLC

Vemurafenib

Melanoma (BRAF mutated)

Dabrafenib

Melanoma (BRAF mutated) single agent and in combination with trametinib

Trametinib

Melanoma (BRAF mutated)

Abbreviations: FDA, U.S. Food and Drug Administration; MAPK, mitogen-activated protein kinase.

How do the MAPK pathway inhibitors work? (Figure 8.1)

• Mutations in the EGFR and BRAF tyrosine kinases lead to hyperstimulation of the EGFR-Ras-Raf-MEK-ERK pathway resulting in hyperproliferation, reduced apoptosis, and increased invasiveness/

metastatic potential

• Gefitinib, erlotinib, and afatinib bind and inhibit the EGFR tyrosine kinase, preventing phosphorylation of downstream targets, thereby inhibiting further MAPK pathway signaling

8. TYROSINE KINASE INHIBITORS 119

• Vemurafenib and dabrafenib bind and inhibit the BRAF kinase, preventing phosphorylation of downstream targets, thereby inhibiting further MAPK signaling

• Trametinib binds to and inhibits MEK, which is downstream of BRAF

What are the common dose ranges for each MAPK pathway inhibitor?

• Gefitinib: 250 mg orally, daily

• Erlotinib: 150 mg orally, daily (non–small cell lung cancer [NSCLC]); 100 mg orally, daily (pancreatic; empty stomach)

• Afatinib: 40 mg orally, daily (empty stomach)

• Vemurafenib: 960 mg orally, BID

• Dabrafenib: 150 mg orally, BID (empty stomach)

• Trametinib: 2 mg orally, daily (empty stomach) Are the MAPK pathway inhibitors metabolized/eliminated renally or hepatically?

• Gefitinib, erlotinib, vemurafenib, and dabrafenib are metabolized hepatically

• Afatinib does not require renal or hepatic adjustments; this agent is covalently adducted to proteins and nucleophilic small molecules and eliminated in feces

• Trametinib does not require renal or hepatic adjustments; this agent is deacetylated by hydrolytic enzymes (carboxylesterases or amidases) and eliminated in feces

Are there drug interactions with any of the MAPK pathway inhibitors?

• Gefitinib, erlotinib, vemurafenib, and dabrafenib have drug interactions with cytochrome P450 inhibitors/inducers

120 II. Next-Generation Antineoplastics

Drug Interactions With MAPK Pathway Inhibitors

CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 UGT1A1

Gefitinib

INH

SUB;

SUB

INH

Erlotinib

SUB

SUB

Afatinib

Vemurafenib INH

INH

SUB;

IND

Dabrafenib

SUB;

IND

IND

SUB;

IND

IND

IND

Trametinib

Abbreviations: IND, inducer (bold if strong); INH, inhibitor (bold if strong); SUB, substrate (bold if major).

• Gefitinib, erlotinib, and dabrafenib require an acidic pH for absorption; avoid with agents that raise gastric pH. Consider use of short-acting antacids separated by several hours from administration over longer-acting agents such as PPIs (suppress acid for ~24 hrs) or H2RAs (suppress acid for ~12 hrs)

• Afatinib and dabrafenib: P-gp substrates/inhibitors/inducers (afatinib and dabrafenib are both substrates and inhibitors of P-gp) What are the most common adverse effects of each MAPK pathway inhibitor?

• Gefitinib: rash, diarrhea, stomatitis, alopecia, pruritus, dry skin, conjunctivitis, paronychia; also monitor for pneumonitis, hepatotoxicity, GI perforation, ocular disorders (inflammation, blurred vision, eye pain, lacrimation, light sensitivity, keratitis)

• Erlotinib: similar toxicity profile as gefitinib (possibly increased rash, fatigue, stomatitis, anorexia, less diarrhea, and less nail changes compared with gefitinib)

• Afatinib: diarrhea (more than erlotinib/gefitinib), rash, acne, stomatitis, paronychia, dry skin, pruritus, epistaxis, cheilitis; also monitor for pneumonitis, hepatotoxicity, GI perforation, and ocular toxicities

• Vemurafenib: arthralgia, rash, fatigue, photosensitivity, cutaneous squamous cell carcinoma, QT prolongation, hepatotoxicity

8. TYROSINE KINASE INHIBITORS 121

• Dabrafenib: hand-foot syndrome, pyrexia, hyperglycemia, hypophosphatemia; the following adverse effects occur but at a lower rate than with vemurafenib: rash, photosensitivity, squamous cell carcinoma, arthralgia

• Trametinib: rash, diarrhea, peripheral edema, fatigue, dermatitis acneiform, decreased ejection fraction, ocular disorders (blurred vision) What is the emetogenicity level of the MAPK pathway inhibitors?

• All agents are considered minimal to low risk





122 II. Next-Generation Antineoplastics

MISCELLANEOUS ORAL TARGETED THERAPIES

What are the agents in the category?

• Ruxolitinib (Jakafi™), crizotinib (Xalkori®), ceritinib (Zykadia™), lapatinib (Tykerb®), palbociclib (Ibrance®), olaparib (Lynparza™), vismodegib (Erivedge™), sonidegib (Odomzo®)

What malignancies are each agent FDA approved for?

FDA-Approved Uses of Miscellaneous Oral Targeted Therapies

Agent

FDA Approval

Ruxolitinib

Myelofibrosis, polycythemia vera

Crizotinib

Myelofibrosis, polycythemia vera

Ceritinib

Myelofibrosis, polycythemia vera

Lapatinib

Breast cancer (in combination with capecitabine or letrozole)

Palbociclib

Breast cancer (in combination with letrozole) Olaparib

Ovarian cancer (with suspected or proven germline BRCA mutation)

Vismodegib

Basal cell carcinoma

Sonidegib

Basal cell carcinoma

Abbreviation: FDA, U.S. Food and Drug Administration.

How do these agents work?

• Ruxolitinib: Janus Kinases (JAKs) are nonreceptor tyrosine kinases that mediate signaling of cytokines and growth factors responsible for hematopoiesis. JAK stimulates signal transducers and activators of transcription (STATs), which leads to gene expression. Aberrant activation of the JAK/STAT pathway is implicated in a number of disease states. JAK2-V617F mutations, other point mutations, excess cytokines, and other aberrations lead to dysregulated JAK signaling, ultimately resulting in myelofibrosis. Ruxolitinib inhibits JAK1 and JAK2 (the presence of the JAK2-V617F mutation specifically is not required for activity).

8. TYROSINE KINASE INHIBITORS 123

• Crizotinib and ceritinib: Anaplastic lymphoma receptor tyrosine kinase (ALK) is a transmembrane protein and echinoderm microtubule-associated protein like 4 (EML4) is a cytoplasmic protein involved in microtubule formation. ALK and EML4 reside in close proximity on chromosome 2. An intrachromosomal rearrangement can occur, resulting in the juxtaposition of ALK and EML4 creating a fusion protein.

The EML4-ALK fusion protein leads to constitutive activation of downstream signal transduction pathways leading to the hyperproliferation of cells and inhibition of apoptosis. Crizotinib and ceritinib both bind to and inhibit the EML4-ALK fusion protein. ALK also may have other fusion partners that lead to oncogenesis (eg, NPM-ALK in anaplastic large cell lymphoma).



– Crizotinib also inhibits c-ros oncogene 1 (ROS1), hepatocyte growth factor receptor (HGFR)/mesenchymal epithelial transition growth factor (c-MET), and recepteur d’origine nantais (RON)



– Ceritinib also inhibits insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1

• Lapatinib: In human epidermal receptor type 2 (HER2)+ breast cancer, the HER2 gene is amplified increasing the expression of the HER2

tyrosine kinase receptor. Several phenotypic consequences result from HER2 overexpression such as increased proliferation and survival, increased mutagenesis, increased metastatic potential and cellular motility, and increased secretion of growth factors. Lapatinib is an inhibitor of the intracellular tyrosine kinase domains of both EGFR and the HER2 receptor.

• Palbociclib: Many signal transduction pathways converge at the level of cyclinD1. CyclinD1 activates cyclin-dependent kinase (CDK4/6) and the two form a complex. This complex phosphorylates the retinoblas-toma (RB) tumor suppressor protein, which inactivates the RB protein.

Normally, RB inhibits E2F (a transcription factor) from interacting with the cell’s transcription machinery. However, RB protein inactivation by the complex results in the release of E2F transcription factors, which allows for continuous cell cycle progression from the G1 phase to S phase. Palbociclib competitively blocks CDK4/6 from binding and forming a complex with cyclinD1, thus preventing continuous cell cycle progression.

124 II. Next-Generation Antineoplastics

• Olaparib: Poly ADP ribose polymerase (PARP) is a DNA repair enzyme responsible for repairing single-strand DNA breaks. During DNA replication, single-strand breaks occur. If unrepaired, collision of the replication fork with the lesion produces a double-strand DNA break. Several mechanisms of DNA repair exist to restore double-strand breaks. One such mechanism is homologous recombination.

Normal cells have intact homologous recombination; however, a subset of tumor cells are deficient in homologous recombination. The most notable deficiencies occur in tumors with breast cancer type suscep-tibility protein 1 or 2 (BRCA1 and/or BRCA2) mutations. Inhibition of PARP with olaparib prevents single-strand DNA repair, which leads to double-strand DNA breaks upon collision of the replication fork.

In normal cells, homologous recombination repairs the double-strand DNA breaks. However, in tumor cells with deficiencies in homologous recombination repair pathways (such as BRCA1/2), repair of double-strand breaks cannot occur, resulting in the accumulation of defective DNA lesions. Ultimately, cessation of DNA synthesis and apoptosis occurs.

• Vismodegib and sonidegib: The hedgehog pathway has several key components: the hedgehog ligand (hedgehog), the hedgehog receptor (patched), the cell surface signal transducer (smoothened), and its downstream effector (GLI transcription factors). In the absence of the hedgehog ligand, Patched normally inhibits Smoothened, preventing activation of downstream signaling via GLI transcription factors.

Mutations can occur in Patched (the inhibitory receptor) or Smoothened, both inducing aberrant activation of downstream signaling to GLI and thus increasing expression of various genes that promote cell proliferation and differentiation.

What are the common dose ranges for each agent?

• Ruxolitinib: Starting dose for myelofibrosis is based on the patient’s baseline platelet count (20 mg orally BID, 15 mg orally BID, or 5 mg orally BID for platelets of 200, 100, and 50 109/L, respectively); 10 mg orally, BID for polycythemia vera

• Crizotinib: 250 mg orally, BID

• Ceritinib: 750 mg orally, daily (empty stomach)

8. TYROSINE KINASE INHIBITORS 125

• Lapatinib: 1,250 mg orally, daily (empty stomach) when in combination with capecitabine; 1,500 mg orally, daily (empty stomach) when in combination with letrozole

• Palbociclib: 125 mg orally, daily (with food); 21 days on, 7 days off

• Olaparib: 400 mg orally, BID

• Vismodegib: 150 mg orally, daily

• Sonidegib: 200 mg orally, daily (empty stomach) Are these agents metabolized/eliminated renally or hepatically?

• All agents are metabolized hepatically

• Ruxolitinib is also eliminated renally

Are there drug interactions with any of these agents?

• All drugs except vismodegib will have drug interactions with cytochrome P450 inhibitors/inducers (although vismodegib is a CYP substrate, CYP inhibitors are not predicted to alter its systemic concentrations)

Drug Interactions With Miscellaneous Oral Targeted Therapies

CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4

UGT1A1

Ruxolitinib

SUB

Crizotinib

SUB;

INH

Ceritinib

INH

SUB;

INH

Lapatinib

INH

SUB;

INH

Palbociclib

SUB;

INH

Olaparib

SUB

Vismodegib

INH

SUB;

INH

SUB

INH

Sonidegib

INH

SUB

Abbreviations: IND, inducer (bold if strong); INH, inhibitor (bold if strong); SUB, substrate (bold if major).

126 II. Next-Generation Antineoplastics

• Crizotinib, ceritinib, lapatinib, and vismodegib are P-gp substrates; crizotinib and lapatinib are inhibitors of P-gp. Crizotinib, ceritinib, lapatinib, vismodegib, palbociclib, and sonidegib concentrations can be reduced with the coadministration of antacids What are the most common adverse effects of each agent?

• Ruxolitinib: anemia, thrombocytopenia, neutropenia, ecchymosis, dizziness, headache, pyrexia, hypercholesterolemia

• Crizotinib: nausea/vomiting, diarrhea, ocular toxicities, hepatotoxicity, pneumonitis, hypogonadism, QT prolongation

• Ceritinib: nausea/vomiting, diarrhea (more severe than crizotinib), hepatotoxicity, hyperglycemia, hypophosphatemia, anemia, increased lipase levels

• Lapatinib: reduced ejection fraction (appears to be less than trastuzumab), rash, hand-foot syndrome, dry skin, diarrhea (generally within 6 days and duration of 4–5 days), fatigue, QT prolongation, hepatotoxicity (patients who carry the human leukocyte antigen [HLA] alleles DQA1*02:01 and DRV1*07:01 may be at greater risk)

• Palbociclib: neutropenia, leukopenia, fatigue, stomatitis, anemia, thrombocytopenia, neuropathy

• Olaparib: anemia, nausea/vomiting, dyspnea, arthralgia, myalgia, rash, increased serum creatinine, dysgeusia

• Vismodegib: nausea/vomiting, diarrhea, muscle spasms, arthralgia, alopecia, dysgeusia, possibility for promotion of cutaneous squamous cell carcinoma

• Sonidegib: Elevations in creatine kinase and lipase, hyperglycemia, increased LFTs, muscle spasms and myalgia, alopecia, dysgeusia, nausea, fatigue, weight loss, diarrhea, pruritus, possibility for promotion of cutaneous squamous cell carcinoma

What is the emetogenicity level of these agents?

• Crizotinib, ceritinib, olaparib, and vismodegib are considered moderate to high

8. TYROSINE KINASE INHIBITORS 127

• All other agents are considered minimal to low

• Sonidegib has not been assigned a category at the time of writing; however, this agent likely fits within the moderate to high category





9

Antiandrogen Therapies

What are the agents in the antiandrogen class?

• Abiraterone (Zytiga®) and enzalutamide (Xtandi®) What malignancies are each antiandrogen FDA approved for?

FDA-Approved Uses of Antiandrogen Therapies

Agent

FDA Approval

Abiraterone

Prostate cancer

Enzalutamide

Prostate cancer

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the antiandrogens work?

• Abiraterone: inhibits the 17 α-hydroxylase/C17,20-lyase enzyme required for androgen biosynthesis (expressed in testicular, adrenal, and prostate tumor tissues); inhibits formations of the testosterone precursors, dehydroepiandrosterone (DHEA) and androstenedione



– Due to the inhibition of steroid synthesis by abiraterone, this agent must be taken with prednisone (see the following text) in order to avoid mineralocorticoid excess (caused by a rise in adrenocorti-cotropic hormone [ACTH] via a positive feedback loop) and consequences of low cortisol

• Enzalutamide: a pure androgen receptor inhibitor which, unlike traditional antiandrogens (eg, bicalutamide, flutamide), does not exhibit agonistic properties upon binding to the androgen receptor. Enzalutamide binds to the androgen receptor with much higher

130 II. Next-Generation Antineoplastics affinity than traditional antiandrogens, prevents nuclear translocation of the androgen receptor, and prevents androgen receptor association with DNA

What are the common dose ranges for each antiandrogen?

• Abiraterone: 1,000 mg orally daily (empty stomach) with prednisone 5 mg orally (PO) BID

• Enzalutamide: 160 mg orally once daily (with or without food) Are the antiandrogens metabolized/eliminated renally or hepatically?

• Both agents are metabolized hepatically

• Enzalutamide is also renally eliminated (primarily as inactive metabolites)

Are there drug interactions with any of the antiandrogens?

• Abiraterone: CYP3A4 inhibitors/inducers; spironolactone (activates the androgen receptor); abiraterone inhibits CYP2C8/2C19/2C9/2D6/

3A4

• Enzalutamide: a CYP2C8 and 3A4 substrate—reduce dose (80 mg) with strong CYP2C8 inhibitors; enzalutamide is an inducer of CYP3A4, CYP2C9, and CYP2C19

What are the adverse effects of each agent?

• Abiraterone: fluid retention/edema, hypokalemia, hypertension, cardiac disorders (ischemic heart disease, myocardial infarction, arrhythmias, heart failure), hepatotoxicity, hot flushes

• Enzalutamide: asthenia/fatigue is the most common side effect; arthralgia, hot flushes, hypertension, seizures are rare What is the emetogenicity level of the antiandrogens?

• These agents are not chemotherapy and therefore are not in the National Comprehensive Cancer Network (NCCN) categorization; emetogenicity is minimal to low





10

Mammalian Target of Rapamycin

(mTOR) Inhibitors

What are the agents in the mTOR inhibitor class?

• Everolimus (Afinitor®) and temsirolimus (Torisel®) What malignancies are each mTOR inhibitor FDA approved for?

FDA-Approved Uses of mTOR Inhibitors

Agent

FDA Approval

Everolimus

Renal cell carcinoma, breast cancer (in

combination with letrozole or anastrozole), primitive neuroectodermal tumor (PNET)

Temsirolimus

Renal cell carcinoma

Abbreviations: FDA, U.S. Food and Drug Administration; mTOR, mammalian target of rapamycin.

How do the mTOR inhibitors work?

• The PI3K/AKT/mTOR pathway is dysregulated in various malignancies, leading to uncontrolled cell growth, proliferation, motility, and survival. This pathway can also become constitutively activated as a mechanism for resistance

• The mTOR inhibitors first bind to the FK binding protein 12 (FKBP-12). This complex binds to the mTOR complex 1 (mTORc1) and inhibits downstream signaling of the PI3K/AKT/mTOR pathway

132 II. Next-Generation Antineoplastics What are the common dose ranges for each mTOR inhibitor?

• Everolimus: 10 mg orally, daily

• Temsirolimus: 25 mg intravenous, weekly

Are the mTOR inhibitors metabolized/eliminated renally or hepatically?

• Both agents are metabolized hepatically

Are there drug interactions with any of the mTOR inhibitors?

• Everolimus and temsirolimus are substrates of CYP3A4 and P-glycoprotein (P-gp); thus, inhibitors/inducers of this enzyme and transporter may increase or decrease levels, respectively. Of note, one of the metabolites of temsirolimus is sirolimus, an active metabolite also metabolized by CYP3A4.

What are the major adverse effects of the mTOR inhibitors?

• Hyperlipidemia

• Hyperglycemia

• Dyspnea and pneumonitis

• Mucositis, stomatitis, and diarrhea

• Edema

• Rash, pruritus

• Decreased wound healing

• Infections due to increased immunosuppression

• Hypophosphatemia

• Hypertriglyceridemia

What is the emetogenicity level of the mTOR inhibitors?

• Everolimus is categorized as minimal to low emetic risk

• Temsirolimus is categorized as minimal emetic risk





11

Histone Deacetylase (HDAC) Inhibitors

What are the chemotherapy agents in the HDAC inhibitor class?

• Vorinostat (Zolinza®), romidepsin (Istodax®), belinostat (Beleodaq®), panobinostat (Farydaq®)

What malignancies are each HDAC inhibitor approved for?

FDA-Approved Uses of HDAC Inhibitors

Agent

FDA Approval

Vorinostat

Cutaneous T-cell lymphoma (CTCL)

Romidepsin

CTCL, peripheral T-cell lymphoma (PTCL)

Belinostat

PTCL

Panobinostat

Multiple myeloma

Abbreviations: FDA, U.S. Food and Drug Administration; HDAC, histone deacetylase.

How do the HDAC inhibitors work?

• HDAC is an enzyme that catalyzes the removal of acetyl groups from histones. By removing acetyl groups, DNA wraps more tightly around histones, preventing gene expression of tumor suppressor genes

• HDAC inhibitors bind to this enzyme and inhibit its function, leading to increased acetylation of DNA and expression of previously silenced genes

• Ultimately, reactivated gene effects lead to cell cycle arrest and apoptosis

134 II. Next-Generation Antineoplastics

• In patients with multiple myeloma, panobinostat and other HDAC

inhibitors act synergistically with proteasome inhibitors. Proteasome inhibitors lead to the accumulation of ubiquitinated protein aggregates, which contribute to cell death. Ubiquitinated proteins can be alternatively degraded by the aggresome pathway, which is dependent on HDAC6. Inhibition of HDAC6 by HDAC inhibitors leads to synergistic cytotoxicity of myeloma cells in combination with proteasome inhibitors.

What are the common mechanisms of resistance to HDAC inhibitor therapy?

• Romidepsin, belinostat, and panobinostat are substrates for P-glycoprotein (P-gp). Increased P-gp expression can increase active drug efflux from malignant cells

• Overexpression of antiapoptotic proteins, such as BCL-2 or BCL-XL

• Overexpression and increased activation of the Jak/STAT pathway What are the common dosing ranges for each HDAC inhibitor?

• Vorinostat: 400 mg orally (PO) once daily with food

• Romidepsin: 14 mg/m2 intravenous (IV) on days 1, 8, and 15 of a 28-day cycle

• Belinostat: 1,000 mg/m2 IV daily 5 days of a 21-day cycle



– Patients homozygous for the UGT1A1*28 allele have significantly reduced UGT1A1 activity (responsible for the metabolism of belinostat) and require a lower starting dose of belinostat (750 mg/m2)

• Panobinostat: 20 mg PO every other day for three doses each week for 2 weeks of a 21-day cycle (days 1, 3, 5, 8, 10, and 12) Are the HDAC inhibitors metabolized/eliminated renally or hepatically?

• The HDAC inhibitors are all metabolized hepatically and require dose adjustment for hepatic dysfunction

11. HISTONE DEACETYLASE (HDAC) INHIBITORS 135

Are there drug interactions with any of the HDAC inhibitors?

• All HDAC inhibitors: additional QTc prolonging agents

• Vorinostat: warfarin (increases in international normalized ratio

[INR] have been documented)

• Romidepsin: modulators of the CYP3A4 pathway (responsible for romidepsin metabolism), warfarin (increases in INR have been documented)

• Belinostat: inhibitors or inducers of UGT1A1

• Panobinostat: modulators of the CYP3A4 pathway (responsible for the metabolism of panobinostat); drugs metabolized through CYP2D6

(panobinostat inhibits CYP2D6)

What are the most common adverse effects of the HDAC inhibitors?

• EKG changes (including QTc prolongation)

• Nausea, vomiting, dysgeusia, diarrhea

• Mild myelosuppression (typically more thrombocytopenia and anemia)

What is the emetogenicity level of the HDAC inhibitors?

• All six agents are categorized as low (10%–30% frequency) Are the HDAC inhibitors vesicants or irritants?

• The HDAC inhibitors are neither vesicants nor irritants





12

Hypomethylating Agents

What are the chemotherapy agents in the hypomethylating agent class?

• Azacitidine (Vidaza®), decitabine (Dacogen®) What malignancies are each hypomethylating agent FDA approved for?

• Both are approved for the treatment of myelodysplastic syndrome (MDS)

How do the hypomethylating agents work? (Figure 12.1)

• Summary: Hypomethylating agents are epigenetic modifiers, which cause global DNA hypomethylation, resulting in the transcription of previously aberrantly silenced genes such as tumor suppressor genes

• Azacitidine and decitabine are cytidine nucleoside analogues that are incorporated into DNA and RNA as false base pairs



– Azacitidine has a greater propensity to incorporate into RNA, while decitabine is exclusively incorporated into DNA

• After incorporation into DNA, azacitidine and decitabine inhibit DNA methyltransferase, the epigenetic enzyme responsible for adding methyl groups to DNA bases and preventing gene transcription

• Previously methylated and silenced genes including tumor suppressor genes and those that control cancer cell differentiation are expressed





138 II. Next-Generation Antineoplastics

DNMT

DNA

Cancer cell proliferation

polymerase

Tumor suppressor gene

NH2

DNMT

N

N

N

O

HO

Hypomethylating

O

agent

OH

DNA

Cancer cell proliferation

polymerase

Tumor suppressor gene

FIGURE 12.1. Hypomethylating agent MOA: The hypomethylating agents, azacitidine and decitabine, are cytidine analogues that are incorporated into DNA and inhibit DNA methyltransferase (DNMT). DNMT

is an enzyme responsible for the epigenetic modifi cation of DNA base pairs via methylation. This methylation of DNA prevents transcription of genes critical for tumor suppression and differentiation. By inhibiting DNMT, DNA becomes globally hypomethylated, and these genes are expressed, preventing tumor cell proliferation.

What are the common dosing ranges for the hypomethylating agents?

• Azacitidine: 75 mg/m2 subcutaneous/intravenous (IV) daily 7 days every 28 days

• Decitabine: 20 mg/m2 IV daily 5 to 10 days every 28 days Are the hypomethylating agents metabolized/eliminated renally or hepatically?

• Azacitidine and decitabine are primarily metabolized by cytidine deaminase, and azacitidine is eliminated renally; however, initial dosage adjustments for renal or hepatic impairment are generally not required for either agent

12. HYPOMETHYLATING AGENTS 139

Are there drug interactions with any of the hypomethylating agents?

• No clinically significant drug interactions exist for the hypomethylating agents

What are the most common adverse effects of the hypomethylating agents?

• Myelosuppression

• Fever

• Fatigue

• Diarrhea/constipation

What is the emetogenicity level of the hypomethylating agents?

• The National Comprehensive Cancer Network (NCCN) characterizes azacitidine as moderate (30%–90% frequency)

• Decitabine has minimal emetogenic potential (10% frequency) Are the hypomethylating agents vesicants or irritants?

• Decitabine and azacitidine are neither vesicants nor irritants





13

Proteasome Inhibitors

What are the chemotherapy agents in the proteasome inhibitor class?

• Bortezomib (Velcade®), carfilzomib (Kyprolis®) What malignancies are each proteasome inhibitor FDA approved for?

FDA-Approved Uses of Proteasome Inhibitors

Bortezomib

Carfilzomib

Multiple myeloma, mantle

Multiple myeloma, relapsed/

cell lymphoma

refractory

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the proteasome inhibitors work?

• In normal cells, the proteasome works to degrade intracellular proteins and maintain homeostasis

• Proteasome inhibitors bind and inhibit the chymotrypsin-like activity of the proteasome, preventing degradation of intracellular proteins



– Bortezomib binds reversibly to the proteasome



– Carfilzomib binds irreversibly, is more potent than bortezomib, more selective for the chymotrypsin-like activity of the proteasome, and is active in bortezomib-resistant cells

• Accumulation of proteins normally marked for degradation leads to cell death through the unfolded protein response and the endoplasmic reticulum stress pathway

142 II. Next-Generation Antineoplastics

• Accumulation of proteins critical for regulating cell cycle progression (eg, p27, cyclin B) leads to cell cycle arrest

• Proteasome inhibitors also inhibit nuclear factor kappa B (NF-KB) activity of cancer cells through preventing degradation of the inhibitor of NF-KB (IKB); NF-KB activation is heavily involved in cell proliferation, angiogenesis, and suppression of apoptosis What are the common mechanisms of resistance to proteasome inhibitor therapy?

• Alternative degradation of ubiquitinated proteins through the aggresome pathway, dependent on histone deacetylase 6 (HDAC6) (HDAC inhibitors can synergize with proteasome inhibitors through inhibition of this resistance pathway—see Chapter 11)

• Mutations in the β-subunits of the proteasome that alter proteasome inhibitor binding

• Upregulation of proteasomal subunits

What are the common dosing ranges for each proteasome inhibitor?

• Bortezomib: 1.3 mg/m2 intravenously (IV)/subcutaneously (subQ) days 1, 4, 8, and 11 of a 21-day cycle; 1.5 mg/m2 IV weekly, days 1, 8, 15, and 22 of a 28-day cycle

• Carfilzomib: 20 mg/m2 IV days 1, 2, 8, 9, 15, and 16 (cycle 1; 28-day cycle), then 27 mg/m2 IV days 1, 2, 8, 9, 15, and 16 of subsequent 28-day cycles

Are the proteasome inhibitors metabolized/eliminated renally or hepatically?

• The proteasome inhibitors are metabolized hepatically and require dose adjustment for hepatic dysfunction

Are there drug interactions with any of the proteasome inhibitors?

• Drugs that modulate the CYP3A4 pathway may increase/decrease bortezomib concentrations

13. PROTEASOME INHIBITORS 143

What are the most common adverse effects of the proteasome inhibitors?

• Peripheral neuropathy



– Typically a reversible sensory neuropathy



– More common with bortezomib than carfilzomib



– SubQ administration and weekly administration of bortezomib have both been shown (individually) to reduce peripheral neuropathy without impacting efficacy

• Myelosuppression (primarily thrombocytopenia)

• Herpes zoster and herpes simplex reactivation (prophylaxis with acyclovir is recommended)

• Nausea, vomiting, and diarrhea (typically mild)

• Fevers, fatigue, and weakness

• Congestive heart failure, dyspnea, peripheral edema, and renal failure (more common with carfilzomib)

What are the premedications required?

Premedications Required for Proteasome Inhibitors

Drug

Premedication

Bortezomib

None

Carfilzomib 250–500 mL normal saline (or other intravenous [IV]

fluid) predose; can also give another 250–500 mL

postdose if needed

Dexamethasone 4 mg (oral or IV) prior to all doses in cycle 1, all doses with dose escalation cycle, and as needed with future cycles to reduce infusion reaction risk What is the emetogenicity level of the proteasome inhibitors?

• Both agents are categorized as low (10%–30% frequency) Are the proteasome inhibitors vesicants or irritants?

• Bortezomib and carfilzomib are neither vesicants nor irritants





14

Immunomodulatory Agents

What are the chemotherapy agents in the immunomodulatory agent (IMiD) class?

• Thalidomide (Thalomid®), lenalidomide (Revlimid®), pomalidomide (Pomalyst®)

What malignancies are the IMiDs FDA approved for?

FDA-Approved Uses of Immunomodulatory Agents (IMiDs)

Agent

FDA Approval

Thalidomide

Multiple myeloma

Lenalidomide

Multiple myeloma, mantle cell lymphoma,

myelodysplastic syndrome (with deletion 5q) Pomalidomide

Multiple myeloma

Abbreviation: FDA, U.S. Food and Drug Administration.

How do the IMiDs work?

• IMiDs work by directly inducing apoptosis, enhancing T-cell and natural killer (NK) cell-mediated cytotoxicity, inhibiting the production of proinflammatory cytokines (eg, interleukin 6 [IL-6], tumor necrosis factor alpha [TNF-alpha]), and inhibiting angiogenesis

• In multiple myeloma, the efficacy of the IMiDs is now thought to be related to the binding of these agents to cereblon, a protein of the E3

ubiquitin ligase complex. Binding of the IMiDs to cereblon leads to the enhancement of ubiquitination and degradation of transcription factors (Ikaros and Ailos) important in B-cell development

146 II. Next-Generation Antineoplastics What are the common dosing ranges for the IMiDs?

• Thalidomide: 200 to 400 mg orally (PO) once daily

• Lenalidomide: 25 mg PO once daily days 1 to 21 of a 28-day cycle or days 1 to 14 of a 21-day cycle; 10 mg PO once daily for patients with myelodysplastic syndrome (MDS) with deletion 5q

• Pomalidomide: 4 mg PO once daily days 1 to 21 of a 28-day cycle Are the IMiDs metabolized/eliminated renally or hepatically?

• Thalidomide: no dose adjustments necessary for hepatic or renal impairment

• Lenalidomide: eliminated renally—dose adjust for renal dysfunction

• Pomalidomide: metabolized in the liver—dose adjust for hepatic dysfunction

Are there drug interactions with any of the IMiDs?

• Pomalidomide: drugs that modulate the CYP3A4 and 1A2 pathway (the primary enzymes that metabolize pomalidomide; CYP2C19 and 2D6 also contribute to a lesser degree) may increase or decrease pomalidomide concentrations; drugs that inhibit or induce P-glycoprotein (P-gp) may increase or decrease pomalidomide concentrations, respectively.

What are the most common adverse effects of the IMiDs?

Most Common Adverse Effects of IMiDs

Thalidomide Lenalidomide Pomalidomide

Myelosuppression





Embryo-fetal toxicity





DVT/PE





Neuropathy





Constipation





( continued)

14. IMMUNOMODULATORY AGENTS 147

Most Common Adverse Effects of IMiDs ( continued ) Thalidomide Lenalidomide Pomalidomide

Rash





Fatigue/sedation





Notes: does not typically occur, rare, occasional, common.

Abbreviations: DVT, deep vein thrombosis; ImiD, immunomodulatory agent; PE, pulmonary embolism.

What is the significance of the REMS programs associated with the IMiDs?

• There are risk evaluation and mitigation strategies (REMS) programs associated with each of the IMiDs—the goal is to prevent the risk of embryo-fetal exposure and to educate on the serious risks of these agents

• The prescriber, patient, and pharmacy must all be enrolled in the REMS programs and agree to comply with all requirements

• Full, specific requirements are available on the Celgene website



– Thalidomide—www.thalomidrems.com



– Lenalidomide—www.revlimidrems.com



– Pomalidomide—www.pomalystrems.com

• Highlights of the program:



– Prescribers enroll and certify for the REMS program



– Prescribers counsel patients on benefits, risks, and appropriate con-traception



– Prescribers verify negative pregnancy test for females of reproductive potential



– After completion of a patient-physician agreement form and man-datory prescriber/patient confidential survey, an authorization number is obtained for each prescription. This authorization number is written on the prescription, along with the patient risk category



– Prescribers may write for no more than a 28-day supply at a time (no refills); prescriptions are sent to a certified pharmacy

148 II. Next-Generation Antineoplastics



– The pharmacy obtains a confirmation number from Celgene, counsels the patient, and completes an education and counseling checklist with the patient, prior to dispensing (along with a medication guide) What is the emetogenicity level of the IMiDs?

• The IMiDs have minimal to low emetogenic risk





15

L-Asparaginase Enzymes

What are the chemotherapy agents in the asparaginase enzyme class?

• Pegaspargase (Oncaspar®)

• Asparaginase Erwinia chrysanthemi (Erwinaze®), also known as

“Erwinia”

What malignancy are the asparaginase enzymes approved for?

• Acute lymphoblastic leukemia (ALL)

How do the asparaginase enzymes work?

• Lymphoblasts lack the enzyme asparagine synthetase and require exogenous asparagine for survival.

• Asparaginase cleaves asparagine into aspartic acid and ammonia, thus reducing the asparagine pool available for lymphoblast growth and protein synthesis, leading to apoptosis in these cells; asparaginase enzymes also have glutaminase activity, which may be responsible for their cytotoxicity as well.

• L-asparaginase products are derived from bacteria; pegaspargase is derived from Escherichia coli and Erwinia is derived from Erwinia chrysanthemi.

• Erwinia was developed for patients with hypersensitivity to E.

coli–derived formulations; patients with allergic reactions or antibody formation toward the E. coli–derived products do not cross-react with Erwinia.

• Pegaspargase is a pegylated enzyme product and has a significantly longer half-life than Erwinia (5–12 days vs. ~16 hours);

150 II. Next-Generation Antineoplastics pegylation of pegaspargase is also thought to reduce immuno-genicity compared to the historical, non-pegylated, E. coli– derived asparaginase product (no longer on the market), potentially reducing allergic reactions and formation of antibodies to the product.

What are the common dosing ranges for the asparaginase enzymes?

• Pegaspargase: 1,000 to 2,500 units/m2 intramuscular (IM) or intravenous (IV) (some protocols cap the dose at 1 vial or 3,750 units); do not administer more frequently than every 14 days

• Erwinia:



– As a substitute for pegaspargase: 25,000 units/m2 IM or IV three times weekly for six doses for each planned pegaspargase dose



– As a substitute for asparaginase ( E. coli): 25,000 units/m2 IM or IV

for each planned asparaginase ( E. coli) dose Are the asparaginase enzymes metabolized/eliminated renally or hepatically?

• The asparaginase enzymes are not eliminated hepatically or renally.

Because of hepatotoxicity with asparaginase, caution is warranted in those with preexisting liver dysfunction.

Are there drug interactions with any of the asparaginase enzymes?

• Methotrexate—Asparaginase enzymes also display potent glutaminase activities. Methotrexate’s activity depends on polyglutamation for optimal accumulation and activity within cancer cells. Thus, administration of asparaginase prior to methotrexate is antagonistic. In contrast, administration of methotrexate prior to asparaginase may be synergistic (eg, MOAD regimen for ALL).

What are the most common adverse effects of the asparaginase enzymes?

• Hypersensitivity reactions—urticaria, erythema, edema, chills, fever, rash, anaphylaxis



– Can premedicate with diphenhydramine, acetaminophen, and corticosteroids

15. L-ASPARAGINASE ENZYMES 151



– Silent inactivation and antibody formation to asparaginase enzymes may occur even in the absence of clinical hypersensitivity

– In the case of anaphylaxis and/or severe hypersensitivity reactions, patients should be switched to an alternative asparaginase product (eg, switching pegaspargase [ E. coli derived] to Erwinia-derived asparaginase)

• Hepatotoxicity

• Thrombosis and hemorrhage

• Hypertriglyceridemia

• Pancreatitis

• The “asparaginase blues”—fatigue, malaise, depression thought to be due to hyperammonemia

• Nausea/vomiting—more common with Erwinia given intravenously; this is thought to be due to rapid formation of high peak levels of ammonia

What is “silent inactivation” and why is this important with asparaginase enzymes?

• Silent inactivation refers to the development of autoantibodies to asparaginase products without evidence of clinical hypersensitivity; clinical hypersensitivity and development of autoantibodies do not correlate well.

• The development of autoantibodies may result in accelerated clearance of asparaginase, preventing asparagine depletion and efficacy of the product.

• In the case of silent inactivation to pegaspargase ( E. coli derived), patients may be switched to Erwinia-derived asparaginase without cross-reactivity, allowing continued asparagine depletion in these patients, essential for optimal outcomes in ALL.

• To monitor for inactivation of asparaginase products, monitoring of asparaginase activity levels is necessary. The exact value is contro-versial; however, targeting nadir serum asparaginase activity levels of 0.2 international units/mL has been associated with optimal asparagine depletion.

152 II. Next-Generation Antineoplastics What is the emetogenicity level of the asparaginase enzymes?

• Both agents are categorized as minimal (10% frequency) Are the asparaginase enzymes vesicants or irritants?

• Pegaspargase and Erwinia are neither vesicants nor irritants





16

Promyelocytic Leukemia Gene Retinoic

Acid Receptor-Alpha (PML-RARα)

Translocation Inhibitors

What are the agents in the PML-RARa inhibitor class?

• Tretinoin/all-trans retinoic acid (ATRA) (Vesanoid®) and arsenic trioxide (Trisenox®)

What malignancies are each PML-RARa inhibitor FDA approved for?

FDA-Approved Uses of PML-RARa Inhibitors

Agent

FDA Approval

ATRA

Acute promyelocytic leukemia (APL)

Arsenic trioxide

APL

Abbreviations: ATRA, all-trans retinoic acid; FDA, U.S. Food and Drug Administration.

How do the PML-RARa inhibitors work?

• The PML-RARα gene fusion results from a balanced translocation involving the PML gene on chromosome 15 and the RARα gene on chromosome 17. The product of this gene fusion binds with genetic promoters and recruits corepressor complexes, which repress normal gene expression and prevents differentiation of promyelocytes

• ATRA: causes the corepressor complexes to dissociate from RARα

and allows for transcription and therefore differentiation of promyelocytes

154 II. Next-Generation Antineoplastics

• Arsenic trioxide: creates reactive oxygen species and degrades PML; creates intermolecular disulfide cross-links, which leads to multim-erization and SUMOylation (a posttranslational modification) of PML; proteasome-dependent degradation occurs

What are the common dose ranges for each PML-RARa inhibitor?

• ATRA: 45 mg/m2/day divided BID orally (with meals)

• Arsenic: 0.15 mg/kg/day intravenously

Are the PML-RARa inhibitors metabolized/eliminated renally or hepatically?

• Both agents are metabolized hepatically and renally eliminated Are there drug interactions with any of the PML-RARa inhibitors?

• ATRA will have drug interactions with cytochrome P450 inhibitors/

inducers (ATRA is also an inducer and induces its own metabolism)

• Arsenic: avoid QT prolonging agents

What are the major adverse effects of the PML-RARa inhibitors?

• ATRA: differentiation syndrome, hyperleukocytosis, headache, malaise, dizziness, hypercholesterolemia, hypertriglyceridemia, hepatotoxicity, skin rash, skin/mucous membrane dryness, pseudotumor cerebri, teratogenicity (boxed warning)

• Arsenic: differentiation syndrome, hyperleukocytosis, headache, QT prolongation (EKG twice weekly is recommended), potassium and magnesium wasting, skin rash, facial edema, peripheral neuropathy, musculoskeletal pain, hepatotoxicity, teratogenicity What is differentiation syndrome?

• A relatively frequent complication of differentiating agent therapy (eg, arsenic trioxide, ATRA) in patients with APL, characterized by dyspnea, fever, weight gain, pulmonary infiltrates, pleural effusions, pericardial effusions, acute renal failure; may be fatal

16. PML-RARα TRANSLOCATION INHIBITORS 155

• Treatment: Dexamethasone 10 mg BID; usually can continue ATRA and arsenic (in severe cases, both agents should be discontinued) What is the emetogenicity level of the PML-RARa inhibitors?

• ATRA is categorized as minimal to low

• Arsenic is categorized as moderate emetic risk Are the PML-RARa inhibitors vesicants or irritants?

• Arsenic is an irritant





III

Miscellaneous Oncolytics





17

Sipuleucel-T (Provenge®)

What malignancy is sipuleucel-T approved for?

• Metastatic castration-resistant prostate cancer How does sipuleucel-T work?

• Sipuleucel-T is an autologous, dendritic cell–based immunotherapy directed against prostate cancer cells

• The patient undergoes leukopheresis to remove white blood cells, including antigen-presenting cells (APCs)

• The APCs are exposed to a fusion protein antigen consisting of pro-static acid phosphatase (PAP) (expressed on 95% of prostate cancers) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)

• Antigen is processed and presented on the surface of the APCs. GM-CSF acts to help stimulate APC activity

• The activated APC product is infused into the patient. Upon infusion, the activated APCs present the PAP antigen to T cells, leading to T-cell activation and proliferation toward prostate cancer cells expressing PAP

What is the dose of sipuleucel-T?

• 50 million CD54 cells intravenously (IV) every 2 weeks three doses

Is sipuleucel-T metabolized/eliminated renally or hepatically?

• Sipuleucel-T is neither eliminated renally nor metabolized hepatically

160 III. Miscellaneous Oncolytics Are there drug interactions with sipuleucel-T?

• Concurrent immunosuppressive therapies may alter the efficacy of sipuleucel-T

What premedications are required for sipuleucel-T?

• Acetaminophen

• Diphenhydramine

What are the most common adverse effects of sipuleucel-T?

• Infusion-related reactions (usually within the first 24 hrs after administration)



– Chills, fever, bronchospasm, hypertension, and so on

• Nausea, vomiting

• Myalgias and an influenza-like illness

• Headache, dizziness

• Citrate toxicity (due to the apheresis procedure) What is the emetogenicity level of sipuleucel-T?

• Although not in the 2015 National Comprehensive Cancer Network (NCCN) antiemetic guidelines, sipuleucel-T would be categorized as low

Is sipuleucel-T a vesicant or irritant?

• Sipuleucel-T is neither a vesicant nor an irritant





18

Omacetaxine (Synribo®)

What malignancy is omacetaxine approved for?

• Chronic myeloid leukemia (CML), chronic or accelerated phase How does omacetaxine work?

• Omacetaxine is an inhibitor of protein synthesis; thus, it does not require binding to the breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) kinase in CML and has activity against tyrosine kinase inhibitor–resistant BCR-ABL mutations (including the T315I mutation)

• Omacetaxine is a homoharringtonine derivative that binds to the A-site cleft on the ribosome, inhibiting protein synthesis by preventing amino acid chain elongation

• This action rapidly reduces short-lived proteins, including the BCR-ABL protein and others crucial for proliferation and cell survival (eg, C-myc, Mcl-1, Cyclin D1, XIAP)

What is the normal dose of omacetaxine?

• Induction: 1.25 mg/m2 subcutaneously twice daily 14 days (until achievement of hematologic response; every 28 days)

• Maintenance: 1.25 mg/m2 subcutaneously twice daily 7 days (every 28 days)

Is omacetaxine metabolized/eliminated renally or hepatically?

• Omacetaxine is not metabolized hepatically nor is the drug renally eliminated

162 III. Miscellaneous Oncolytics Are there drug interactions with omacetaxine?

• No significant drug interactions have been characterized for omacetaxine

What are the most common adverse effects of omacetaxine?

• Myelosuppression

• Hyperglycemia

• Nausea/diarrhea (typically mild)

• Injection site reactions

• Arthralgia

• Fatigue

What is the emetogenicity level of omacetaxine?

• Omacetaxine has low emetogenic risk





19

Estramustine (Emcyt®)

What malignancy is estramustine approved for?

• Progressive or metastatic prostate cancer How does estramustine work?

• Estramustine is a carbamate-linked conjugate of nor-nitrogen mustard (an alkylating agent) and estradiol

• It was synthesized on the premise that the estradiol component would bind to the estrogen receptor in breast cancer cells and selectively deliver the alkylating agent, nor-nitrogen mustard; however, it was neither found to have clinical activity in breast cancer, nor did it demonstrate alkylating agent activity

• Estramustine instead accumulates in the prostate by binding to a prostate-specific protein and inhibits microtubule function in prostate cancer cells

• Estramustine is cell cycle specific to the G2/M phase What is the usual dose of estramustine?

• 14 mg/kg/day orally in 3 to 4 divided doses Is estramustine metabolized/eliminated renally or hepatically?

• Estramustine is eliminated hepatically

164 III. Miscellaneous Oncolytics Are there drug interactions with estramustine?

• Absorption of estramustine can be significantly decreased by coadministration with calcium (including antacids) and calcium-rich foods; patients should take estramustine on an empty stomach, at least 1 hour before or 2 hours after eating.

What are the most common adverse effects of estramustine?

• Nausea, vomiting, and diarrhea

• Gynecomastia, breast tenderness, decreased libido

• Fluid retention

• Increased liver enzymes

• Thromboembolism, congestive heart failure (CHF), myocardial infarction (MI) (rare, but serious)

What is the emetogenicity level of estramustine?

• Estramustine is categorized as moderate to high emetogenic risk





Appendix A: Agents Requiring Renal

and/or Hepatic Dose Adjustments

Hepatic

Renal

All taxanes

NOT taxanes

All anthracyclines

NOT anthracyclines (except

epirubicin)

All vinca alkaloids

NOT vinca alkaloids

NOT platinums

All platinums

All-trans retinoic acid (ATRA)

ATRA

Altretamine

Altretamine

Arsenic trioxide

Arsenic trioxide

5-Fluorouracil

Bleomycin

Belinostat

Capecitabine

Bendamustine

Carmustine

Bortezomib

Cladribine

Busulfan

Clofarabine

Carfilzomib

Cyclophosphamide

Carmustine

Cytarabine (200 mg/m2)

Chlorambucil

Dacarbazine

Cyclophosphamide

Dactinomycin

Cytarabine

Etoposide

Dacarbazine

Fludarabine

Dactinomycin

Hydroxyurea

( continued)

166 Appendix A

( continued)

Hepatic

Renal

Estramustine

Ifosfamide

Etoposide

Lenalidomide

Ifosfamide

Lomustine

Irinotecan

Melphalan (only high doses)

Lomustine

Mercaptopurine

Mercaptopurine

Methotrexate

Methotrexate

Mitomycin

Mitomycin

Nelarabine

Panobinostat

Pemetrexed

Pomalidomide

Pentostatin

Procarbazine

Pralatrexate

Romidepsin

Streptozocin

Streptozocin

Temozolomide

Teniposide

Thiotepa

Thioguanine

Thioguanine

Thiotepa

Topotecan

Vorinostat





Appendix B: Extravasation Risk

of Chemotherapeutic Agents

Vesicants

Irritants

Dactinomycin*

Abraxane (paclitaxel albumin

Daunorubicin*‡

bound)*

Doxorubicin*‡

Ado-trastuzumab*

Epirubicin*‡

Arsenic trioxide*

Idarubicin*‡

Bendamustine*#

Liposomal vincristine†$

Busulfan*

Mechlorethamine*#

Cabazitaxel

Mitomycin*

Carboplatin*

Mitoxantrone*

Carmustine (BCNU)*^

Vinblastine†$

Cladribine*

Vincristine†$

Cisplatin*#

Vinorelbine†$

Dacarbazine*

Docetaxel*

Doxorubicin liposomal*

Etoposide†$

Fluorouracil

Gemcitabine

Ixabepilone

Ifosfamide*^

Irinotecan*

Melphalan

Oxaliplatin†#

Paclitaxel*

( continued)

168 Appendix B

( continued)

Vesicants

Irritants

Streptozocin

Teniposide†$

Topotecan*

Antidote and local care: *topical cooling, †topical heat, ‡dexrazoxane,

#sodium thiosulfate, $hyaluronidase, ^topical dimethyl sulfoxide

( DMSO).

Management of Extravasation

1. Stop infusion and intravenous (IV) fluids. Leave IV catheter in place.

Do not flush the extravasated IV catheter

2. Disconnect IV tubing from IV catheter

3. Attach small syringe and attempt to aspirate as much fluid as possible (drug, fluid in tissue) to clear IV catheter of chemotherapy 4. Estimate amount of drug that was extravasated 5. If peripheral IV, remove IV catheter—avoid pressure to site of extravasation; mark area of induration or swelling 6. Administer appropriate antidote, if needed. Apply topical cooling or heat if indicated as well (see table in preceding text). Rest and elevate extremity

7. Consider plastic surgery expert consultation depending on severity and agent extravasated

Specific Extravasation Interventions

1. Dexrazoxane

a. Dose: 1,000 mg/m2 (max 2,000 mg) IV daily days 1 to 2,500 mg/m2

(max 1,000 mg) day 3

b. Administration:



i. First dose should be given within 6 hours of extravasation ii. IV infusion over 1 hour into a functioning IV line that is not affected by the extravasation (ideally in the opposite arm)

Appendix B 169



iii. Avoid cooling procedures within 15 minutes of dexrazoxane administration



iv.

Do NOT use topical dimethyl sulfoxide (DMSO) if using dexrazoxane

2. DMSO (topical)

a. Dose/administration:



i. 50% solution, 1 to 2 mL onto a sterile gauze pad and gently apply to the skin surface of extravasated site every 8 hours 7 days 3. Hyaluronidase

a. Dose: 150 international units subcutaneously b. Administration:



i. Administer subcutaneously with a small needle (eg, 25 gauge), distributing dose around the perimeter of the extravasation site in four or more equal injections, pointing the medication inward toward the center of the extravasated site ii. Do not rub site; use new needle for each injection given 4. Sodium thiosulfate

a. Dose: 10% solution, 4 mL diluted with 6 mL sterile water; 2 mL of a solution for:



i. Each mg of mechlorethamine or bendamustine suspected of extravasating



ii. Each 100 mg of cisplatin suspected of extravasating b. Administration:



i. Administer subcutaneously with a small needle (eg, 25 gauge), distributing dose around the perimeter of the extravasation site in four or more equal injections, pointing the medication inward toward the center of the extravasated site ii. Do not rub site; use new needle for each injection given iii. Avoid pressure to site; allow to air-dry—do not cover the site iv. Do not use topical DMSO if using dexrazoxane





Index

abiraterone (Zytiga®), 129

FDA approved uses of, 23

adverse effects of, 130

side effects of, 29

dosage, 130

angiogenesis inhibitors

drug interactions with, 130

adverse effects, 108–109

FDA approved uses of, 129

agents in, 105

working of, 129

dosage for, 107

ADCC. See antibody-dependent cell-

drug interactions with, 107–108

mediated cytotoxicity

emetogenicity level of, 109

adotrastuzumab emtansine

metabolism, 107

(Kadcyla®), 100

targets for tyrosine kinase inhibitors,

afatinib (Gilotrif™), 118

106

adverse effects, 120

working of, 106

dosage, 119

anthracyclines

dose adjustments, 119

adverse effects of, 54–55

drug interactions with, 120

chemotherapy agents in, 51

FDA approved uses of, 118

dosage, 53

working of, 118

dose adjustments, 54

alemtuzumab (Campath®), 88

drug interactions with, 54

adverse effects, 88

emetogenicity level of, 55

dosage, 88

FDA approved uses of, 51–52

FDA approved uses of, 88

lifetime doses of, 56

targets, 88

premedications, 55

alkylating agents, 15–39. See also resistance mechanism of, 52–53

antitumor antibiotics; nitrogen

vesicant/irritant properties, 55

mustard; non-nitrogen mustard;

working of, 52

platinum

antiandrogen

altretamine (Hexalen®), 23

adverse effects of, 130

dosage, 26

chemotherapy agents in, 129

dose adjustments, 27

dosage, 130

drug interactions with, 28

dose adjustments, 130

emetogenicity level of, 30

drug interactions with, 130

172 Index

antiandrogen ( cont.)

drug interactions with, 154

emetogenicity level of, 130

emetogenicity level of, 155

FDA approved uses of, 129

FDA approved uses of, 153

working of, 129–130

irritant properties, 155

antibodies

working of, 154

binding of, 85

L-asparaginase enzyme, 60,

monoclonal, 85–101

149–152

antibody-dependent cell-mediated

adverse effects of, 150–151

cytotoxicity (ADCC), 85

chemotherapy agents in, 149

antifolates

dosage, 150

adverse effects of, 61–62

dose adjustments, 150

chemotherapy agents in, 57

drug interactions with, 150

dosage, 59–60

emetogenicity level of, 152

dose adjustments, 60

FDA approved uses of, 149

drug interactions with, 60–61

silent inactivation, 151

emetogenicity level of, 63

vesicant/irritant properties, 152

FDA approved uses of, 57

working of, 149–150

premedications, 62–63

axitinib (Inlyta®), 105

resistance mechanism of, 59

adverse effects, 109

side effects of, 61

dosage, 107

vesicant/irritant properties, 63

drug interactions with, 108

working of, 58–59

FDA approved uses of, 105

antimetabolites, 57–82. See also targets for, 106

deoxycytidine analogue;

azacitidine (Vidaza®), 137

fl uoropyrimidine; purine

dosage, 138

analogue; purine antagonist;

dose adjustments, 138

pyrimidine analogues

emetogenicity level of, 139

antitumor antibiotics

FDA approved uses of, 137

adverse effects of, 38

working of, 137–138

chemotherapy agents in, 35

dosage, 36–37

dose adjustments, 37

B-cell receptor (BCR) pathway

drug interactions with, 37

inhibitors. See BCR pathway

emetogenicity level of, 39

inhibitors

FDA approved uses of, 35

BCR pathway inhibitors

premedications, 38

adverse effects of, 117

resistance mechanism of, 36

chemotherapic agents in, 114

vesicants/irritant properties, 39

drug interactions with, 116

working of, 35–36

emetogenicity level of, 117

arsenic trioxide (Trisenox®), 153

FDA approved uses of, 114

adverse effects of, 154

mechanism of, 114–116

dosage, 154

metabolism, 116

dose adjustments, 154

working of, 114

Index 173

BCR-ABL inhibitors

blinatumoma (Blincyto™), 89

adenosine triphosphate (ATP)

adverse effects, 89

binding site of, 111

dosage, 89

adverse effects of, 113

FDA approved uses of, 89

chemotherapic agents in, 110

targets, 89

in chronic myeloid leukemia

bortezomib (Velcade®), 141

(CML), 110–111

dosage, 142

dosage, 111–112

emetogenicity level of, 143

dose adjustments, 112

FDA approved uses of, 141

drug interactions with, 112

premedications, 143

emetogenicity level of, 113

vesicant/irritant properties, 143

FDA approved uses of, 110

working of, 141

metabolism, 112

bosutinib (Bosulif®), 110

targets, 111

adverse effects of, 113

belinostat (Beleodaq®), 133

dosage, 112

dosage, 134

drug interactions with, 112

emetogenicity level of, 135

FDA approved uses of, 110

FDA approved uses of, 133

targets for, 111

resistance mechanism of, 134

breakpoint cluster region-abelson

bendamustine (Treanda®), 15

murine leukemia viral oncogene

dosage, 19

homolog 1 (BCR-ABL) inhibitors.

dose adjustments, 19

See BCR-ABL inhibitors

drug interactions with, 20

brentuximab vedotin (Adcetris®), 90

FDA approved uses of, 16

adverse effects, 90

irritant properties, 22

dosage, 90

side effects of, 21

FDA approved uses of, 90

structure of, 18

targets for, 90

bevacizumab (Avastin®), 89

busulfan (Busulfex®, Myleran®), 23

adverse effects, 89

dosage, 25

dosage, 89

dose adjustments, 27

FDA approved uses of, 89

drug interactions with, 28

targets for, 89

emetogenicity level of, 30

bleomycin (Blenoxane®), 35

FDA approved uses of, 23

adverse effects of, 38

irritant properties, 30

dose adjustments, 37

premedications, 29

dosage, 36–37

side effects of, 29

drug interactions with, 37

emetogenicity level of, 39

cabazitaxel (Jevtana®), 3

FDA approved uses of, 35

adverse effects of, 8

premedications, 38

dosage, 6

resistance mechanism of, 36

drug interactions with, 7

vesicant/irritant properties, 39

FDA approved uses of, 3

working of, 35–36

irritant properties, 10

174 Index

cabazitaxel (Jevtana®) ( cont.)

adverse effects of, 126

mechanisms of, 5

dosage, 124

premedications, 9

drug interactions with, 125–126

solvents, 6

emetogenicity level of, 126

cabozantinib (Cometriq®), 105

FDA approved uses of, 122

adverse effects of, 109

working of, 122

dosage, 107

cetuximab (Erbitux®), 91

drug interactions with, 108

adverse effects, 91

FDA approved uses of, 105

FDA approved uses of, 91

targets for, 106, 107

dosage, 91

camptothecans, 41–45

targets for, 91

capecitabine (Xeloda®), 73

chemotherapy agents

adverse effects of, 76

angiogenesis inhibitors, 105

dosage, 75

anthracyclines, 51

drug interactions with, 76

antiandrogen, 129

FDA approved uses of, 73

antifolates, 57

metabolism/mechanisms of, 73

antitumor antibiotics, 35

carboplatin (Paraplatin®), 31

asparaginase enzyme, 149

adverse effects of, 33

BCR pathway inhibitors, 114

dosage, 32

BCR-ABL inhibitors, 110

dose adjustments, 33

deoxycytidine analogue, 78

drug interactions with, 33

extravasation risk of, 167–168

emetogenicity level of, 34

fl uoropyrimidine, 73

FDA approved uses of, 31

HDAC inhibitor, 133

structure and mechanism of action,

hypomethylating agent, 137

32

immunomodulatory agents (IMiDs),

carfi lzomib (Kyprolis®), 141

145

dosage, 142

mitogen-activated protein kinase

emetogenicity level of, 143

(MAPK) pathway inhibitor, 118

FDA approved uses of, 141

monoclonal antibodies, 88–101

premedications, 143

mTOR inhibitors, 131

vesicant/irritant properties, 143

nitrogen mustard, 15

working of, 141

non-nitrogen mustard, 23

carmustine (BiCNU®, Gliadel®), 23

oral targeted therapies, 122

dosage, 26

platinum, 31

dose adjustments, 27

PML-RARα inhibitor, 153

emetogenicity level of, 30

proteasome inhibitor, 141

FDA approved uses of, 23

purine analogue, 69

irritant properties, 30

purine antagonist, 64

side effects of, 29

renal/hepatic dose adjustments,

CDC. See complement-dependent

165–166

cytotoxicity

topoisomerase I inhibitors, 41

ceritinib (Zykadia™), 122

topoisomerase II inhibitor, 47

Index 175

vinca alkaloids, 11

drug interactions with, 20

chlorambucil (Leukeran®), 15

emetogenicity level of, 21

dosage, 19

FDA approved uses of, 15

dose adjustments, 19

metabolic pathway of, 17

emetogenicity level of, 21

premedications, 21

FDA approved uses of, 16

side effects of, 20–21

side effects of, 21

cytarabine, 78

cimetidine, drug interactions with, 28

adverse effects of, 81

cisplatin (Platinol®), 31

clinical features of, 81

adverse effects of, 33

dosage, 80

dosage, 32

drug interactions with, 80

drug interactions with, 33

emetogenicity level of, 82

emetogenicity level of, 34

FDA approved uses of, 78

FDA approved uses of, 31

resistance mechanism of, 79

structure and mechanism of action,

working of, 78–79

32

cytotoxicity, in monoclonal antibodies,

cladribine (Leustatin®), 69

85

adverse effects of, 72

dosage, 70

drug interactions with, 71

dabrafenib (Tafi nlar®), 118

emetogenicity level of, 72

adverse effects, 121

FDA approved uses of, 69

dosage, 119

irritant properties, 72

dose adjustments, 119

working of, 69

drug interactions with, 119–120

clofarabine (Clolar®), 69

FDA approved uses of, 118

adverse effects of, 72

working of, 119

dosage, 70–71

dacarbazine (DTIC-Dome®), 23

drug interactions with, 71

dosage, 26

emetogenicity level of, 72

dose adjustments, 27

FDA approved uses of, 69

drug interactions with, 28

working of, 69–70

emetogenicity level of, 30

complement-dependent cytotoxicity

FDA approved uses of, 24

(CDC), 85

irritant properties, 30

crizotinib (Xalkori®), 122

resistance mechanism of, 25

adverse effects of, 126

side effects of, 29

dosage, 124

working of, 24

drug interactions with, 125–126

dactinomycin (Cosmegen®,

emetogenicity level of, 126

actinomycin D), 35

FDA approved uses of, 122

adverse effects of, 38

working of, 123

dosage, 37

cyclophosphamide (Cytoxan®), 15

dose adjustments, 37

dosage, 18–19

drug interactions with, 37

dose adjustments, 19

emetogenicity level of, 39

176 Index

dactinomycin (Cosmegen®,

defi ciencies, 77

actinomycin D) ( cont.)

dinutuximab (Unituxin™), 92

FDA approved uses of, 35

adverse effects, 92

resistance mechanism of, 36

FDA approved uses of, 92

vesicants, 39

dosage, 92

working of, 36

targets for, 92

dasatinib (Sprycel®), 100

DMSO (topical), 169

adverse effects, 100

docetaxel (Taxotere®), 3

FDA approved uses of, 100

adverse effects of, 8

dosage, 100

dosage, 6

targets for, 100

drug interactions with, 7

daunorubicin (Cerubidine®), 51

FDA approved uses of, 3

dosage, 53

irritant properties, 10

drug interactions with, 54

mechanism of, 5

emetogenicity level of, 55

premedications, 9

FDA approved uses of, 52

side effects of, 9

lifetime doses of, 56

solvents, 6

decitabine (Dacogen®), 137

dosage

dosage, 138

anthracyclines, 53

dose adjustments, 138

antiandrogen, 130

emetogenicity level of, 139

antifolates, 59–60

FDA approved uses of, 137

antitumor antibiotics, 36–37

working of, 137–138

asparaginase enzyme, 150

denosumab (Xgeva®), 92

BCR-ABL inhibitors, 111–112

adverse effects, 92

deoxycytidine analogue, 80

FDA approved uses of, 92

estramustine (Emcyt®), 163

dosage, 92

fl uoropyrimidine, 75

targets for, 92

HDAC inhibitor, 134

deoxycytidine analogue

hypomethylating agent, 138

adverse effects of, 81

immunomodulatory agents (IMiDs),

chemotherapy agents in, 78

146

dosage, 80

mitogen-activated protein kinase

dose adjustments, 80

(MAPK) pathway inhibitors, 119

drug interactions with, 80

mTOR inhibitor, 132

emetogenicity level of, 82

nitrogen mustard, 18–19

FDA approved uses of, 78

non-nitrogen mustard, 25–26

premedications, 81

omacetaxine (Synribo®), 161

resistance mechanism of, 79

platinum, 32

vesicant/irritant properties, 82

PML-RARα inhibitor, 154

working of, 78–79

proteasome inhibitor, 142

dexrazoxane, 168–169

purine analogue, 70–71

dihydropyrimidine dehydrogenase

purine antagonist, 66

(DPD), 75

sipuleucel-T (Provenge®), 159

Index 177

topoisomerase I inhibitors, 42–44

emetogenicity level of, 55

topoisomerase II inhibitor, 48–49

FDA approved uses of, 51

vinca alkaloids, 12

lifetime doses of, 56

ziv-afl ibercept (Zaltrap®), 103

drug interactions

dose adjustments

anthracyclines, 54

agents required for renal/hepatic,

antiandrogen, 130

165–166

antifolates, 60–61

angiogenesis inhibitors, 107

antitumor antibiotics, 37

anthracyclines, 54

asparaginase enzyme, 150

antiandrogen, 130

BCR pathway inhibitors, 116

antifolates, 60

BCR-ABL inhibitors, 112

antitumor antibiotics, 37

deoxycytidine analogue, 80

asparaginase enzyme, 150

estramustine (Emcyt®), 164

BCR pathway inhibitors, 116

fl uoropyrimidine, 76

BCR-ABL inhibitors, 112

HDAC inhibitor, 135

deoxycytidine analogue, 80

hypomethylating agent, 139

estramustine (Emcyt®), 163

immunomodulatory agents (IMiDs),

fl uoropyrimidine, 75–76

146

HDAC inhibitor, 134

MAPK pathway inhibitors,

hypomethylating agent, 138

119–120

immunomodulatory agents (IMiDs),

monoclonal antibodies, 87

146

mTOR inhibitor, 132

MAPK pathway inhibitors, 119

nitrogen mustard, 20

miscellaneous oral targeted

non-nitrogen mustard, 27–28

therapies, 125

omacetaxine (Synribo®), 162

monoclonal antibodies, 86

oral targeted therapies, 125–126

mTOR inhibitor, 132

platinum, 33

nitrogen mustard, 19–20

PML-RARα inhibitor, 154

non-nitrogen mustard, 27

proteasome inhibitor, 142

omacetaxine (Synribo®), 161

purine analogue, 71

platinum, 33

purine antagonist, 66–67

PML-RARα inhibitor, 154

sipuleucel-T (Provenge®), 160

proteasome inhibitor, 142

topoisomerase I inhibitors, 44

purine analogue, 71

topoisomerase II inhibitor, 49

purine antagonist, 66

vinca alkaloids, 12

sipuleucel-T (Provenge®), 159

ziv-afl ibercept (Zaltrap®), 103

topoisomerase I inhibitors, 44

topoisomerase II inhibitor, 49

vinca alkaloids, 12

eculizumab (Soliris®), 93

ziv-afl ibercept (Zaltrap®), 103

adverse effects, 93

doxorubicin (Adriamycin®), 51

FDA approved uses of, 93

dosage, 53

dosage, 93

drug interactions with, 54

targets for, 93

178 Index

emetogenicity level

epipodophyllotoxins, 47–50

anthracyclines, 55

epirubicin (Ellence®), 51

antiandrogen, 130

dosage, 53

antifolates, 63

drug interactions with, 54

antitumor antibiotics, 39

emetogenicity level of, 55

asparaginase enzyme, 152

FDA approved uses of, 51

BCR pathway inhibitors, 117

lifetime doses of, 56

BCR-ABL inhibitors, 113

eribulin (Halaven®)3

deoxycytidine analogue, 82

adverse effects of, 8

estramustine (Emcyt®), 164

dosage, 6

fl uoropyrimidine, 77

dose adjustments, 7

HDAC inhibitor, 135

drug interactions with, 7

hypomethylating agent, 139

FDA approved uses of, 3

immunomodulatory agents

irritant properties, 10

(IMiDs), 148

mechanisms of, 5

MAPK pathway inhibitors, 121

premedications, 9

monoclonal antibodies, 87

solvents, 6

mTOR inhibitor, 132

erlotinib (Tarceva®), 118

nitrogen mustard, 21

adverse effects, 120

non-nitrogen mustard, 30

dosage, 119

omacetaxine (Synribo®), 162

dose adjustments, 119

oral targeted therapies, 126–127

drug interactions with, 119–120

platinum, 34

FDA approved uses of, 118

PML-RARα inhibitor, 155

working of, 118

proteasome inhibitor, 143

erwinia (Erwinaze®), 149

purine analogue, 72

dosage, 150

purine antagonist, 67

emetogenicity level of, 152

sipuleucel-T (Provenge®), 160

silent inactivation, 151

taxanes, 10

working of, 149

topoisomerase I inhibitors, 45

estramustine (Emcyt®)

topoisomerase II inhibitor, 50

adverse effects of, 164

vinca alkaloids, 13

dosage, 163

ziv-afl ibercept (Zaltrap®), 104

dose adjustments, 163

enzalutamide (Xtandi®), 129

drug interactions with, 164

adverse effects of, 130

emetogenicity level of, 164

dose adjustments, 130

FDA approved uses of, 163

dosage, 130

working of, 163

drug interactions with, 130

etoposide (Toposar®; Vepesid®; VP-16),

FDA approved uses of, 129

47

working of, 129–130

adverse effects of, 50

enzyme inhibitors, 41–56. See also

dosage, 48–49

topoisomerase I inhibitor;

dose adjustment, 49

topoisomerase II inhibitor

emetogenicity level of, 50

Index 179

FDA approved uses, 47

proteasome inhibitor, 141

irritant properties, 50

purine analogue, 69

etoposide phosphate

purine antagonist, 64

(Etopophos®), 47

sipuleucel-T (Provenge®), 159

everolimus (Afi nitor®), 131

topoisomerase I inhibitors, 41

dosage, 132

topoisomerase II inhibitor, 47

drug interactions with, 132

VEGFR inhibitor, 105

emetogenicity level of, 132

vinca alkaloids, 11

FDA approved uses of, 131

ziv-afl ibercept (Zaltrap®), 103

extravasation

fl oxuridine (FUDR®), 73

dexrazoxane, 168–169

adverse effects of, 76–77

DMSO (topical), 169

dosage, 75

interventions, 168–169

drug interactions with, 76

management of, 168

FDA approved uses of, 73

risk of chemotherapic agents,

metabolism/mechanisms of,

167–168

74–75

sodium thiosulfate, 169

fl udarabine (Fludara®), 69

adverse effects of, 72

dosage, 71

FDA approved uses

drug interactions with, 71

anthracyclines, 51–52

emetogenicity level of, 72

antiandrogen, 129

FDA approved uses of, 69

antifolates, 57

working of, 69

antitumor antibiotics, 35

fl uoropyrimidine

asparaginase enzyme, 149

adverse effects of, 76–77

BCR pathway inhibitors, 114

chemotherapy agents in, 73

BCR-ABL inhibitors, 110

dosage, 75

deoxycytidine analogue, 78

dose adjustments, 73–76

estramustine (Emcyt®), 163

DPD defi ciencies in, 77

fl uoropyrimidine, 73

drug interactions with, 76

HDAC inhibitor, 133

of emetogenicity level, 77

hypomethylating agent, 137

FDA approved uses of, 73

immunomodulatory agents

metabolism/mechanisms of,

(IMiDs), 145

73–75

MAPK pathway inhibitors, 118

premedications, 77

monoclonal antibodies, 88–101

resitance mechanism of, 75

mTOR inhibitor, 131

vesicant/irritant properties, 77

nitrogen mustard, 15–16

working of, 73

non-nitrogen mustard, 23–24

fl uorouracil (5-FU) (Adrucil®), 73

omacetaxine (Synribo®), 161

adverse effects of, 76

oral targeted therapies, 122

dosage, 75

platinum, 31

drug interactions with, 76

PML-RARα inhibitor, 153

FDA approved uses of, 73

180 Index

fl uorouracil (5-FU) (Adrucil®) ( cont.) histone deacetylase (HDAC)

irritant properties, 77

inhibitors. See HDAC inhibitor

metabolism/mechanisms of, 73

hyaluronidase, 169

hypomethylating agent

chemotherapy agents in, 137

gastrointestinal stromal tumor

dosage adjustements of, 138

(GIST), 107

dosage, 138

gefi tinib (Iressa®), 118

drug interactions with, 139

adverse effects, 120

emetogenicity level of, 139

dosage, 119

FDA approved uses of, 137

dose adjustments, 119

vesicant/irritant properties, 139

drug interactions with, 119–120

working of, 137–138

FDA approved uses of, 118

working of, 118

ibritumomab tiuxetan (Zevalin®), 94

gemcitabine (Gemzar®), 78

adverse effects, 94

adverse effects of, 81

FDA approved uses of, 94

dosage, 80

dosage, 94

drug interactions with, 80

targets for, 94

emetogenicity level of, 82

ibrutinib (Imbruvica®), 114

FDA approved uses of, 78

adverse effects, 117

irritant properties, 82

dosage, 116

resistance mechanism of, 79

drug interactions with, 116

working of, 78–79

FDA approved uses of, 114

gemtuzumab ozogamicin

mechanism of, 114–116

(Mylotarg®), 93

idarubicin (Idamycin PFS®), 51

adverse effects, 93

dosage, 53

FDA approved uses of, 93

drug interactions with, 54

dosage, 93

emetogenicity level of, 55

targets for, 93

FDA approved uses of, 52

GIST. See gastrointestinal stromal

lifetime doses of, 56

tumor

idelalisib (Zydelig®), 114

adverse effects, 117

HDAC inhibitor

dosage, 116

adverse effects of, 135

drug interactions with, 116

chemotherapy agents in, 133

FDA approved uses of, 114

dosage, 134

mechanism of, 114–115

dose adjustments, 134

ifosfamide (Ifex®), 15

drug interactions with, 135

dosage, 19

emetogenicity level of, 135

dose adjustments, 19

FDA approved uses of, 133

drug interactions with, 20

resistance mechanism of, 134

FDA approved uses of, 16

vesicant/irritant properties, 135

irritant properties, 22

working of, 133–134

metabolic pathway of, 17

Index 181

premedications, 21

premedications, 9

side effects of, 21

solvents, 6

IgG, 85

imatinib (Gleevec®), 110

lapatinib (Tykerb®), 122

activity against, 111

adverse effects, 126

adverse effects of, 113

dosage, 125

dosage, 111

drug interactions with, 125–126

dose adjustments, 112

FDA approved uses of, 122

drug interactions with, 112

working of, 123

FDA approved uses of, 110

lenalidomide (Revlimid®)

immunomodulatory agents (IMiDs)

dosage, 146

adverse effects of, 146–147

dose adjustments, 146

chemotherapy agents in, 145

FDA approved uses of, 145

dosage, 146

lenvatinib (Lenvima™), 105

dose adjustments, 146

dosage, 107

drug interactions with, 146

drug interactions with, 108

emetogenicity level of, 148

emetogenicity level of, 109

FDA approved uses of, 145

FDA approved uses of, 105

signifi cance of the REMS programs

targets for, 106

with, 147–148

leucovorin, 61

working of, 145

liposomal daunorubicin

ipilimumab (Yervoy®), 94–95

(DaunoXome®), 51

adverse effects, 94–95

FDA approved uses of, 52

dosage, 94–95

liposomal doxorubicin (Doxil®,

FDA approved uses of, 94–95

Lipodox®), 51

targets for, 94–95

dosage, 53

irinotecan (Camptosar®), 42

drug interactions with, 54

adverse effects of, 44

emetogenicity level of, 55

dosage, 42

FDA approved uses of, 51

dose adjustments, 44

irritant properties, 55

drug interactions with, 44

liposomal vincristine (Marqibo®), 11

emetogenicity level of, 45

adverse effects of, 12

FDA approved uses of, 42

dosage, 12

irritant properties, 45

drug interactions with, 12

metabolism, 43

emetogenicity level of, 13

working of, 42

FDA approved for, 11

ixabepilone (Ixempra®), 3

vesicants, 13

adverse effects of, 8

lomustine (CeeNU®), 23

dosage, 6

dosage, 26

drug interactions with, 7

dose adjustments, 27

FDA approved uses of, 3

emetogenicity level of, 30

irritant properties, 10

FDA approved uses of, 23

mechanisms of, 5

side effects of, 29

182 Index

mammalian target of rapamycin

mitogen-activated protein kinase

(mTOR) inhibitors. See mTOR

(MAPK) pathway inhibitors. See

inhibitors

MAPK pathway inhibitors

MAPK pathway inhibitors

mitomycin C (Mutamycin®, MMC), 35

adverse effects of, 120–121

adverse effects of, 38

chemotherapy agents in, 118

dosage, 37

dosage, 119

dose adjustments, 37

drug interactions with, 119–120

drug interactions with, 37

emetogenicity level of, 121

emetogenicity level of, 39

FDA approved uses of, 118

FDA approved uses of, 35

metabolism of, 119

resistance mechanism of, 36

working of, 118–119

vesicants, 39

mechlorethamine (Mustargen®), 15

working of, 36

dosage, 18

mitoxantrone (Novantrone®), 51

dose adjustments, 20

dosage, 53

FDA approved uses of, 15

drug interactions with, 54

vesicant, 22

emetogenicity level of, 55

medullary thyroid cancer, 107

FDA approved uses of, 52

melphalan (Alkeran®), 15

lifetime doses of, 56

dosage, 19

monoclonal antibodies, 85–101

dose adjustments, 20

chemotherapic agents in, 88–101

FDA approved uses of, 16

classifi cation of, 87

irritant properties, 22

cytotoxicity in, 85

side effects of, 21

drug interactions with, 86

mercaptopurine (Purinethol®, 6-MP), 64

emetogenicity level of, 87

adverse effects of, 67

isotopes of, 85

dosage, 66, 68

metabolism of, 86

dosing adjustment for, 66

naming of, 86

drug interactions with, 66–67

mTOR inhibitors

emetogenicity level of, 67

adverse effects of, 132

FDA approved uses of, 64

chemotherapy agents in, 131

working of, 64–65

dosage, 132

metabolism/mechanisms

dose adjustments, 132

MAPK pathway inhibitors, 119

drug interactions with, 132

fl uoropyrimidine, 73–75

emetogenicity level of, 132

methotrexate (Trexall®), 57

FDA approved uses of, 131

adverse effects of, 61

working of, 131

dosage, 59–60

multi-kinase inhibitors, 105–109

drug interaction with, 60

FDA approved uses of, 57

nanoparticle albumin-bound (nab)

premedications, 62–63

paclitaxel (Abraxane®), 3

microtubule inhibitors, 3–13.

adverse effects of, 8

See also taxanes; vinca alkaloids dosage, 6

Index 183

drug interactions with, 7

FDA approved uses of, 23–24

FDA approved uses of, 3

premedications, 29

irritant properties, 10

resistance mechanism of, 25

mechanisms of, 5

side effects of, 28–29

premedications, 9

vesicant/irritant properties, 30

solvents, 6

working of, 24–25

nelarabine (Arranon®), 69

adverse effects of, 72

dosage, 71

obinutuzumab (Gazyva™), 96

drug interactions with, 71

adverse effects, 96

emetogenicity level of, 72

dosage, 96

FDA approved uses of, 69

FDA approved uses of, 96

nilotinib (Tasigna®), 110

targets, 96

adverse effects, 113

ofatumumab (Arzerra®), 96

dosage, 112

adverse effects, 96

drug interactions with, 112

dosage, 96

FDA approved uses of, 110

FDA approved uses of, 96

targets for, 111

targets for, 96

nitrogen mustard

olaparib (Lynparza™), 122

adverse effects of, 20

adverse effects of, 126

chemotherapy agents in, 15

dosage, 125

dosage, 18–19

drug interactions with, 125

dose adjustments, 19–20

emetogenicity level of, 126

drug interactions with, 20

FDA approved uses of, 122

emetogenicity level of, 21

working of, 124

FDA approved uses of, 15–16

omacetaxine (Synribo®)

premedications, 21

adverse effects of, 162

resistance mechanism of, 16–18

dosage, 161

side effects of, 20–21

dose adjustments, 161

vesicant/irritant properties, 22

drug interactions with, 162

working of, 16

emetogenicity level of, 162

nivolumab (Opdivo®), 95

FDA approved uses of, 161

adverse effects, 95

working of, 161

dosage, 95

oral targeted therapies

FDA approved uses of, 95

adverse effects of, 126

targets for, 95

chemotherapic agents in, 122

non-nitrogen mustard

dosage, 124–125

adverse effects of, 28

drug interactions with, 125–126

chemotherapy agents in, 23

emetogenicity level of, 126–127

dosage, 25–26

FDA approved uses of, 122

dose adjustments, 27

working of, 122–124

drug interactions with, 27–28

oxaliplatin (Eloxatin®), 31

emetogenicity level of, 30

adverse effects of, 34

184 Index

oxaliplatin (Eloxatin®) ( cont.)

PDGF. See platelet-derived growth

dosage, 32

factor

drug interactions with, 33

pegaspargase (Oncaspar®), 149

emetogenicity level of, 34

dosage, 150

FDA approved uses of, 31

emetogenicity level of, 152

structure and mechanism of action,

working of, 149–150

32

pembrolizumab (Keytruda®), 97

adverse effects, 97

dosage, 97

paclitaxel (Taxol®), 3

FDA approved uses of, 97

adverse effects of, 8

targets for, 97

dosage, 6

pemetrexed (Alimta®), 57

drug interactions with, 7

adverse effects of, 62

FDA approved uses of, 3

dosage, 60

irritant with vesicant like properties,

FDA approved uses of, 57

10

premedications, 63

premedications, 9

pentostatin (Nipent®), 69

side effects of, 9

adverse effects of, 72

solvents, 6

dosage, 71

palbociclib (Ibrance®), 122

drug interactions with, 71

adverse effects of, 126

emetogenicity level of, 72

dosage, 125–126

FDA approved uses of, 69

drug interactions with, 125

working of, 70

emetogenicity level of, 126

pertuzumab (Perjeta®), 98

FDA approved uses of, 122

adverse effects, 98

working of, 123

dosage, 98

panitumumab (Vectibix®), 97

FDA approved uses of, 98

adverse effects, 97

targets for, 98

dosage, 97

pharmacodynamic interactions, 86

FDA approved uses of, 97

pharmacokinetic drug interactions,

targets for, 97

86

panobinostat (Farydaq®), 133

platelet-derived growth factor

dosage, 134

(PDGF), 106

drug interactions with, 135

platinum

emetogenicity level of, 135

adverse effects of, 33–34

FDA approved uses of, 133

chemotherapy agents in, 31

resistance mechanism of, 134

dose adjustments, 33

pazopanib (Votrient®), 105

dosage, 32

adverse effects of, 109

drug interactions with, 33

dosage, 107

emetogenicity level of, 34

drug interactions with, 108

FDA approved uses of, 31

FDA approved uses of, 105

premedications, 34

targets for, 106

resistance mechanism of, 32

Index 185

structure and mechanism of action,

drug interactions with, 27–28

32

emetogenicity level of, 30

vesicants/irritants properties, 34

FDA approved uses of, 24

working of, 31–32

resistance mechanism of, 25

PML-RARα inhibitor

side effects of, 28

adverse effects of, 154

working of, 24

chemotherapic agents in, 153

promyelocytic leukemia gene retinoic

differentiating agent therapy in,

acid receptor-alpha (PML-RARα)

154–155

translocation inhibitors. See PML-

dosage, 154

RARα inhibitor

dose adjustments, 154

proteasome inhibitor

drug interactions with, 154

adverse effects of, 143

emetogenicity level of, 155

chemotherapy agents in, 141

FDA approved uses of, 153

dosage, 142

vesicant/irritant properties, 155

dose adjustments, 142

working of, 153–154

drug interactions with, 142

pomalidomide (Pomalyst®)

emetogenicity level of, 143

dosage, 146

FDA approved uses of, 141

dose adjustments, 146

premedications, 143

drug interactions with, 146

resistance mechanism of, 142

FDA approved uses of, 145

vesicant/irritant properties, 143

ponatinib (Iclusig®), 110

working of, 141–142

pralatrexate (Folotyn®), 57

purine analogue

adverse effects of, 62

adverse effects of, 71–72

dosage, 60

chemotherapy agents in, 69

FDA approved uses of, 57

dosage, 70–71

premedications, 63

dose adjustments, 71

premedications

drug interactions with, 71

anthracyclines, 55

emetogenicity level of, 72

antifolates, 62–63

FDA approved uses of, 69

antitumor antibiotics, 38

premedications, 72

deoxycytidine analogue, 81

resistance mechanism of, 70

fl uoropyrimidine, 77

vesicant/irritant properties, 72

for nitrogen mustard, 21

working of, 69–70

of non-nitrogen mustard, 29

purine antagonist

platinum, 34

adverse effects of, 67

proteasome inhibitor, 143

chemotherapy agents in, 64

purine analogue, 72

defi ciencies of TPMT, 67–68

sipuleucel-T (Provenge®), 160

dosage, 66

topoisomerase I inhibitors, 45

dose adjustments, 66

topoisomerase II inhibitor, 50

drug interaction with, 66–67

procarbazine (Matulane®), 23

emetogenicity level of, 67

dose adjustments, 27

FDA approved uses of, 64

186 Index

purine antagonist ( cont.)

FDA approved uses of, 133

resistance mechanism of, 65

resistance mechanism of, 134

working of, 64–65

ruxolitinib (Jakafi ™), 122

pyrimidine analogues, 73–77

adverse effects of, 126

dosage, 124

dose adjustments, 125

ramucirumab (Cyramza®), 98

drug interactions with, 125

adverse effects, 98

FDA approved uses of, 122

dosage, 98

working of, 122

FDA approved uses of, 98

targets for, 98

regorafenib (Stivarga®), 105

side effects

adverse effects, 109

antifolates, 61

dosage, 107

nitrogen mustard, 20–21

drug interactions with, 108

non-nitrogen mustard, 28–29

FDA approved uses of, 105

sipuleucel-T (Provenge®), 159

targets for, 106

adverse effects of, 160

resistance mechanism

dosage, 159

anthracyclines, 52–53

dose adjustments, 159

antifolates, 59

drug interactions with, 160

antitumor antibiotics, 36

emetogenicity level of, 160

deoxycytidine analogue, 79

FDA approved uses of, 159

fl uoropyrimidine, 75

premedications, 160

HDAC inhibitor, 134

vesicant/irritant properties, 160

nitrogen mustard, 16–18

working of, 159

non-nitrogen mustard, 25

sodium thiosulfate, 169

platinum, 32

sonidegib (Odomzo®), 122

proteasome inhibitor, 142

adverse effects of, 126

purine analogue, 70

dosage, 125

purine antagonist, 65

dose adjustments, 125

topoisomerase I inhibitors, 42

drug interactions with, 125, 126

topoisomerase II inhibitor, 48

emetogenicity level of, 127

vinca alkaloids, 12

FDA approved uses of, 122

reticuloendothelial system, 86

working of, 124

rituximab (Rituxan®), 99

sorafenib (Nexavar®), 105

adverse effects, 97

adverse effects of, 109

dosage, 99

dosage, 107

FDA approved uses of, 97

drug interactions with, 108

targets for, 99

FDA approved uses of, 105

romidepsin (Istodax®), 133

targets for, 106

dosage, 134

streptozocin (Zanosar®), 23

drug interactions with, 135

dosage, 26

emetogenicity level of, 135

dose adjustments, 27

Index 187

emetogenicity level of, 30

drug interactions with, 132

FDA approved uses of, 23

emetogenicity level of, 132

irritant properties, 30

FDA approved uses of, 131

side effects of, 29

teniposide (Vumon®; VM-26), 47

working of, 24

adverse effects of, 50

sulfonamides, 60

dosage, 49

sunitinib (Sutent®), 105

dose adjustments, 49

adverse effects of, 109

emetogenicity level of, 50

dosage, 107

FDA approved uses, 47

drug interactions with, 108

irritant properties, 50

FDA approved uses of, 105

thalidomide (Thalomid®), 145

targets for, 106–107

dosage, 146

dose adjustments, 146

FDA approved uses of, 145

targets

thioguanine (Tabloid®), 64

BCR pathway inhibitors, 114–116

adverse effects of, 67

BCR-ABL inhibitors, 111

dosage, 66, 68

MAPK pathway inhibitors, 118–119

dose adjustments, 66

monoclonal antibodies, 88–101

drug interactions with, 67

tyrosine kinase inhibitors, 106–107

emetogenicity level of, 67

taxanes

FDA approved uses of, 64

adverse effects, 7–8

working of, 64–65

chemotherapy agents, 3

thiopurine methyltransferase

dosage, 6

(TPMT)

dose adjustments, 7

defi ciencies of, 67–68

drug interactions with, 7

thiotepa (Tepadina®), 23

emetogenicity level of, 10

dosage, 26

FDA approved uses of, 3

dose adjustments, 27

premedications, 9

emetogenicity level of, 30

resistance mechanism, 5–6

FDA approved uses of, 24

solvents, 6–7

side effects of, 29

vesicants/irritants properties, 10

topoisomerase I inhibitor

working of, 4–5

adverse effects of, 44–45

temozolomide (Temodar®), 23

chemotherapy agents in, 41

dosage, 26

dosage, 42–44

dose adjustments, 27

dose adjustments, 44

emetogenicity level of, 30

drug interactions with, 44

FDA approved uses of, 24

emetogenicity level of, 45

resistance mechanism of, 25

FDA approved uses of, 41

side effects of, 29

premedications, 45

working of, 24

resistance mechanism of, 42

temsirolimus (Torisel®), 131

vesicant/irritant properties, 45

dosage, 132

working of, 41–42

188 Index

topoisomerase II inhibitor

emetogenicity level of, 155

adverse effects of, 49–50

FDA approved uses of, 153

chemotherapy agents in, 47

working of, 153

dosage, 48–49

tyrosine kinase inhibitors, 106

dose adjustments, 49

angiogenesis inhibitors and multi-

drug interactions with, 49

kinase inhibitors, 105–109

emetogenicity level of, 50

BCR pathway inhibitor, 114–117

FDA approved uses of, 47

BCR-ABL inhibitor, 110–113

premedications, 50

MAPK pathway inhibitors, 118–121

resistance mechanism of, 48

oral targeted therapies, 122–127

vesicant/irritant properties, 50

targets for, 106–107

working of, 47–48

topotecan (Hycamtin®), 42

adverse effects of, 45

vandetanib (Caprelsa®), 105

dosage, 42, 44

adverse effects of, 109

dose adjustments, 44

dosage, 107

drug interactions with, 44

dose adjustments, 107

emetogenicity level of, 45

FDA approved uses of, 105

FDA approved uses of, 42

targets for, 106–107

irritant properties, 45

vascular endothelial growth factor

tositumomab (Bexxar®), 99–100

(VEGF), 106

adverse effects, 99–100

VEGF. See vascular endothelial growth dosage, 99–100

factor

FDA approved uses of, 99–100

VEGFR inhibitor

targets for, 99–100

FDA approved uses of, 105

trametinib (Mekinist™), 118

vemurafenib (Zelboraf®), 118

adverse effects, 121

adverse effects of, 121

dosage, 119

dosage, 119

dose adjustments, 119

dose adjustments, 119

drug interactions with, 120

drug interactions with, 119–120

FDA approved uses of, 118

emetogenicity level of, 126

working of, 119

FDA approved uses of, 118

trastuzumab (Herceptin®), 100

working of, 119

adverse effects, 100

vesicant/irritant properties

dosage, 100

anthracyclines, 55

FDA approved uses of, 100

antifolates, 63

targets for, 100

antitumor antibiotics, 39

tretinoin/all-trans retinoic acid

asparaginase enzyme, 152

(ATRA) (Vesanoid®), 153

deoxycytidine analogue, 82

adverse effects of, 154

fl uoropyrimidine, 77

dosage, 154

HDAC inhibitor, 135

dose adjustments, 154

hypomethylating agent, 139

drug interactions with, 154

nitrogen mustard, 22

Index 189

non-nitrogen mustard, 30

emetogenicity level of, 13

platinum, 34

FDA approved for, 11

PML-RARα inhibitor, 155

Vesicant properties, 13

proteasome inhibitor, 143

vinorelbine (Navelbine®), 11

purine analogue, 72

adverse effects of, 13

sipuleucel-T (Provenge®), 160

dosage, 12

taxanes, 10

drug interactions with, 12

topoisomerase I inhibitors, 45

emetogenicity level of, 13

topoisomerase II inhibitor, 50

FDA approved for, 11

vinca alkaloids, 13

vesicants, 13

ziv-afl ibercept (Zaltrap®), 104

vismodegib (Erivedge™), 122

vinblastine (Velban®), 11

adverse effects of, 126

adverse effects of, 12

dosage, 125

dosage, 12

drug interactions with, 125, 126

drug interactions with, 12

emetogenicity level of, 126

emetogenicity level of, 13

FDA approved uses of, 122

FDA approved for, 11

working of, 124

vesicants, 13

vorinostat (Zolinza®), 133

vinca alkaloids

dosage, 134

adverse effects of, 12–13

drug interactions with, 135

chemotherapy agents of, 11

emetogenicity level of, 135

dosage, 12

FDA approved uses of, 133

dose adjustments, 12

drug interactions with, 12

emetogenicity level of, 13

ziv-afl ibercept (Zaltrap®), 103

FDA approved treatments for, 11

adverse effects of, 104

resistance mechanism of, 12

dosage, 103

vesicants/irritant properties, 13

dose adjustments, 103

working of, 11

drug interactions with, 103

vincristine (Oncovin®), 11

emetogenicity level of, 104

adverse effects of, 12

FDA approved uses of, 103

dosage, 12

vesicant/irritant properties, 104

drug interactions with, 12

working of, 103





Document Outline


Cover

Title

Copyright

Contents

List of Figures

List of Tables

Preface

Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams

Part I: Traditional Chemotherapy Chapter 1: Microtubule Inhibitors Taxanes and Related Agents

Vinca Alkaloids





Chapter 2: Alkylating Agents Nitrogen Mustards

Non-Nitrogen Mustards

Platinums

Antitumor Antibiotics





Chapter 3: Enzyme Inhibitors—Topoisomerase I Inhibitors Camptothecans





Chapter 4: Enzyme Inhibitors—Topoisomerase II Inhibitors Epipodophyllotoxins

Anthracyclines





Chapter 5: Antimetabolites Antifolates

Purine Antagonists

Purine Analogues

Pyrimidine Analogues/Fluoropyrimidines

Pyrimidine Analogues/Deoxycytidine Analogues





Part II: Next-Generation Antineoplastics Chapter 6: Monoclonal Antibodies

Chapter 7: VEGF Trap Ziv-Aflibercept (Zaltrap®)





Chapter 8: Tyrosine Kinase Inhibitors Angiogenesis Inhibitors and Multi-Kinase Inhibitors

Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors

B-Cell Receptor (BCR) Pathway Inhibitors

EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors

Miscellaneous Oral Targeted Therapies





Chapter 9: Antiandrogen Therapies

Chapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors

Chapter 11: Histone Deacetylase (HDAC) Inhibitors

Chapter 12: Hypomethylating Agents

Chapter 13: Proteasome Inhibitors

Chapter 14: Immunomodulatory Agents

Chapter 15: L-Asparaginase Enzymes

Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors





Part III: Miscellaneous Oncolytics Chapter 17: Sipuleucel-T (Provenge®)

Chapter 18: Omacetaxine (Synribo®)

Chapter 19: Estramustine (Emcyt®)





Appendix A: Agents Requiring Renal and/or Hepatic Dose Adjustments

Appendix B: Extravasation Risk of Chemotherapeutic Agents

Index





